{"initialLink":"https://www.nejm.org/doi/full/10.1056/nejmoa2110475","sanitizedLink":"https://www.nejm.org/doi/full/10.1056/nejmoa2110475","finalLink":"https://www.nejm.org/doi/full/10.1056/NEJMoa2110475","htmlEmbed":"<script>window.contexterSetup=window.contexterSetup||function(){window.contexterSetupComplete=!0;class ContexterLink extends HTMLAnchorElement{constructor(){super()}connectedCallback(){this.setAttribute(\"target\",\"_blank\")}}customElements.define(\"contexter-link\",ContexterLink,{extends:\"a\"}),customElements.define(\"contexter-inner\",class extends HTMLElement{constructor(){super()}attributeChangedCallback(name,oldValue,newValue){}connectedCallback(){this.className=\"contexter-box__inner\"}}),customElements.define(\"contexter-thumbnail\",class extends HTMLElement{constructor(){super()}attributeChangedCallback(name,oldValue,newValue){}connectedCallback(){this.className=\"contexter-box__thumbnail\"}}),customElements.define(\"contexter-byline\",class extends HTMLElement{constructor(){super()}attributeChangedCallback(name,oldValue,newValue){}connectedCallback(){this.className=\"contexter-box__byline\"}}),customElements.define(\"contexter-keywordset\",class extends HTMLElement{constructor(){super()}attributeChangedCallback(name,oldValue,newValue){}connectedCallback(){this.className=\"contexter-box__keywordset\"}}),customElements.define(\"contexter-linkset\",class extends HTMLElement{constructor(){super()}attributeChangedCallback(name,oldValue,newValue){}connectedCallback(){this.className=\"contexter-box__linkset\"}}),customElements.define(\"contexter-meta\",class extends HTMLElement{constructor(){super()}attributeChangedCallback(name,oldValue,newValue){}connectedCallback(){this.className=\"contexter-box__meta\"}}),customElements.define(\"contexter-summary\",class extends HTMLElement{constructor(){super()}attributeChangedCallback(name,oldValue,newValue){}connectedCallback(){this.className=\"p-summary entry-summary\"}}),customElements.define(\"contexter-box-head\",class extends HTMLElement{constructor(){super()}connectedCallback(){this.className=\"contexter-box__head\"}}),customElements.define(\"contexter-box-inner\",class extends HTMLElement{constructor(){super()}connectedCallback(){}});class ContexterBox extends HTMLElement{constructor(){super(),this.first=!0,this.shadow=this.attachShadow({mode:\"open\"})}connectedCallback(){if(this.first){this.first=!1;var style=document.createElement(\"style\"),lightDomStyle=(style.innerHTML=`:host {--background: #f5f6f7;--border: darkblue;--blue: #0000ee;--font-color: black;--inner-border: black;font-family: Franklin,Arial,Helvetica,sans-serif;font-size: 14px;background: var(--background);width: 600px;color: var(--font-color);min-height: 90px;display: block;padding: 8px;border: 1px solid var(--border);cursor: pointer;box-sizing: border-box;margin: 6px;contain: content;margin: 6px auto;}// can only select top-level nodes with slotted::slotted(*) {max-width: 100%;display:block;}::slotted([slot=thumbnail]) {max-width: 100%;display:block;}::slotted([slot=header]) {width: 100%;font-size: 1.25rem;font-weight: bold;display:block;margin-bottom: 6px;}::slotted([slot=author]) {max-width: 50%;font-size: 12px;display:inline-block;float: left;}::slotted([slot=time]) {max-width: 50%;font-size: 12px;display:inline-block;float: right;}::slotted([slot=summary]) {width: 100%;margin-top: 6px;padding: 10px 2px;border-top: 1px solid var(--inner-border);font-size: 15px;display:inline-block;margin-bottom: 6px;}contexter-meta {height: auto;margin-bottom: 4px;width: 100%;display: grid;position: relative;min-height: 16px;grid-template-columns: repeat(2, 1fr);}::slotted([slot=keywords]) {width: 80%;padding: 2px 4px;border-top: 1px solid var(--inner-border);font-size: 11px;display: block;float: right;font-style: italic;text-align: right;grid-column: 2/2;grid-row: 1;align-self: end;justify-self: end;}::slotted([slot=keywords]):empty {border-top: 0px solid var(--inner-border);}::slotted([slot=archive-link]) {font-size: 1em;display: inline;}::slotted([slot=archive-link])::after {content: \"|\";display: inline;color: var(--font-color);text-decoration: none;margin: 0 .5em;}::slotted([slot=read-link]) {font-size: 1em;display: inline;}contexter-linkset {width: 80%;padding: 2px 4px;font-size: 13px;float: left;font-weight: bold;grid-row: 1;grid-column: 1/2;align-self: end;justify-self: start;}/* Extra small devices (phones, 600px and down) */@media only screen and (max-width: 600px) {:host {width: 310px;}}/* Small devices (portrait tablets and large phones, 600px and up) */@media only screen and (min-width: 600px) {...}/* Medium devices (landscape tablets, 768px and up) */@media only screen and (min-width: 768px) {...}/* Large devices (laptops/desktops, 992px and up) */@media only screen and (min-width: 992px) {...}/* Extra large devices (large laptops and desktops, 1200px and up) */@media only screen and (min-width: 1200px) {...}@media (prefers-color-scheme: dark){:host {--background: #354150;--border: #1f2b37;--blue: #55b0ff;--font-color: #ffffff;--inner-border: #787a7c;background: var(--background);border: 1px solid var(--border)}}`,document.createElement(\"style\"));lightDomStyle.innerHTML=`contexter-box {contain: content;}contexter-box .read-link {font-weight: bold;}contexter-box a {color: #0000ee;}contexter-box img {width: 100%;border: 0;padding: 0;margin: 0;}/* Extra small devices (phones, 600px and down) */@media only screen and (max-width: 600px) {...}/* Small devices (portrait tablets and large phones, 600px and up) */@media only screen and (min-width: 600px) {...}/* Medium devices (landscape tablets, 768px and up) */@media only screen and (min-width: 768px) {...}/* Large devices (laptops/desktops, 992px and up) */@media only screen and (min-width: 992px) {...}/* Extra large devices (large laptops and desktops, 1200px and up) */@media only screen and (min-width: 1200px) {...}@media (prefers-color-scheme: dark){contexter-box a {color: #55b0ff;}}`,this.appendChild(lightDomStyle),this.shadow.appendChild(style);const innerContainer=document.createElement(\"contexter-box-inner\"),innerSlotThumbnail=(this.shadow.appendChild(innerContainer),document.createElement(\"slot\")),innerSlotHeader=(innerSlotThumbnail.name=\"thumbnail\",innerContainer.appendChild(innerSlotThumbnail),document.createElement(\"slot\")),innerSlotAuthor=(innerSlotHeader.name=\"header\",innerContainer.appendChild(innerSlotHeader),document.createElement(\"slot\")),innerSlotTime=(innerSlotAuthor.name=\"author\",innerContainer.appendChild(innerSlotAuthor),document.createElement(\"slot\")),innerSlotSummary=(innerSlotTime.name=\"time\",innerContainer.appendChild(innerSlotTime),document.createElement(\"slot\")),metaContainer=(innerSlotSummary.name=\"summary\",innerContainer.appendChild(innerSlotSummary),document.createElement(\"contexter-meta\")),innerSlotInfo=(innerContainer.appendChild(metaContainer),document.createElement(\"slot\")),linkContainer=(innerSlotInfo.name=\"keywords\",metaContainer.appendChild(innerSlotInfo),document.createElement(\"contexter-linkset\")),innerSlotArchiveLink=(metaContainer.appendChild(linkContainer),document.createElement(\"slot\")),innerSlotReadLink=(innerSlotArchiveLink.name=\"archive-link\",linkContainer.appendChild(innerSlotArchiveLink),document.createElement(\"slot\"));innerSlotReadLink.name=\"read-link\",linkContainer.appendChild(innerSlotReadLink),this.className=\"contexter-box\",this.onclick=e=>{if(!e.target.className.includes(\"read-link\")&&!e.target.className.includes(\"title-link\")){const mainLinks=this.querySelectorAll(\"a.main-link\");mainLinks[0].click()}}}}}customElements.define(\"contexter-box\",ContexterBox)},window.contexterSetupComplete||window.contexterSetup();</script><contexter-box class=\"link-card h-entry hentry\" itemscope=\"\" itemtype=\"https://schema.org/CreativeWork\"><contexter-thumbnail class=\"thumbnail\" slot=\"thumbnail\"></contexter-thumbnail><contexter-box-head slot=\"header\" class=\"p-name entry-title\" itemprop=\"headline\"><contexter-box-head slot=\"header\" class=\"p-name entry-title\" itemprop=\"headline\"><a is=\"contexter-link\" href=\"https://www.nejm.org/doi/full/10.1056/NEJMoa2110475\" itemprop=\"url\">Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting | NEJM</a></contexter-box-head></contexter-box-head><time class=\"dt-published published\" slot=\"time\" itemprop=\"datePublished\" datetime=\"2024-10-10T15:43:34.765Z\">10/10/2024</time><contexter-summary class=\"p-summary entry-summary\" itemprop=\"abstract\" slot=\"summary\"><p>Preapproval trials showed that messenger RNA (mRNA)–based vaccines against severeacute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yetthese trials were subject to s...</p></contexter-summary><contexter-keywordset itemprop=\"keywords\" slot=\"keywords\"></contexter-keywordset><a is=\"contexter-link\" href=\"https://www.nejm.org/doi/full/10.1056/NEJMoa2110475\" class=\"read-link main-link\" itemprop=\"sameAs\" slot=\"read-link\">Read</a></contexter-box>","linkId":"7ac9b037cce6f9f9cd6ba25ae3b2f287b58e05d8","data":{"originalLink":"https://www.nejm.org/doi/full/10.1056/nejmoa2110475","sanitizedLink":"https://www.nejm.org/doi/full/10.1056/nejmoa2110475","canonical":"https://www.nejm.org/doi/full/10.1056/NEJMoa2110475","htmlText":"<!DOCTYPE html>\n<html lang=\"en\"                              class=\"pb-page\"          data-request-id=\"1154a385-7b47-40a1-8a40-39d71eea2458\"  \n>    <head data-pb-dropzone=\"head\"><meta charset=\"UTF-8\">\n\n<title>Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting | New England Journal of Medicine</title>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n    \n\n    \n    \n\n    \n    \n    \n    \n        \n            \n                <link rel=\"stylesheet\" type=\"text/css\" href=\"/wro/nlv6~article-metrics.css\">\n            \n            \n            \n        \n    \n\n\n\n    \n\n    \n    \n            <link rel=\"stylesheet\" href=\"/products/mms-nextgen/mms/releasedAssets/css/build-e661706876996e0d3688.css\" media=\"all\">\n        <link rel=\"stylesheet\" href=\"/products/mms-nextgen/mms/releasedAssets/css/print-e661706876996e0d3688.css\"media=\"print\">\n           <link rel=\"stylesheet\" href=\"/products/mms-nextgen/mms/releasedAssets/css/build-article-e661706876996e0d3688.css\" media=\"all\" id=\"article-style-sheet\">\n    \n        <script>\n        try {\n            document.documentElement.classList.add('js');\n        } catch (e) {\n        }\n    </script>\n     \n    \n\n\n<meta name = \"format-detection\" content = \"telephone=no\">\n<!-- TrustArc Scripts -->\n<script async=\"async\" src=\"https://consent.trustarc.com/notice?domain=nejm.com&c=teconsent&js=nj&noticeType=bb&gtm=1&text=true\" crossorigin=\"\"></script>\n<script src=\"https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com\"></script>\n<script src=\"https://consent.trustarc.com/autoblockoptout?domain=nejm.com\"></script>\n<!-- /TrustArc Scripts -->\n\n<meta http-equiv=\"X-UA-Compatible\" content=\"IE=edge\">\n\n\n\n\n\n    \n        \n        \n        <link rel=\"canonical\" href=\"https://www.nejm.org/doi/full/10.1056/NEJMoa2110475\"/>\n    \n    \n\n\n\n\n\n\n<script src=\"//scholar.google.com/scholar_js/casa.js\" async></script>\n\n<script type=\"text/javascript\">var mmsData = {\"access\":{\"isFreeCountry\":\"n\"},\"ad\":{\"category\":\"article\"},\"imageChallenge\":{\"id\":null},\"article\":{\"doi\":\"10.1056/NEJMoa2110475\",\"title\":\"Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting\",\"category\":\"Research\",\"type\":\"Original Article\",\"topics\":\"Vaccines|Coronavirus|Cardiomyopathy/Myocarditis/Pericarditis\",\"specialties\":\"Cardiology|Infectious Disease\",\"seriesTitle\":\"\",\"viewType\":\"Full\",\"age\":\"2Years-1990\",\"issueDate\":\"2021-09-16T00:00Z\",\"isFree\":\"y\",\"broadTopics\":\"\",\"perspectiveTopics\":\"\",\"granularTopics\":\"\",\"methodologicalArea\":\"\",\"isOnlineFirst\":\"n\",\"isCurrentIssue\":\"n\"},\"page\":{\"activity\":\"showFullText\",\"url\":\"www.nejm.org/doi/full/10.1056/nejmoa2110475\",\"viewType\":\"desktop\",\"journal\":\"NEJM\"},\"user\":{\"ucid\":null,\"audienceSegment\":null,\"specialtyGroupCode\":null,\"meterCountRemaining\":null,\"totalMeterCount\":null},\"object\":[]};</script>\n    <script type=\"text/javascript\">var mmsDataAdd = {\"user\":{\"customerType\":\"null\",\"accessInstitutionID\":\"null\"}};</script>\n    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->\n    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--\n  Adobe Target - Prehiding Snippet\n  v2.0.0\n-->\n<script>\nfunction tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName(\"head\")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement(\"style\");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf(\"mboxDisable\")>-1?(a(d(),t),console.log(\"[TARGET] - Disabled, removing prehiding style\")):(m=function(e){e&&(a(d(),t),console.log(\"[TARGET] - Blocked, removing prehiding style\"))},fetch(\"//cdn.tt.omtrdc.net/cdn/target-vec.js\",{method:\"HEAD\",mode:\"no-cors\"}).then(e=>m(!1)).catch(e=>m(!0)))}\n\ntgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name=\"Anonymous Module\"], div[data-location-name=\"Anonymous Banner\"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*=\"u-hide\"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*=\"/10.1056/NEJMoa2116747\"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);\n\ntgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);\n</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->\n    <!-- Launch Header Embed Code -->\n    <script src=\"//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js\" async></script>\n    <!-- /Launch Header Embed Code -->\n<link rel=\"schema.DC\" href=\"http://purl.org/DC/elements/1.0/\"></link><meta name=\"citation_journal_title\" content=\"New England Journal of Medicine\"></meta><meta name=\"dc.Title\" content=\"Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting\"></meta><meta name=\"dc.Creator\" content=\"Noam Barda\"></meta><meta name=\"dc.Creator\" content=\"Noa Dagan\"></meta><meta name=\"dc.Creator\" content=\"Yatir Ben-Shlomo\"></meta><meta name=\"dc.Creator\" content=\"Eldad Kepten\"></meta><meta name=\"dc.Creator\" content=\"Jacob Waxman\"></meta><meta name=\"dc.Creator\" content=\"Reut Ohana\"></meta><meta name=\"dc.Creator\" content=\"Miguel A. Hernán\"></meta><meta name=\"dc.Creator\" content=\"Marc Lipsitch\"></meta><meta name=\"dc.Creator\" content=\"Isaac Kohane\"></meta><meta name=\"dc.Creator\" content=\"Doron Netzer\"></meta><meta name=\"dc.Creator\" content=\"Ben Y. Reis\"></meta><meta name=\"dc.Creator\" content=\"Ran D. Balicer\"></meta><meta name=\"dc.Description\" content=\"Preapproval trials showed that messenger RNA (mRNA)–based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet these trials were subject to s...\"></meta><meta name=\"Description\" content=\"Preapproval trials showed that messenger RNA (mRNA)–based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet these trials were subject to s...\"></meta><meta name=\"dc.Publisher\" content=\"Massachusetts Medical Society\"></meta><meta name=\"dc.Date\" scheme=\"WTN8601\" content=\"2021-09-16\"></meta><meta name=\"dc.Type\" content=\"research-article\"></meta><meta name=\"dc.Format\" content=\"text/HTML\"></meta><meta name=\"dc.Identifier\" scheme=\"doi\" content=\"10.1056/NEJMoa2110475\"></meta><meta name=\"dc.Identifier\" scheme=\"publisher-id\" content=\"NJ202109163851206\"></meta><meta name=\"dc.Language\" content=\"EN\"></meta><meta name=\"dc.Relation\" content=\"10.1056/NEJMe2112543\"></meta><meta name=\"dc.Relation\" content=\"YXQYoa2110475\"></meta><meta name=\"dc.Coverage\" content=\"world\"></meta><meta name=\"dc.Rights\" content=\"Copyright © 2021 Massachusetts Medical Society. All rights reserved.\"></meta>\n\n\n\n\n<link rel=\"meta\" type=\"application/atom+xml\" href=\"https://doi.org/10.1056%2FNEJMoa2110475\"></link>\n<link rel=\"meta\" type=\"application/rdf+json\" href=\"https://doi.org/10.1056%2FNEJMoa2110475\"></link>\n<link rel=\"meta\" type=\"application/unixref+xml\" href=\"https://doi.org/10.1056%2FNEJMoa2110475\"></link>\n\n\n<meta charset=\"UTF-8\">\n\n\n\n\n\n\n<meta name=\"robots\" content=\"noarchive\"/>\n\n\n\n\n\n    \n\n\n\n\n\n    \n    \n        \n        <meta name=\"twitter:title\" content=\"Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting &#124; NEJM\">\n        <meta property=\"og:title\" content=\"Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting &#124; NEJM\"/>\n    \n\n\n    <meta property=\"og:type\" content=\"article\" />\n\n\n    \n    \n        <meta property=\"og:url\" content=\"https://www.nejm.org/doi/full/10.1056/nejmoa2110475\"/>\n    \n    \n\n\n    \n    \n        <meta property=\"og:image\" content=\"https://www.nejm.org/cms/asset/03921378-0cc4-472f-ac47-21060786e63e/nejmoa2110475_f1.jpg\" />\n        <meta name=\"twitter:image\" content=\"https://www.nejm.org/cms/asset/03921378-0cc4-472f-ac47-21060786e63e/nejmoa2110475_f1.jpg\" />\n    \n\n\n\n    <meta property=\"og:site_name\" content=\"The New England Journal of Medicine\" />\n\n\n    \n    \n        \n        <meta property=\"og:description\" content=\"Preapproval trials showed that messenger RNA (mRNA)&ndash;based vaccines against severe\nacute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet\nthese trials were subject to s...\"/>\n        <meta name=\"twitter:description\" content=\"Preapproval trials showed that messenger RNA (mRNA)&ndash;based vaccines against severe\nacute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet\nthese trials were subject to s...\">\n    \n\n\n    \n    \n        <meta property=\"og:image:width\" content=\"988\">\n    \n\n\n    \n    \n        <meta property=\"og:image:height\" content=\"1500\">\n    \n\n\n    <meta name=\"twitter:card\" content=\"summary\">\n\n\n    <meta name=\"twitter:site\" content=\"@NEJM\">\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1\"><meta name=\"citation_fulltext_world_readable\" content=\"\"/>\n    <meta name=\"publication_doi\" content=\"10.1056/NEJMoa2110475\"/>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n<meta name=\"pbContext\" content=\";requestedJournal:journal:nejm;issue:issue:doi\\:10.1056/nejm_2021.385.issue-12;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:doi\\:10.1056/NEJMoa2110475;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms\"/></head>\n        <body class=\"pb-ui website-mms-site\">\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n<input type=\"hidden\" id=\"isRoMode\" name=\"isRoMode\" value=\"false\">\n    <div id=\"pb-page-content\" data-ng-non-bindable>\n        <div data-pb-dropzone=\"main\" data-pb-dropzone-name=\"Main\">\n\n\n\n\n        \n        <header data-sticky=\"false\" class=\"ng-header js_stickyAd\"><a href=\"#mainContent\" class=\"ng-skipToMainContent\">Skip to main content</a><div class=\"ng-header_topAd\"><div class=\"ng-header_topAd-content d-flex justify-content-center align-items-center\">\n\n\n\n        \n        <div id=\"DTM_Position_Topbanner\" class=\"ad\"></div>\n</div></div><div class=\"ng-header_logoBar\"><div class=\"container-fluid\"><div class=\"row\"><div data-location=\"logo\" class=\"ng-header_logoBar_left col-6 d-flex align-items-center\"><a href=\"/\" title=\"The New England Journal of Medicine homepage\" class=\"ng-header_logo-link\"><img src=\"/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg\" alt=\"The New England Journal of Medicine homepage\" class=\"ng-header_logo-image\"/></a></div><div class=\"ng-header_logoBar_right col-6 col-6 d-flex align-items-center justify-content-end\"><div class=\"ng-header_instBanner d-none d-xl-block\"></div><div class=\"ng-header_topRightAd d-none d-md-block\">\n\n\n\n\n\n\n\n\n\n    \n    \n        <div data-widget-def=\"literatumAd\" data-widget-id=\"b6b84e08-27cc-42dd-9b33-252dc352b0be\" class=\"ad-global-top-right-240x64-1\" data-location=\"ad_global_top_right\">\n        \n\n\n\n        \n        \n\n\n\n    \n        <div class=\"pb-house-message adplaceholder exists\">\n            \n<!-- START: Global Header -->\n<style> \n.bads_global-header--007 {\n    background: url(/pb-assets/contextual_messaging/global-header-yell-background-2x-1513956907243.jpg)no-repeat center center;\n    background-size: cover;\n    padding: 7px 0 7px 15px;\n    display: block;\n    margin: 0;\n    position: relative;\n    color: 000;\n    text-align: left;\n    height: 64px;\n    width: 240px;\n}\n\n.bads_global-header--007 .bads_global-header-image {\n    position: relative;\n    padding-right: 110px\n}\n\n.bads_global-header--007 .bads_global-header-image>a {\n    width: 92px;\n    display: block;\n    height: auto;\n    position: absolute;\n    right: 0;\n    top: -1px;\n}\n\n.bads_global-header--007 .bads_global-header-image>a>img {\n    display: block;\n    max-width: 100%;\n    height: auto\n}\n\n.bads_global-header--007 .bads_global-header-text {\n    padding: 15px 0\n}\n.bads_global-header--007 .bads_global-header-text>p {\n    text-transform: uppercase;\n    margin: 0;\n    font-size: 14px;\n    line-height: 18px;\n    color: #000;\n    font-family: ff-scala-sans-pro,ff-scala-sans-web-pro, Helvetica, Arial, sans-serif;\n    font-weight: 700;\n    letter-spacing: .3px\n}\n.bads_global-header--007 .bads_global-header-text .a-btn {\n    width: 24px;\n    height: 24px;\n    min-width: 24px;\n    padding: 0;\n    background: transparent!important;\n    float: right;\n    margin-top: -3px;\n    color: #000!important\n}\n.bads_global-header--007 .bads_global-header-text .a-btn .icon-component {\n    position: static;\n    margin-top: 16px\n}\n.bads_global-header--007 .bads_clink {\n    color: inherit!important;\n    text-decoration: none!important;\n    display: inline-block!important;\n    vertical-align: middle!important\n}\n.bads_global-header--007 .bads_global-header-image>a {\n    width: 70px}\n\n.bads_global-header--007 .bads_global-header-text {\n    padding: 5px 0}\n\n.bads_global-header--007 .bads_global-header-image {\n    padding-right: 100px\n}\n@media screen and (min-width:320px) and (max-width:767px) {\n.bads_global-header--007 {   width: 100%;    min-height: 64px;}\n.bads_global-header--007 .bads_global-header-text p {font-size: 18px; line-height: 42px;}\n.bads_global-header--007 .bads_clink br {display: none;}\n.bads_global-header--007 .bads_global-header-text .a-btn {float: none;}\n.bads_global-header--007 .bads_global-header-text .a-btn .icon-component {\n     margin-top: 0;}\n}\n</style>\n<div class=\"bads_global-header--007\" data-location=\"ad_global_top_right\"> \n <div class=\"bads_global-header-image\"> <a href=\"/action/clickThrough?id=125703&url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252Fnejmoa2110475%26promo%3DONFQNRH5&loc=%2Fdoi%2Ffull%2F10.1056%2Fnejmoa2110475&pubId=41290331&placeholderId=101351&productId=1058\" data-interactiontype=\"subscribe_click\" data-element-name=\"image\"><img src=\"/pb-assets/contextual_messaging/device-glbal-header-2x-1515103614157.png\" alt=\"Device Global Header\"></a>\n  <div class=\"bads_global-header-text\">\n   <p><a class=\"bads_clink\" href=\"/action/clickThrough?id=125703&url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26promo%3DONFQNRH5&loc=%2Fdoi%2Ffull%2F10.1056%2Fnejmoa2110475&pubId=41290331&placeholderId=101351&productId=1058\" data-interactiontype=\"subscribe_click\">Subscribe<br>\n    or Renew</a> <a href=\"/action/clickThrough?id=125703&url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252Fnejmoa2110475%26promo%3DONFQNRH5&loc=%2Fdoi%2Ffull%2F10.1056%2Fnejmoa2110475&pubId=41290331&placeholderId=101351&productId=1058\" data-interactiontype=\"subscribe_click\" data-element-name=\"arrow\" class=\"a-btn \">\n    <span class=\"icon-component\"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight\"></use></svg></span>\n    </a></p>\n  </div>\n </div>\n</div>\n<!--/END: Global Header -->\n            \n        </div>\n    \n\n    \n\n    \n\n\n\n        </div>\n    \n\n</div><div class=\"ng-header_openCloseBtns text-right d-block d-xl-none\"><button class=\"ng-header_openBtn\"><span class=\"icon-component \"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-a5d5b6d8a6cc46cb61c3d16941f26e75.spritemap.svg#burger\"></use></svg></span></button><button class=\"ng-header_closeBtn\"><span class=\"icon-component \"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-a5d5b6d8a6cc46cb61c3d16941f26e75.spritemap.svg#close\"></use></svg></span></button></div></div></div></div></div><div class=\"ng-header_navBar\"><div class=\"ng-header_navBar-content\"><div class=\"container-fluid\"><div class=\"row\"><div class=\"ng-header_instBanner-md col-12 d-block d-xl-none\"></div><div class=\"ng-header_loginBar-md col-12 d-block d-xl-none\"></div><div class=\"ng-header_quickSearch col-12\"><div class=\"ng-header_quickSearch-content\">\n\n\n\n        \n        <div class=\"ng-quick-search js-ng-quick-search\"><form action=\"/search\" method=\"get\" class=\"ng-quick-search_form js-form\"><div class=\"ng-quick-search_inputArea js-inputArea\"><input type=\"search\" name=\"q\" placeholder=\"Enter keyword, author, title or citation\" autocomplete=\"off\" value=\"\" required=\"required\" class=\"ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl\"/><button type=\"submit\" class=\"ng-quick-search_iconBtn d-xl-none d-block js-submitBtn\"><span class=\"icon-component \"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-a5d5b6d8a6cc46cb61c3d16941f26e75.spritemap.svg#search\"></use></svg></span></button></div><div class=\"ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end\"><a href=\"/search/advanced\" class=\"ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink\">Advanced Search</a><button type=\"submit\" class=\"ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn\"><span class=\"ng-btn_text\">SEARCH</span><span class=\"icon-component \"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-a5d5b6d8a6cc46cb61c3d16941f26e75.spritemap.svg#arrows-right\"></use></svg></span></button></div></form></div>\n</div></div><div class=\"ng-header_navBar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center\"><div class=\"ng-header_stickyLogo mr-32\"><a href=\"/\" title=\"The New England Journal of Medicine homepage\" class=\"ng-header_stickyLogo-link\"><img src=\"/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg\" alt=\"The New England Journal of Medicine homepage\" class=\"ng-header_stickyLogo-image\"/></a></div><div class=\"ng-header_mainMenu\">\n\n\n\n\n\n\n\n\n\n    \n    \n        <div data-widget-def=\"menuWidget\" data-widget-id=\"97fb3983-db63-4b0b-97dd-d9bb7929fce1\" data-location=\"main_nav\">\n        \n\n\n\n        \n        <nav class=\"ng-menu\"><ul class=\"ng-menu_list ng-simple-menu\"><li class=\"ng-menu_list-item ng-simple-menu_item hasChildren\"><a href=\"/medical-specialties\" class=\"ng-simple-menu_mainLink\"><span class=\"ng-simple-menu_mainLink-text\">SPECIALTIES</span><span class=\"ng-simple-menu_mainLink-arrowIcon\"><span class=\"icon-component \"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-a5d5b6d8a6cc46cb61c3d16941f26e75.spritemap.svg#arrows-down\"></use></svg></span></span></a><div class=\"ng-simple-menu_dropblock\"><div class=\"ng-simple-menu_dropblock-cont\"><div class=\"ng-simple-menu_list\"><ul class=\"ng-simple-menu_list-items\"><li class=\"ng-simple-menu_list-item\"><a href=\"/browse/specialty/cardiology\" class=\"ng-simple-menu_list-link\">Cardiology</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/browse/specialty/clinical-medicine\" class=\"ng-simple-menu_list-link\">Clinical Medicine</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/browse/specialty/emergency-medicine\" class=\"ng-simple-menu_list-link\">Emergency Medicine</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/browse/specialty/endocrinology\" class=\"ng-simple-menu_list-link\">Endocrinology</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/browse/specialty/gastroenterology\" class=\"ng-simple-menu_list-link\">Gastroenterology</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/browse/specialty/hematology-oncology\" class=\"ng-simple-menu_list-link\">Hematology/Oncology</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/browse/specialty/infectious-disease\" class=\"ng-simple-menu_list-link\">Infectious Disease</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/browse/specialty/nephrology\" class=\"ng-simple-menu_list-link\">Nephrology</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/browse/specialty/neurology-neurosurgery\" class=\"ng-simple-menu_list-link\">Neurology/Neurosurgery</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/browse/specialty/obstetrics-gynecology\" class=\"ng-simple-menu_list-link\">Obstetrics/Gynecology</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/browse/specialty/pediatrics\" class=\"ng-simple-menu_list-link\">Pediatrics</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/browse/specialty/pulmonary-critical-care\" class=\"ng-simple-menu_list-link\">Pulmonary/Critical Care</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/medical-specialties\" class=\"ng-simple-menu_list-link\">View All Specialties</a></li></ul></div></div></div></li><li class=\"ng-menu_list-item ng-simple-menu_item hasChildren\"><a href=\"/topics\" class=\"ng-simple-menu_mainLink\"><span class=\"ng-simple-menu_mainLink-text\">TOPICS</span><span class=\"ng-simple-menu_mainLink-arrowIcon\"><span class=\"icon-component \"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-a5d5b6d8a6cc46cb61c3d16941f26e75.spritemap.svg#arrows-down\"></use></svg></span></span></a><div class=\"ng-simple-menu_dropblock\"><div class=\"ng-simple-menu_dropblock-cont\"><div class=\"ng-simple-menu_list\"><ul class=\"ng-simple-menu_list-items\"><li class=\"ng-simple-menu_list-item\"><a href=\"/ai-in-medicine\" class=\"ng-simple-menu_list-link\">AI in Medicine</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/browse/specialty/climate-change\" class=\"ng-simple-menu_list-link\">Climate Crisis and Health</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/coronavirus\" class=\"ng-simple-menu_list-link\">Coronavirus</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/fundamentals-of-health-law\" class=\"ng-simple-menu_list-link\">Fundamentals of Health Law</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/fundamentals-of-medical-ethics\" class=\"ng-simple-menu_list-link\">Fundamentals of Medical Ethics</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/gray-matters\" class=\"ng-simple-menu_list-link\">Gray Matters</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/browse/specialty/health-policy\" class=\"ng-simple-menu_list-link\">Health Policy</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/medicine-and-society\" class=\"ng-simple-menu_list-link\">Medicine and Society</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/nutrition-in-medicine\" class=\"ng-simple-menu_list-link\">Nutrition in Medicine</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/race-and-medicine\" class=\"ng-simple-menu_list-link\">Race and Medicine</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/recognizing-historical-injustices\" class=\"ng-simple-menu_list-link\">Recognizing Historical Injustices and the Journal</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/topics\" class=\"ng-simple-menu_list-link\">View All Topics</a></li></ul></div></div></div></li><li class=\"ng-menu_list-item ng-simple-menu_item hasChildren\"><a href=\"/multimedia\" class=\"ng-simple-menu_mainLink\"><span class=\"ng-simple-menu_mainLink-text\">MULTIMEDIA</span><span class=\"ng-simple-menu_mainLink-arrowIcon\"><span class=\"icon-component \"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-a5d5b6d8a6cc46cb61c3d16941f26e75.spritemap.svg#arrows-down\"></use></svg></span></span></a><div class=\"ng-simple-menu_dropblock\"><div class=\"ng-simple-menu_dropblock-cont\"><div class=\"ng-simple-menu_list\"><ul class=\"ng-simple-menu_list-items\"><li class=\"ng-simple-menu_list-item\"><a href=\"/rss-feed\" class=\"ng-simple-menu_list-link\">Podcasts</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/double-take\" class=\"ng-simple-menu_list-link\">Double Takes</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"https://illustrated-glossary.nejm.org/\" class=\"ng-simple-menu_list-link\">Illustrated Glossary</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/image-challenge\" class=\"ng-simple-menu_list-link\">Image Challenge</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/browse/nejm-media-type/images-in-clinical-medicine\" class=\"ng-simple-menu_list-link\">Images in Clinical Medicine</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/browse/nejm-media-type/interactive-medical-case\" class=\"ng-simple-menu_list-link\">Interactive Medical Cases</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/plain-language-research-summaries\" class=\"ng-simple-menu_list-link\">Plain Language/Research Summaries</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/multimedia/quick-take-video\" class=\"ng-simple-menu_list-link\">Quick Takes</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/browse/nejm-media-type/videos-in-clinical-medicine\" class=\"ng-simple-menu_list-link\">Videos in Clinical Medicine</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/multimedia\" class=\"ng-simple-menu_list-link\">View All Multimedia</a></li></ul></div></div></div></li><li class=\"ng-menu_list-item ng-simple-menu_item hasChildren\"><a href=\"/toc/nejm/current\" class=\"ng-simple-menu_mainLink\"><span class=\"ng-simple-menu_mainLink-text\">current issue</span><span class=\"ng-simple-menu_mainLink-arrowIcon\"><span class=\"icon-component \"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-a5d5b6d8a6cc46cb61c3d16941f26e75.spritemap.svg#arrows-down\"></use></svg></span></span></a><div class=\"ng-simple-menu_dropblock\"><div class=\"ng-simple-menu_dropblock-cont\"><div class=\"ng-simple-menu_list\"><ul class=\"ng-simple-menu_list-items\"><li class=\"ng-simple-menu_list-item\"><a href=\"/toc/nejm/current\" class=\"ng-simple-menu_list-link\">CURRENT ISSUE</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/toc/nejm/recently-published\" class=\"ng-simple-menu_list-link\">BROWSE RECENTLY PUBLISHED</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/loi/nejm\" class=\"ng-simple-menu_list-link\">BROWSE FULL ISSUE INDEX</a></li></ul></div></div></div></li><li class=\"ng-menu_list-item ng-simple-menu_item hasChildren\"><a href=\"/learning\" class=\"ng-simple-menu_mainLink\"><span class=\"ng-simple-menu_mainLink-text\">LEARNING/CME</span><span class=\"ng-simple-menu_mainLink-arrowIcon\"><span class=\"icon-component \"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-a5d5b6d8a6cc46cb61c3d16941f26e75.spritemap.svg#arrows-down\"></use></svg></span></span></a><div class=\"ng-simple-menu_dropblock\"><div class=\"ng-simple-menu_dropblock-cont\"><div class=\"ng-simple-menu_list\"><ul class=\"ng-simple-menu_list-items\"><li class=\"ng-simple-menu_list-item\"><a href=\"/continuing-medical-education\" class=\"ng-simple-menu_list-link\">Weekly CME</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"https://www.nejm.org/cme-ce/obesity\" class=\"ng-simple-menu_list-link\">Obesity CME/CE</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"/learning\" class=\"ng-simple-menu_list-link\">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class=\"ng-menu_list-item ng-simple-menu_item\"><a href=\"/author-center/home\" class=\"ng-simple-menu_mainLink\"><span class=\"ng-simple-menu_mainLink-text\">AUTHOR CENTER</span></a></li><li class=\"ng-menu_list-item ng-simple-menu_item hasChildren\"><a class=\"ng-simple-menu_mainLink\"><span class=\"ng-simple-menu_mainLink-text\">Publications</span><span class=\"ng-simple-menu_mainLink-arrowIcon\"><span class=\"icon-component \"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-a5d5b6d8a6cc46cb61c3d16941f26e75.spritemap.svg#arrows-down\"></use></svg></span></span></a><div class=\"ng-simple-menu_dropblock\"><div class=\"ng-simple-menu_dropblock-cont\"><div class=\"ng-simple-menu_list\"><ul class=\"ng-simple-menu_list-items\"><li class=\"ng-simple-menu_list-item\"><a href=\"https://catalyst.nejm.org/\" class=\"ng-simple-menu_list-link\">NEJM Catalyst</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"https://evidence.nejm.org/\" class=\"ng-simple-menu_list-link\">NEJM Evidence</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"https://ai.nejm.org/\" class=\"ng-simple-menu_list-link\">NEJM AI</a></li><li class=\"ng-simple-menu_list-item\"><a href=\"https://www.jwatch.org/\" class=\"ng-simple-menu_list-link\">NEJM Journal Watch</a></li></ul></div></div></div></li></ul></nav>\n\n        </div>\n    \n\n</div><button aria-label=\"Search\" class=\"ng-header_searchBtn d-none d-xl-block ml-24\"><span class=\"icon-component \"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-a5d5b6d8a6cc46cb61c3d16941f26e75.spritemap.svg#search\"></use></svg></span></button></div><div class=\"ng-header_navBar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end\"><div class=\"ng-header_loginBar d-xl-flex align-items-lg-center\">\n\n\n\n        \n        <div data-location=\"authstring_nav\" class=\"ng-header_loginBar-menu\"><span class=\"ng-header_loginBar-signIn\"><a href=\"/sign-in?uri=/doi/full/10.1056/nejmoa2110475\" class=\"ng-header_loginBar-signIn-link\">Sign In</a></span><span class=\"ng-header_loginBar-separator\">|</span><span class=\"ng-header_loginBar-createAcc\"><a href=\"/action/storeProxy?action=register&amp;promo=ONFLNRC1\" class=\"ng-header_loginBar-createAcc-link ro-mode_disabled\">Create Account</a></span></div><div data-location=\"authstring_nav\" class=\"ng-header_loginBar-subscribe pl-xl-16\"><a href=\"/action/storeProxy?action=subscribe&promo=ONF4NRS1\" class=\"ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled\">Subscribe</a></div>\n</div></div><div class=\"ng-header_mobileAd col-12 pl-0 pr-0\">\n\n\n\n\n\n\n\n\n\n    \n    \n        <div data-widget-def=\"literatumAd\" data-widget-id=\"d65290e9-3904-4074-8b9b-67fb7e3bd285\" class=\"ad-global-top-right-240x64-1\" data-location=\"ad_global_top_right\">\n        \n\n\n\n        \n        \n\n\n\n    \n        <div class=\"pb-house-message adplaceholder exists\">\n            \n<!-- START: Global Header -->\n<style> \n.bads_global-header--007 {\n    background: url(/pb-assets/contextual_messaging/global-header-yell-background-2x-1513956907243.jpg)no-repeat center center;\n    background-size: cover;\n    padding: 7px 0 7px 15px;\n    display: block;\n    margin: 0;\n    position: relative;\n    color: 000;\n    text-align: left;\n    height: 64px;\n    width: 240px;\n}\n\n.bads_global-header--007 .bads_global-header-image {\n    position: relative;\n    padding-right: 110px\n}\n\n.bads_global-header--007 .bads_global-header-image>a {\n    width: 92px;\n    display: block;\n    height: auto;\n    position: absolute;\n    right: 0;\n    top: -1px;\n}\n\n.bads_global-header--007 .bads_global-header-image>a>img {\n    display: block;\n    max-width: 100%;\n    height: auto\n}\n\n.bads_global-header--007 .bads_global-header-text {\n    padding: 15px 0\n}\n.bads_global-header--007 .bads_global-header-text>p {\n    text-transform: uppercase;\n    margin: 0;\n    font-size: 14px;\n    line-height: 18px;\n    color: #000;\n    font-family: ff-scala-sans-pro,ff-scala-sans-web-pro, Helvetica, Arial, sans-serif;\n    font-weight: 700;\n    letter-spacing: .3px\n}\n.bads_global-header--007 .bads_global-header-text .a-btn {\n    width: 24px;\n    height: 24px;\n    min-width: 24px;\n    padding: 0;\n    background: transparent!important;\n    float: right;\n    margin-top: -3px;\n    color: #000!important\n}\n.bads_global-header--007 .bads_global-header-text .a-btn .icon-component {\n    position: static;\n    margin-top: 16px\n}\n.bads_global-header--007 .bads_clink {\n    color: inherit!important;\n    text-decoration: none!important;\n    display: inline-block!important;\n    vertical-align: middle!important\n}\n.bads_global-header--007 .bads_global-header-image>a {\n    width: 70px}\n\n.bads_global-header--007 .bads_global-header-text {\n    padding: 5px 0}\n\n.bads_global-header--007 .bads_global-header-image {\n    padding-right: 100px\n}\n@media screen and (min-width:320px) and (max-width:767px) {\n.bads_global-header--007 {   width: 100%;    min-height: 64px;}\n.bads_global-header--007 .bads_global-header-text p {font-size: 18px; line-height: 42px;}\n.bads_global-header--007 .bads_clink br {display: none;}\n.bads_global-header--007 .bads_global-header-text .a-btn {float: none;}\n.bads_global-header--007 .bads_global-header-text .a-btn .icon-component {\n     margin-top: 0;}\n}\n</style>\n<div class=\"bads_global-header--007\" data-location=\"ad_global_top_right\"> \n <div class=\"bads_global-header-image\"> <a href=\"/action/clickThrough?id=125703&url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252Fnejmoa2110475%26promo%3DONFQNRH5&loc=%2Fdoi%2Ffull%2F10.1056%2Fnejmoa2110475&pubId=41290331&placeholderId=101351&productId=1058\" data-interactiontype=\"subscribe_click\" data-element-name=\"image\"><img src=\"/pb-assets/contextual_messaging/device-glbal-header-2x-1515103614157.png\" alt=\"Device Global Header\"></a>\n  <div class=\"bads_global-header-text\">\n   <p><a class=\"bads_clink\" href=\"/action/clickThrough?id=125703&url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26promo%3DONFQNRH5&loc=%2Fdoi%2Ffull%2F10.1056%2Fnejmoa2110475&pubId=41290331&placeholderId=101351&productId=1058\" data-interactiontype=\"subscribe_click\">Subscribe<br>\n    or Renew</a> <a href=\"/action/clickThrough?id=125703&url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252Fnejmoa2110475%26promo%3DONFQNRH5&loc=%2Fdoi%2Ffull%2F10.1056%2Fnejmoa2110475&pubId=41290331&placeholderId=101351&productId=1058\" data-interactiontype=\"subscribe_click\" data-element-name=\"arrow\" class=\"a-btn \">\n    <span class=\"icon-component\"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight\"></use></svg></span>\n    </a></p>\n  </div>\n </div>\n</div>\n<!--/END: Global Header -->\n            \n        </div>\n    \n\n    \n\n    \n\n\n\n        </div>\n    \n\n</div></div></div></div></div></header><div class=\"ng-header_overlay\"></div><div class=\"ng-header_after\">\n\n\n\n\n\n\n\n\n\n    \n    \n        <div data-widget-def=\"literatumAd\" data-widget-id=\"4931ddbd-d46e-4597-b4fd-92549e9847ca\" id=\"ad-global-banner-FULLx64-1\">\n        \n\n\n\n        \n        \n\n\n\n    \n\n    \n\n    \n        \n    \n\n\n\n        </div>\n    \n\n</div>\n\n\n\n\n        \n        <div>\n\n\n\n\n\n\n\n\n\n    \n    \n        <main data-widget-def=\"axelPublicationContent\" data-widget-id=\"fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1\" id=\"mainContent\">\n        \n\n\n\n        \n        <div class=\"article-tools__savePopup\"><div class=\"ng-save\"><input type=\"hidden\" value=\"/action/getSavedTags\" class=\"getKeywordsServiceUrl\"/><input type=\"hidden\" value=\"/action/mmsSaveItemsService?itemType=article\" class=\"saveServiceUrl\"/><input type=\"hidden\" value=\"article\" class=\"saveType\"/><input type=\"hidden\" value=\"10.1056/NEJMoa2110475\" class=\"inputDoi\"/><input type=\"hidden\" value=\"N. Barda and Others\" class=\"inputAuthor\"/><input type=\"hidden\" value=\"N Engl J Med 2021;385:1078-1090\" class=\"inputCitation\"/><input type=\"hidden\" value=\"08-25-2021\" class=\"inputEPubDate\"/><input type=\"hidden\" value=\"September 2021\" class=\"inputCoverDate\"/><input type=\"hidden\" value=\"Original Article\" class=\"inputContentType\"/><input type=\"hidden\" value=\"Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting\" class=\"inputArticleTitle\"/><input type=\"hidden\" value=\"/browse/nejm-article-type/original-article\" class=\"inputContentTypeUrl\"/><button type=\"button\" id=\"saveArticleShowPopupBtn\" disabled=\"disabled\" class=\"ng-save-btn ng-btn_secondary isLoggedOut\">Save</button></div></div><div class=\"article-tools__articleAlertPopup\"><div id=\"articleAlertModal\" tabindex=\"-1\" role=\"dialog\" aria-labelledby=\"exampleModalCenterTitle\" aria-hidden=\"true\" class=\"ng-modal modal\"><div role=\"document\" class=\"ng-modal_dialog modal-dialog modal-dialog-centered\"><div class=\"ng-modal_content modal-content\"><div class=\"ng-modal_header modal-header\"><h5 id=\"articleAlertModalTitle\" class=\"ng-modal_title modal-title\">Create an E-mail Alert for This Article</h5><button type=\"button\" data-dismiss=\"modal\" aria-label=\"Close\" class=\"ng-modal_close close\"><span aria-hidden=\"true\"><span class=\"icon-component \"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-a5d5b6d8a6cc46cb61c3d16941f26e75.spritemap.svg#close\"></use></svg></span></span></button></div><div class=\"ng-modal_body modal-body\"></div></div></div></div></div><div class=\"ng-do-media_popup\"><div id=\"doPopup\" tabindex=\"-1\" role=\"dialog\" aria-labelledby=\"exampleModalCenterTitle\" aria-hidden=\"true\" class=\"ng-modal modal\"><div role=\"document\" class=\"ng-modal_dialog modal-dialog modal-dialog-centered\"><div class=\"ng-modal_content modal-content\"><div class=\"ng-modal_header modal-header\"><button type=\"button\" data-dismiss=\"modal\" aria-label=\"Close\" class=\"ng-modal_close close\"><span aria-hidden=\"true\"><span class=\"icon-component \"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-a5d5b6d8a6cc46cb61c3d16941f26e75.spritemap.svg#close\"></use></svg></span></span></button></div><div class=\"ng-modal_body modal-body\"></div></div></div></div></div><link id=\"build-style-article\" rel=\"stylesheet\" type=\"text/css\" href=\"/products/mms-nextgen/mms/releasedAssets/css/build-article-e661706876996e0d3688.css\"/><article xmlns=\"http://www.w3.org/1999/xhtml\" data-design=\"pill\" data-has=\"right-rail\" data-type=\"research-article\" vocab=\"http://schema.org/\" typeof=\"ScholarlyArticle\" lang=\"en\" dir=\"ltr\"><header data-extent=\"frontmatter\" data-location=\"header_article\"><div class=\"core-container\"><div data-article-access=\"free\" data-article-access-type=\"free\" class=\"meta-panel\"><div class=\"meta-panel__left-content\"><div class=\"meta-panel__type\"><a href=\"/browse/nejm-article-type/original-article\">Original Article</a></div></div><div class=\"meta-panel__right-content\"><div class=\"meta-panel__share\">\n\n\n\n\n\n\n\n\n\n    \n    \n        <div data-widget-def=\"UX3share\" data-widget-id=\"aaed4046-107e-4d7c-83c8-19a6841356e6\" data-location=\"share_tools_article\">\n        \n\n\n\n        \n        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type=\"text/javascript\" defer=\"defer\" src=\"https://static.addtoany.com/menu/page.js\"></script><div class=\"share\"><div class=\"share__block share__inline-links\"><div class=\"pb-dropzone\" data-pb-dropzone=\"shareBlock\" title=\"shareBlock\"></div><span class=\"sr-only\">Share on</span><ul class=\"d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32\"><li class=\"a2a_listitem_custom\"><a role=\"link\" title=\"Facebook\" data-interactiontype=\"social\" class=\"share__link a2a_button_facebook\"><i aria-hidden=\"true\" class=\"at-icon-wrapper icon-facebook\"></i></a></li><li class=\"a2a_listitem_custom\"><a role=\"link\" title=\"X (formerly Twitter)\" data-interactiontype=\"social\" class=\"share__link a2a_button_twitter\"><i aria-hidden=\"true\" class=\"at-icon-wrapper icon-twitter\"></i></a></li><li class=\"a2a_listitem_custom\"><a role=\"link\" title=\"Linked In\" data-interactiontype=\"social\" class=\"share__link a2a_button_linkedin\"><i aria-hidden=\"true\" class=\"at-icon-wrapper icon-LinkedIn2\"></i></a></li><li class=\"a2a_listitem_custom\"><a role=\"link\" title=\"Email\" data-interactiontype=\"content_email_click\" class=\"share__link a2a_button_email\"><i aria-hidden=\"true\" class=\"at-icon-wrapper icon-mail\"></i></a></li></ul></div></div>\n\n        </div>\n    \n\n</div></div></div><h1 property=\"name\">Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting</h1><div class=\"core-relations my-3\"></div><div class=\"contributors\"><span class=\"authors\"><span class=\"heading\">Authors</span>: <span role=\"list\"><span property=\"author\" typeof=\"Person\" role=\"listitem\"><span property=\"givenName\">Noam</span> <span property=\"familyName\">Barda</span>, <span property=\"honorificSuffix\">M.D.</span></span>, <span property=\"author\" typeof=\"Person\" role=\"listitem\"><span property=\"givenName\">Noa</span> <span property=\"familyName\">Dagan</span>, <span property=\"honorificSuffix\">M.D.</span> <a class=\"orcid-id\" href=\"https://orcid.org/0000-0001-8811-7825\" property=\"identifier\" aria-label=\"ORCID identifier\" target=\"_blank\">https://orcid.org/0000-0001-8811-7825</a></span>, <span property=\"author\" typeof=\"Person\" role=\"listitem\"><span property=\"givenName\">Yatir</span> <span property=\"familyName\">Ben-Shlomo</span>, <span property=\"honorificSuffix\">B.Sc.</span></span>, <span property=\"author\" typeof=\"Person\" role=\"listitem\"><span property=\"givenName\">Eldad</span> <span property=\"familyName\">Kepten</span>, <span property=\"honorificSuffix\">Ph.D.</span></span>, <span property=\"author\" typeof=\"Person\" role=\"listitem\"><span property=\"givenName\">Jacob</span> <span property=\"familyName\">Waxman</span>, <span property=\"honorificSuffix\">M.D.</span></span>, <span property=\"author\" typeof=\"Person\" role=\"listitem\"><span property=\"givenName\">Reut</span> <span property=\"familyName\">Ohana</span>, <span property=\"honorificSuffix\">M.Sc.</span></span>, <span property=\"author\" typeof=\"Person\" role=\"listitem\"><span property=\"givenName\">Miguel A.</span> <span property=\"familyName\">Hernán</span>, <span property=\"honorificSuffix\">M.D.</span> <a class=\"orcid-id\" href=\"https://orcid.org/0000-0003-1619-8456\" property=\"identifier\" aria-label=\"ORCID identifier\" target=\"_blank\">https://orcid.org/0000-0003-1619-8456</a></span>, <span property=\"author\" typeof=\"Person\" role=\"listitem\"><span property=\"givenName\">Marc</span> <span property=\"familyName\">Lipsitch</span>, <span property=\"honorificSuffix\">D.Phil.</span> <a class=\"orcid-id\" href=\"https://orcid.org/0000-0003-1504-9213\" property=\"identifier\" aria-label=\"ORCID identifier\" target=\"_blank\">https://orcid.org/0000-0003-1504-9213</a></span>, <span property=\"author\" typeof=\"Person\" role=\"listitem\"><span property=\"givenName\">Isaac</span> <span property=\"familyName\">Kohane</span>, <span property=\"honorificSuffix\">M.D.</span></span>, <span property=\"author\" typeof=\"Person\" role=\"listitem\"><span property=\"givenName\">Doron</span> <span property=\"familyName\">Netzer</span>, <span property=\"honorificSuffix\">M.D.</span></span>, <span property=\"author\" typeof=\"Person\" role=\"listitem\"><span property=\"givenName\">Ben Y.</span> <span property=\"familyName\">Reis</span>, <span property=\"honorificSuffix\">Ph.D.</span></span>, and <span property=\"author\" typeof=\"Person\" role=\"listitem\"><span property=\"givenName\">Ran D.</span> <span property=\"familyName\">Balicer</span>, <span property=\"honorificSuffix\">M.D.</span></span></span></span><a href=\"#tab-contributors\" class=\"to-authors-affiliations\" data-id=\"article-authors-viewall\">Author Info &amp; Affiliations</a></div><div class=\"core-self-citation\"><div class=\"core-date-published\">Published <span property=\"datePublished\">August 25, 2021</span></div><div property=\"isPartOf\" typeof=\"Periodical\"><span property=\"name\">N Engl J Med</span> 2021<span property=\"isPartOf\" typeof=\"PublicationVolume\">;<span property=\"volumeNumber\">385</span></span>:<span property=\"pageStart\">1078</span>-<span property=\"pageEnd\">1090</span></div><div class=\"doi\">DOI: 10.1056/NEJMoa2110475</div><div class=\"core-enumeration\"><a href=\"/toc/nejm/385/12\"><span property=\"isPartOf\" typeof=\"PublicationVolume\">VOL. <span property=\"volumeNumber\">385</span></span> <span property=\"isPartOf\" typeof=\"PublicationIssue\">NO. <span property=\"issueNumber\">12</span></span></a></div></div><div class=\"info-panel\"><div class=\"info-panel__left-content\"><div class=\"info-panel__metrics info-panel__item\"></div></div><div data-location=\"tools_article\" class=\"info-panel__right-content\"><div class=\"info-panel__article_tools info-panel__item\">\n\n\n\n        \n        <div data-permission=\"/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DNoam%2BBarda%252C%2BNoa%2BDagan%252C%2BYatir%2BBen-Shlomo%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D385%26issueNum%3D12%26contentID%3D10.1056%252FNEJMoa2110475%26title%3DSafety%2Bof%2Bthe%2BBNT162b2%2BmRNA%2BCovid-19%2BVaccine%2Bin%2Ba%2BNationwide%2BSetting%26publicationDate%3D09%252F16%252F2021\" class=\"article-tools\"><button id=\"articleToolsAlertBtn\" data-url=\"/action/addCitationAlert?doi=10.1056%2FNEJMoa2110475\" data-toggle=\"\" data-target=\"#articleAlertModal\" aria-label=\"Sign in or create account to add an article alert\" data-interactiontype=\"article_alert\" class=\"article-tools__citation btn btn--slim isLoggedOut\"><span title=\"Sign in or create account to add an article alert\" data-toggle=\"tooltip\" class=\"d-inline-block\"><span class=\"icon-component \"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-a5d5b6d8a6cc46cb61c3d16941f26e75.spritemap.svg#alerts\"></use></svg></span></span></button><button id=\"articleToolsSaveBtn\" data-toggle=\"modal\" data-target=\"#saveArticle\" aria-label=\"Sign in or create account to save this article\" data-interactiontype=\"article_tools_save_click\" class=\"article-tools__favorite btn btn--slim isLoggedOut\"><span title=\"Sign in or create account to save this article\" data-toggle=\"tooltip\" class=\"d-inline-block\"><span class=\"icon-component \"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-a5d5b6d8a6cc46cb61c3d16941f26e75.spritemap.svg#bookmarkFilled\"></use></svg></span></span></button><a href=\"/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DNoam%2BBarda%252C%2BNoa%2BDagan%252C%2BYatir%2BBen-Shlomo%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D385%26issueNum%3D12%26contentID%3D10.1056%252FNEJMoa2110475%26title%3DSafety%2Bof%2Bthe%2BBNT162b2%2BmRNA%2BCovid-19%2BVaccine%2Bin%2Ba%2BNationwide%2BSetting%26publicationDate%3D09%252F16%252F2021\" target=\"_blank\" title=\"Permissions\" data-toggle=\"tooltip\" aria-label=\"Permissions\" data-interactiontype=\"article_tools_permissions_click\" class=\"article-tools__permissions btn btn--slim\"><span class=\"icon-component \"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-a5d5b6d8a6cc46cb61c3d16941f26e75.spritemap.svg#permissions\"></use></svg></span></a><a href=\"/about/reprints\" title=\"Reprints\" data-toggle=\"tooltip\" aria-label=\"Reprints\" data-interactiontype=\"article_tools_reprints_click\" class=\"article-tools__reprints btn btn--slim\"><span class=\"icon-component \"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-a5d5b6d8a6cc46cb61c3d16941f26e75.spritemap.svg#reprints\"></use></svg></span></a><a href=\"/cms/asset/9231f2cc-3860-4cc8-b8d4-4aef2307abd3/nejmoa2110475.pptx\" target=\"_blank\" title=\"Download Slides\" data-toggle=\"tooltip\" aria-label=\"Download Slides\" data-interactiontype=\"article_tools_slide_set_download\" data-multimedia-type=\"Article Slideset\" data-multimedia-filename=\"nejmoa2110475.pptx\" class=\"article-tools__downloadSlides btn btn--slim\"><span class=\"icon-component \"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-a5d5b6d8a6cc46cb61c3d16941f26e75.spritemap.svg#download\"></use></svg></span></a><div class=\"article-tools__permissionsPopup\"><div id=\"permissionsModal\" tabindex=\"-1\" role=\"dialog\" aria-labelledby=\"exampleModalCenterTitle\" aria-hidden=\"true\" class=\"ng-modal modal\"><div role=\"document\" class=\"ng-modal_dialog modal-dialog modal-dialog-centered\"><div class=\"ng-modal_content modal-content\"><div class=\"ng-modal_header modal-header\"><h5 id=\"permissionsModalTitle\" class=\"ng-modal_title modal-title\">Permissions</h5><button type=\"button\" data-dismiss=\"modal\" aria-label=\"Close\" class=\"ng-modal_close close\"><span aria-hidden=\"true\"><span class=\"icon-component \"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-a5d5b6d8a6cc46cb61c3d16941f26e75.spritemap.svg#close\"></use></svg></span></span></button></div><div class=\"ng-modal_body modal-body\">For permission requests, please contact NEJM Reprints at <a href=\"/cdn-cgi/l/email-protection#4a382f3a3823243e390a242f20276425382d\"><span class=\"__cf_email__\" data-cfemail=\"2e5c4b5e5c47405a5d6e404b444300415c49\">[email&#160;protected]</span></a></div></div></div></div></div></div>\n</div><div class=\"info-panel__citations info-panel__item\"><a href=\"#tab-citations\" title=\"View Citations\" data-toggle=\"tooltip\" aria-label=\"View Citations\" class=\"btn btn--slim\" data-interactiontype=\"article_tools_citation_download\" data-multimedia-type=\"Citation\"><i aria-hidden=\"true\" class=\"icon-format_quote\"></i></a></div><div class=\"info-panel__formats info-panel__item\"><a href=\"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2110475\" title=\"View PDF\" data-toggle=\"tooltip\" aria-label=\"View PDF\" class=\"btn btn--pdf btn--slim\" data-behavior=\"trackDownloadEvent\" data-doi=\"10.1056/NEJMoa2110475\" data-interactiontype=\"article_tools_download_pdf\" data-multimedia-type=\"Article PDF\" data-multimedia-filename=\"nejmoa2110475.pdf\"><i aria-hidden=\"true\" class=\"icon-PDF\"></i></a></div></div></div></div></header><div data-core-nav=\"header\" data-extent=\"frontmatter\"><ul class=\"core-nav-wrapper core-container\" role=\"menubar\" aria-label=\"Article navigation\"><li role=\"none\"><button data-id=\"article-toolbar-showhide\" aria-controls=\"article_sections_menu\" aria-expanded=\"false\" aria-haspopup=\"true\" aria-label=\"Toggle section navigation menu\" role=\"menuitem\"><i class=\"icon-list\" aria-hidden=\"true\"></i><span>Contents</span></button><nav id=\"article_sections_menu\" role=\"menu\" aria-label=\"Contents\" data-core-nav=\"article\"><ul role=\"group\"><li role=\"none\"><a role=\"menuitem\" href=\"#summary-abstract\">Abstract</a></li><li role=\"none\"><a role=\"menuitem\" href=\"#sec-1\">Methods</a></li><li role=\"none\"><a role=\"menuitem\" href=\"#sec-2\">Results</a></li><li role=\"none\"><a role=\"menuitem\" href=\"#sec-3\">Discussion</a></li><li role=\"none\"><a role=\"menuitem\" href=\"#backnotes\">Notes</a></li><li role=\"none\"><a role=\"menuitem\" href=\"#supplementary-materials\">Supplementary Material</a></li><li role=\"none\"><a role=\"menuitem\" href=\"#bibliography\">References</a></li></ul></nav></li><li role=\"group\" class=\"collateral-pill\"><div id=\"article_collateral_menu\" role=\"none\" data-location=\"tools_article\"><ul data-core-nav=\"collateral\" role=\"none\"><li role=\"none\"><a role=\"menuitem\" href=\"#core-collateral-info\" aria-label=\"Information &amp; Authors\" data-id=\"article-nav-menubar-info\" data-toggle=\"tooltip\" data-placement=\"left\" data-offset=\"4px, 16px\" data-original-title=\"Information &amp; Authors\" aria-disabled=\"true\" disabled=\"true\"><i aria-hidden=\"true\" class=\"icon-info\"></i><span class=\"sr-only\">Information &amp; Authors</span></a></li><li role=\"none\"><a role=\"menuitem\" href=\"#core-collateral-metrics\" aria-label=\"Metrics &amp; Citations\" data-id=\"article-nav-menubar-metrics\" data-toggle=\"tooltip\" data-placement=\"left\" data-offset=\"4px, 16px\" data-original-title=\"Metrics &amp; Citations\" aria-disabled=\"true\" disabled=\"true\"><i aria-hidden=\"true\" class=\"icon-timeline\"></i><span class=\"sr-only\">Metrics &amp; Citations</span></a></li><li role=\"none\"><a role=\"menuitem\" href=\"#core-collateral-fulltext-options\" aria-label=\"View Options\" data-id=\"article-nav-menubar-metrics\" data-toggle=\"tooltip\" data-placement=\"left\" data-offset=\"4px, 16px\" data-original-title=\"View Options\" aria-disabled=\"true\" disabled=\"true\"><i aria-hidden=\"true\" class=\"icon-eye\"></i><span class=\"sr-only\">View Options</span></a></li><li role=\"none\"><a role=\"menuitem\" href=\"#core-collateral-references\" aria-label=\"References\" data-id=\"article-nav-menubar-references\" data-toggle=\"tooltip\" data-placement=\"left\" data-offset=\"4px, 16px\" data-original-title=\"References\" aria-disabled=\"true\" disabled=\"true\"><i aria-hidden=\"true\" class=\"icon-references\"></i><span class=\"sr-only\">References</span></a></li><li role=\"none\"><a role=\"menuitem\" href=\"#core-collateral-media\" aria-label=\"Media\" data-id=\"article-nav-menubar-media\" data-toggle=\"tooltip\" data-placement=\"left\" data-offset=\"4px, 16px\" data-original-title=\"Media\" aria-disabled=\"true\" disabled=\"true\"><i aria-hidden=\"true\" class=\"icon-photo\"></i><span class=\"sr-only\">Media</span></a></li><li role=\"none\"><a role=\"menuitem\" href=\"#core-collateral-tables\" aria-label=\"Tables\" data-id=\"article-nav-menubar-tables\" data-toggle=\"tooltip\" data-placement=\"left\" data-offset=\"4px, 16px\" data-original-title=\"Tables\" aria-disabled=\"true\" disabled=\"true\"><i aria-hidden=\"true\" class=\"icon-tables\"></i><span class=\"sr-only\">Tables</span></a></li><li role=\"none\"><a role=\"menuitem\" href=\"#core-collateral-share\" aria-label=\"Share\" data-id=\"article-nav-menubar-share\" data-toggle=\"tooltip\" data-placement=\"left\" data-offset=\"4px, 16px\" data-original-title=\"Share\" aria-disabled=\"true\" disabled=\"true\"><i aria-hidden=\"true\" class=\"icon-share\"></i><span class=\"sr-only\">Share</span></a></li></ul></div></li></ul></div><div id=\"abstracts\" data-extent=\"frontmatter\" data-location=\"articleTab_article\"><div class=\"core-container\"><section id=\"summary-abstract\" property=\"abstract\" typeof=\"Text\" role=\"doc-abstract\"><h2 property=\"name\">Abstract</h2><section id=\"abs-sec-1\"><h3>Background</h3><div role=\"paragraph\">Preapproval trials showed that messenger RNA (mRNA)–based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet these trials were subject to size and patient-mix limitations. An evaluation of the safety of the BNT162b2 mRNA vaccine with respect to a broad range of potential adverse events is needed.</div></section><section id=\"abs-sec-2\"><h3>Methods</h3><div role=\"paragraph\">We used data from the largest health care organization in Israel to evaluate the safety of the BNT162b2 mRNA vaccine. For each potential adverse event, in a population of persons with no previous diagnosis of that event, we individually matched vaccinated persons to unvaccinated persons according to sociodemographic and clinical variables. Risk ratios and risk differences at 42 days after vaccination were derived with the use of the Kaplan–Meier estimator. To place these results in context, we performed a similar analysis involving SARS-CoV-2–infected persons matched to uninfected persons. The same adverse events were studied in the vaccination and SARS-CoV-2 infection analyses.</div></section><section id=\"abs-sec-3\"><h3>Results</h3><div role=\"paragraph\">In the vaccination analysis, the vaccinated and control groups each included a mean of 884,828 persons. Vaccination was most strongly associated with an elevated risk of myocarditis (risk ratio, 3.24; 95% confidence interval [CI], 1.55 to 12.44; risk difference, 2.7 events per 100,000 persons; 95% CI, 1.0 to 4.6), lymphadenopathy (risk ratio, 2.43; 95% CI, 2.05 to 2.78; risk difference, 78.4 events per 100,000 persons; 95% CI, 64.1 to 89.3), appendicitis (risk ratio, 1.40; 95% CI, 1.02 to 2.01; risk difference, 5.0 events per 100,000 persons; 95% CI, 0.3 to 9.9), and herpes zoster infection (risk ratio, 1.43; 95% CI, 1.20 to 1.73; risk difference, 15.8 events per 100,000 persons; 95% CI, 8.2 to 24.2). SARS-CoV-2 infection was associated with a substantially increased risk of myocarditis (risk ratio, 18.28; 95% CI, 3.95 to 25.12; risk difference, 11.0 events per 100,000 persons; 95% CI, 5.6 to 15.8) and of additional serious adverse events, including pericarditis, arrhythmia, deep-vein thrombosis, pulmonary embolism, myocardial infarction, intracranial hemorrhage, and thrombocytopenia.</div></section><section id=\"abs-sec-4\"><h3>Conclusions</h3><div role=\"paragraph\">In this study in a nationwide mass vaccination setting, the BNT162b2 vaccine was not associated with an elevated risk of most of the adverse events examined. The vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse event and of many other serious adverse events was substantially increased after SARS-CoV-2 infection. (Funded by the Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute.)</div></section></section></div></div><section id=\"bodymatter\" data-extent=\"bodymatter\" property=\"articleBody\" typeof=\"Text\" data-location=\"articleTab_article\"><div class=\"core-container\"><div role=\"paragraph\">More than 1 year into the pandemic of coronavirus disease 2019 (Covid-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an unprecedented number of mass vaccination efforts are under way worldwide. Globally, nearly 3.4 billion doses of vaccine have been administered over the 6-month period since the first vaccines were approved.<sup><a href=\"#r1\" role=\"doc-biblioref\" data-xml-rid=\"r1\">1</a></sup></div><div role=\"paragraph\">Phase 3 clinical trials showed that several Covid-19 vaccines were efficacious and had an acceptable safety profile.<sup><a href=\"#r2\" role=\"doc-biblioref\" data-xml-rid=\"r2 r3 r4\">2-4</a></sup> A number of potential adverse events were identified during these trials, including lymphadenopathy and idiopathic facial-nerve (Bell’s) palsy.<sup><a href=\"#r2\" role=\"doc-biblioref\" data-xml-rid=\"r2 r3\">2,3</a></sup> Trials of the BNT162b2 vaccine (Pfizer–BioNTech) also showed a mild imbalance between the vaccinated and placebo groups with respect to the number of cases of appendicitis, hypersensitivity reactions, acute myocardial infarction, and cerebrovascular accidents.<sup><a href=\"#r5\" role=\"doc-biblioref\" data-xml-rid=\"r5\">5</a></sup> However, phase 3 trials may have inherent limitations in assessing vaccine safety because of a small number of participants and a healthier-than-average sample population. Hence, they are often underpowered to identify less common adverse events. Postmarketing surveillance is required to monitor the safety of new vaccines in real-world settings.</div><div role=\"paragraph\">Much effort is currently focused on characterizing the safety profiles of the recently approved Covid-19 vaccines. Passive surveillance systems such as the Vaccine Adverse Event Reporting System (VAERS)<sup><a href=\"#r6\" role=\"doc-biblioref\" data-xml-rid=\"r6\">6</a></sup> collect information about adverse events that are potentially related to vaccination. This information is voluntarily reported by health care providers and the public. These systems are useful for quickly identifying potential safety signals, which, along with the findings of phase 3 trials, can be translated to lists of adverse events of interest for further exploration (such as that provided by the Safety Platform for Emergency Vaccines [SPEAC]).<sup><a href=\"#r7\" role=\"doc-biblioref\" data-xml-rid=\"r7 r8\">7,8</a></sup> Active surveillance systems such as the Biologics Effectiveness and Safety (BEST) system (part of the Sentinel Initiative)<sup><a href=\"#r9\" role=\"doc-biblioref\" data-xml-rid=\"r9\">9</a></sup> aim to compare the incidence of adverse events of interest in large electronic health record databases with the background historical incidence. Although active surveillance can help highlight suspicious trends, the lack of a rigorously constructed comparable control group limits the ability of such surveillance to identify causal effects of vaccination.</div><div role=\"paragraph\">The effectiveness of vaccines against SARS-CoV-2 has been confirmed in real-world studies,<sup><a href=\"#r10\" role=\"doc-biblioref\" data-xml-rid=\"r10 r11\">10,11</a></sup> but high-quality real-world safety data on the messenger RNA (mRNA)–based Covid-19 vaccines remain relatively sparse in the literature. The results of a study based on data reported by more than 600,000 vaccinated persons were recently published<sup><a href=\"#r12\" role=\"doc-biblioref\" data-xml-rid=\"r12\">12</a></sup>; that study mainly assessed common and mild side effects. Two additional studies, which were based on surveys of vaccinated participants, involved small cohorts,<sup><a href=\"#r13\" role=\"doc-biblioref\" data-xml-rid=\"r13 r14\">13,14</a></sup> and another study analyzed adverse events reported in the VAERS database.<sup><a href=\"#r15\" role=\"doc-biblioref\" data-xml-rid=\"r15\">15</a></sup> All these studies lacked controls. One study that did incorporate a control group included 8533 long-term care facility residents who had received the first dose of vaccine.<sup><a href=\"#r16\" role=\"doc-biblioref\" data-xml-rid=\"r16\">16</a></sup> The authors of this study concluded that the mRNA-based vaccines had an acceptable safety profile, and no notable adverse events were reported.</div><div role=\"paragraph\">As of May 24, 2021, nearly 5 million people in Israel, comprising more than 55% of the population, had received two doses of the BNT162b2 vaccine.<sup><a href=\"#r1\" role=\"doc-biblioref\" data-xml-rid=\"r1\">1</a></sup> In this study, we used the integrated data repositories of the largest health care organization in Israel to evaluate the safety profile of the BNT162b2 vaccine. We compared the incidence of a broad set of potential short- and medium-term adverse events among vaccinated persons with the incidence among matched unvaccinated persons. Potential adverse events related to medical interventions are best understood in the context of the risks associated with the disease that these interventions aim to prevent or treat, so we also estimated the effects of SARS-CoV-2 infection on this same set of adverse events.</div><section id=\"sec-1\" data-type=\"methods\"><h2>Methods</h2><section id=\"sec-1-1\"><h3>Study Setting</h3><div role=\"paragraph\">We analyzed observational data from Clalit Health Services (CHS) in order to emulate a target trial of the effects of the BNT162b2 vaccine on a broad range of potential adverse events in a population without SARS-CoV-2 infection. CHS is the largest of four integrated payer–provider health care organizations that offer mandatory health care coverage in Israel. CHS insures approximately 52% of the population of Israel (&gt;4.7 million of 9.0 million persons), and the CHS-insured population is approximately representative of the Israeli population at large.<sup><a href=\"#r17\" role=\"doc-biblioref\" data-xml-rid=\"r17\">17</a></sup> CHS directly provides outpatient care, and inpatient care is divided between CHS and out-of-network hospitals. CHS information systems are fully digitized and feed into a central data warehouse. Data regarding Covid-19, including the results of all SARS-CoV-2 polymerase-chain-reaction (PCR) tests, Covid-19 diagnoses and severity, and vaccinations, are collected centrally by the Israeli Ministry of Health and shared with each of the four national health care organizations daily.</div><div role=\"paragraph\">This study was approved by the CHS institutional review board. The study was exempt from the requirement for informed consent.</div></section><section id=\"sec-1-2\"><h3>Eligibility Criteria</h3><div role=\"paragraph\">Eligibility criteria included an age of 16 years or older, continuous membership in the health care organization for a full year, no previous SARS-CoV-2 infection, and no contact with the health care system in the previous 7 days (the latter criterion was included as an indicator of a health event not related to subsequent vaccination that could reduce the probability of receiving the vaccine). Because of difficulties in distinguishing the recoding of previous events from true new events, for each adverse event, persons with a previous diagnosis of that event were excluded.</div><div role=\"paragraph\">As in our previous study of the effectiveness of the BNT162b2 vaccine,<sup><a href=\"#r10\" role=\"doc-biblioref\" data-xml-rid=\"r10\">10</a></sup> we also excluded persons from populations in which confounding could not be adequately addressed — long-term care facility residents, persons confined to their homes for medical reasons, health care workers, and persons for whom data on body-mass index or residential area were missing (missing data for these variables are rare in the CHS data). A complete definition of the study variables is included in Table S1 in the <a href=\"#ap1\">Supplementary Appendix</a>, available with the full text of this article at NEJM.org.</div></section><section id=\"sec-1-3\"><h3>Study Design and Oversight</h3><div role=\"paragraph\">The target trial for this study would assign eligible persons to either vaccination or no vaccination. To emulate this trial, on each day from the beginning of the vaccination campaign in Israel (December 20, 2020) until the end of the study period (May 24, 2021), eligible persons who were vaccinated on that day were matched to eligible controls who had not been previously vaccinated. Since the matching process each day considered only information available on or before that day (and was thus unaffected by later vaccinations or SARS-CoV-2 infections), unvaccinated persons matched on a given day could be vaccinated on a future date, and on that future date they could become newly eligible for inclusion in the study as a vaccinated person.</div><div role=\"paragraph\">In an attempt to emulate randomized assignment, vaccinated persons and unvaccinated controls were exactly matched on a set of baseline variables that were deemed to be potential confounders according to domain expertise — namely, variables that were potentially related to vaccination and to a tendency toward the development of a broad set of adverse clinical conditions. These matching criteria included the sociodemographic variables of age (categorized into 2-year age groups), sex (male or female), place of residence (at city- or town-level granularity), socioeconomic status (divided into seven categories), and population sector (general Jewish, Arab, or ultra-Orthodox Jewish). In addition, the matching criteria included clinical factors to account for general clinical condition and disease load, including the number of preexisting chronic conditions (those considered to be risk factors for severe Covid-19 by the Centers for Disease Control and Prevention [CDC] as of December 20, 2020,<sup><a href=\"#r18\" role=\"doc-biblioref\" data-xml-rid=\"r18\">18</a></sup> divided into four categories), the number of diagnoses documented in outpatient visits in the year before the index date (categorized into deciles within each age group), and pregnancy status.</div><div role=\"paragraph\">All the authors designed the study and critically reviewed the manuscript. The first three authors collected and analyzed the data. A subgroup of the authors wrote the manuscript. The last author vouches for the accuracy and completeness of the data and for the fidelity of the study to the protocol. There was no commercial funding for this study, and no confidentiality agreements were in place.</div></section><section id=\"sec-1-4\"><h3>Adverse Events of Interest</h3><div role=\"paragraph\">The set of potential adverse events for the target trial was drawn from several relevant sources, including the VAERS, BEST, and SPEAC frameworks, information provided by the vaccine manufacturer, and relevant scientific publications. We cast a wide net to capture a broad range of clinically meaningful short- and medium-term potential adverse events that would be likely to be documented in the electronic health record. Accordingly, mild adverse events such as fever, malaise, and local injection-site reactions were not included in this study. The study included 42 days of follow-up, which provided 21 days of follow-up after each of the first and second vaccine doses. A total of 42 days was deemed to be sufficient for identifying medium-term adverse events, without being so long as to dilute the incidence of short-term adverse events. Similarly, adverse events that could not plausibly be diagnosed within 42 days (e.g., chronic autoimmune disease) were not included.</div><div role=\"paragraph\">Adverse events were defined according to diagnostic codes and short free-text phrases that accompany diagnoses in the CHS database. A complete list of the study outcomes (adverse events) and their definitions is provided in Table S2.</div><div role=\"paragraph\">For each adverse event, persons were followed from the day of matching (time zero of follow-up) until the earliest of one of the following: documentation of the adverse event, 42 days, the end of the study calendar period, or death. We also ended the follow-up of a matched pair when the unvaccinated control received the first dose of vaccine or when either member of the matched pair received a diagnosis of SARS-CoV-2 infection.</div></section><section id=\"sec-1-5\"><h3>Risks of SARS-CoV-2 Infection</h3><div role=\"paragraph\">To place the magnitude of the adverse effects of the vaccine in context, we also estimated the effects of SARS-CoV-2 infection on these same adverse events during the 42 days after diagnosis. We used the same design as the one that we used to study the adverse effects of vaccination, except that the analysis period started at the beginning of the Covid-19 pandemic in Israel (March 1, 2020) and persons who had had recent contact with the health care system were not excluded (because such contact may be expected in the days before diagnosis).</div><div role=\"paragraph\">Each day in this SARS-CoV-2 analysis, persons with a new diagnosis of SARS-CoV-2 infection were matched to controls who were not previously infected. As in the vaccine safety analysis, persons could become infected with SARS-CoV-2 after they were already matched as controls on a previous day, in which case their data would be censored from the control group (along with their matched SARS-CoV-2–infected person) and they could then be included in the group of SARS-CoV-2–infected persons with a newly matched control. Follow-up of each matched pair started from the date of the positive PCR test result of the infected member and ended in an analogous manner to the main vaccination analysis, this time ending when the control member was infected or when either of the persons in the matched pair was vaccinated.</div><div role=\"paragraph\">The effects of vaccination and of SARS-CoV-2 infection were estimated with different cohorts. Thus, they should be treated as separate sets of results rather than directly compared.</div></section><section id=\"sec-1-6\"><h3>Statistical Analysis</h3><div role=\"paragraph\">Because a large proportion of the unvaccinated controls were vaccinated during the follow-up period, we opted to estimate the observational analogue of the per-protocol effect if all unvaccinated persons had remained unvaccinated during the follow-up. To do so, we censored data on the matched pair if and when the control member was vaccinated. Persons who were first matched as unvaccinated controls and then became vaccinated during the study period could be included again as vaccinated persons with a new matched control. The same procedure was followed in the SARS-CoV-2 infection analysis (i.e., persons who were first matched as uninfected controls and then became infected during the study period could be included again as infected persons with a new matched control).</div><div role=\"paragraph\">We used the Kaplan–Meier estimator<sup><a href=\"#r19\" role=\"doc-biblioref\" data-xml-rid=\"r19\">19</a></sup> to construct cumulative incidence curves and to estimate the risk of each adverse event after 42 days in each group. The risks were compared with ratios and differences (per 100,000 persons).</div><div role=\"paragraph\">In the vaccination analysis, so as not to attribute complications arising from SARS-CoV-2 infection to the vaccination (or lack thereof), we also censored data on the matched pair if and when either member received a diagnosis of SARS-CoV-2 infection. Similarly, in the SARS-CoV-2 infection analysis, we censored data on the matched pair if and when either member was vaccinated. Additional details are provided in the Supplementary Methods 1 section in the <a href=\"#ap1\">Supplementary Appendix</a>.</div><div role=\"paragraph\">We calculated confidence intervals using the nonparametric percentile bootstrap method with 500 repetitions. As is standard practice for studies of safety outcomes, no adjustment for multiple comparisons was performed. Analyses were performed with the use of R software, version 4.0.4.</div></section></section><section id=\"sec-2\" data-type=\"results\"><h2>Results</h2><section id=\"sec-2-1\"><h3>Vaccination Analysis</h3><div role=\"paragraph\">A total of 1,736,832 persons were eligible for inclusion in the vaccination cohort (<a href=\"#f1\">Figure 1</a>). The median age in the eligible cohort was 43 years (Table S3). The final size of the study population differed for each studied adverse event because of adverse event–specific exclusion of persons with a history of that event. On average, across the adverse event–specific cohorts, 72.4% of the eligible persons were successfully matched. <a href=\"#t1\">Table 1</a> shows the baseline characteristics of the total study population, with the mean distribution of characteristics across the various adverse event–specific cohorts. The characteristics of each adverse event–specific cohort are provided in Table S4. The vaccination cohorts included a mean of 884,828 vaccinated persons, with a median age of 38 years (5 years younger than the median age of the eligible cohort). A total of 48% of the population was female.</div><div class=\"figure-wrap\" data-presentation=\"diminished-in-flow\"><header><div class=\"label\">Figure 1</div></header><figure id=\"f1\" class=\"graphic\"><img src=\"/cms/10.1056/NEJMoa2110475/asset/03921378-0cc4-472f-ac47-21060786e63e/assets/images/large/nejmoa2110475_f1.jpg\" height=\"1500\" width=\"988\" aria-labelledby=\"f1\" loading=\"lazy\" /><figcaption><div class=\"caption\">Study Population for the Vaccination Analysis.</div><div class=\"notes\"><div role=\"doc-footnote\">Absolute numbers and percentage changes are shown for each inclusion and exclusion criterion. The chart focuses on the vaccinated population. The derivation group includes the entire population, including unvaccinated persons. The shaded boxes indicate the two study groups. The same exclusion criteria were applied to the unvaccinated persons for each index date on which they were considered for matching. BMI denotes body-mass index, CHS Clalit Health Services, and PCR polymerase chain reaction.</div></div></figcaption></figure></div><div class=\"figure-wrap\" data-presentation=\"diminished-in-flow\"><header><div class=\"label\">Table 1</div></header><figure id=\"t1\" class=\"table\"><div class=\"graphic-wrap\" data-presentation=\"suppressed-in-viewer\"><img src=\"/cms/10.1056/NEJMoa2110475/asset/9b324f0f-5d76-4651-bc5e-df6b37de5e06/assets/images/large/nejmoa2110475_t1.jpg\" height=\"1500\" width=\"982\" loading=\"lazy\" /></div><div class=\"table-wrap catalyst-standard\" data-presentation=\"suppressed-in-flow\"><table data-shading=\"custom\"><thead><tr class=\"head1\"><th class=\"txlx-borders\" data-xml-align=\"left\">Characteristic</th><th class=\"txxx-borders\" colspan=\"2\"><span>Vaccination Analysis</span></th><th class=\"txxr-borders\" colspan=\"2\"><span>SARS-CoV-2 Analysis</span></th></tr><tr class=\"head2\"><td class=\"xxlx-borders\"> </td><th class=\"xxxx-borders\">Vaccinated<br /> Group<br />(N=884,828)</th><th class=\"xxxx-borders\">Control<br /> Group<br />(N=884,828)</th><th class=\"xxxx-borders\">SARS-CoV-2–Infected Group<br />(N=173,106)</th><th class=\"xxxr-borders\">Control<br /> Group<br />(N=173,106)</th></tr></thead><tbody><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging02 shading\" data-xml-align=\"left\">Median age (IQR) — yr</td><td class=\"xxxx-borders shading\">38 (27–53)</td><td class=\"xxxx-borders shading\">38 (27–53)</td><td class=\"xxxx-borders shading\">34 (24–47)</td><td class=\"xxxr-borders shading\">34 (24–47)</td></tr><tr><td class=\"xxlx-borders hanging02\">Age group — no. (%)</td><td class=\"xxxx-borders\"> </td><td class=\"xxxx-borders\"> </td><td class=\"xxxx-borders\"> </td><td class=\"xxxr-borders\"> </td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12 shading\" data-xml-align=\"left\">16–39 yr</td><td class=\"xxxx-borders shading\">472,095 (53)</td><td class=\"xxxx-borders shading\">472,095 (53)</td><td class=\"xxxx-borders shading\">107,046 (62)</td><td class=\"xxxr-borders shading\">107,046 (62)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12\" data-xml-align=\"left\">40–49 yr</td><td class=\"xxxx-borders\">160,413 (18)</td><td class=\"xxxx-borders\">160,413 (18)</td><td class=\"xxxx-borders\">28,738 (17)</td><td class=\"xxxr-borders\">28,738 (17)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12 shading\" data-xml-align=\"left\">50–59 yr</td><td class=\"xxxx-borders shading\">93,110 (11)</td><td class=\"xxxx-borders shading\">93,110 (11)</td><td class=\"xxxx-borders shading\">17,851 (10)</td><td class=\"xxxr-borders shading\">17,851 (10)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12\" data-xml-align=\"left\">60–69 yr</td><td class=\"xxxx-borders\">87,236 (10)</td><td class=\"xxxx-borders\">87,236 (10)</td><td class=\"xxxx-borders\">12,100 (7)</td><td class=\"xxxr-borders\">12,100 (7)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12 shading\" data-xml-align=\"left\">70–79 yr</td><td class=\"xxxx-borders shading\">51,924 (6)</td><td class=\"xxxx-borders shading\">51,924 (6)</td><td class=\"xxxx-borders shading\">5,371 (3)</td><td class=\"xxxr-borders shading\">5,371 (3)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12\" data-xml-align=\"left\">≥80 yr</td><td class=\"xxxx-borders\">20,050 (2)</td><td class=\"xxxx-borders\">20,050 (2)</td><td class=\"xxxx-borders\">1,999 (1)</td><td class=\"xxxr-borders\">1,999 (1)</td></tr><tr><td class=\"xxlx-borders hanging02 shading\">Sex — no. (%)</td><td class=\"xxxx-borders shading\"> </td><td class=\"xxxx-borders shading\"> </td><td class=\"xxxx-borders shading\"> </td><td class=\"xxxr-borders shading\"> </td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12\" data-xml-align=\"left\">Female</td><td class=\"xxxx-borders\">423,238 (48)</td><td class=\"xxxx-borders\">423,238 (48)</td><td class=\"xxxx-borders\">93,263 (54)</td><td class=\"xxxr-borders\">93,263 (54)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12 shading\" data-xml-align=\"left\">Male</td><td class=\"xxxx-borders shading\">461,590 (52)</td><td class=\"xxxx-borders shading\">461,590 (52)</td><td class=\"xxxx-borders shading\">79,843 (46)</td><td class=\"xxxr-borders shading\">79,843 (46)</td></tr><tr><td class=\"xxlx-borders hanging02\">Population sector — no. (%)</td><td class=\"xxxx-borders\"> </td><td class=\"xxxx-borders\"> </td><td class=\"xxxx-borders\"> </td><td class=\"xxxr-borders\"> </td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12 shading\" data-xml-align=\"left\">General Jewish</td><td class=\"xxxx-borders shading\">595,897 (67)</td><td class=\"xxxx-borders shading\">595,897 (67)</td><td class=\"xxxx-borders shading\">90,903 (53)</td><td class=\"xxxr-borders shading\">90,903 (53)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12\" data-xml-align=\"left\">Ultra-Orthodox Jewish</td><td class=\"xxxx-borders\">24,343 (3)</td><td class=\"xxxx-borders\">24,343 (3)</td><td class=\"xxxx-borders\">20,864 (12)</td><td class=\"xxxr-borders\">20,864 (12)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12 shading\" data-xml-align=\"left\">Arab</td><td class=\"xxxx-borders shading\">264,588 (30)</td><td class=\"xxxx-borders shading\">264,588 (30)</td><td class=\"xxxx-borders shading\">61,339 (35)</td><td class=\"xxxr-borders shading\">61,339 (35)</td></tr><tr><td class=\"xxlx-borders hanging02\">No. of risk factors according to CDC criteria — no. (%)</td><td class=\"xxxx-borders\"> </td><td class=\"xxxx-borders\"> </td><td class=\"xxxx-borders\"> </td><td class=\"xxxr-borders\"> </td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12 shading\" data-xml-align=\"left\">0</td><td class=\"xxxx-borders shading\">571,604 (65)</td><td class=\"xxxx-borders shading\">571,604 (65)</td><td class=\"xxxx-borders shading\">108,980 (63)</td><td class=\"xxxr-borders shading\">108,980 (63)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12\" data-xml-align=\"left\">1</td><td class=\"xxxx-borders\">200,789 (23)</td><td class=\"xxxx-borders\">200,789 (23)</td><td class=\"xxxx-borders\">41,502 (24)</td><td class=\"xxxr-borders\">41,502 (24)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12 shading\" data-xml-align=\"left\">2</td><td class=\"xxxx-borders shading\">61,924 (7)</td><td class=\"xxxx-borders shading\">61,924 (7)</td><td class=\"xxxx-borders shading\">11,976 (7)</td><td class=\"xxxr-borders shading\">11,976 (7)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12\" data-xml-align=\"left\">3</td><td class=\"xxxx-borders\">27,175 (3)</td><td class=\"xxxx-borders\">27,175 (3)</td><td class=\"xxxx-borders\">5,181 (3)</td><td class=\"xxxr-borders\">5,181 (3)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12 shading\" data-xml-align=\"left\">≥4</td><td class=\"xxxx-borders shading\">23,335 (3)</td><td class=\"xxxx-borders shading\">23,335 (3)</td><td class=\"xxxx-borders shading\">5,467 (3)</td><td class=\"xxxr-borders shading\">5,467 (3)</td></tr><tr><td class=\"xxlx-borders hanging02\">CDC “certain” risk criteria — no. (%)</td><td class=\"xxxx-borders\"> </td><td class=\"xxxx-borders\"> </td><td class=\"xxxx-borders\"> </td><td class=\"xxxr-borders\"> </td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12 shading\" data-xml-align=\"left\">Cancer</td><td class=\"xxxx-borders shading\">9,957 (1)</td><td class=\"xxxx-borders shading\">10,300 (1)</td><td class=\"xxxx-borders shading\">2,037 (1)</td><td class=\"xxxr-borders shading\">2,308 (1)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12\" data-xml-align=\"left\">Chronic kidney disease</td><td class=\"xxxx-borders\">39,837 (4)</td><td class=\"xxxx-borders\">40,339 (5)</td><td class=\"xxxx-borders\">8,269 (5)</td><td class=\"xxxr-borders\">8,141 (5)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12 shading\" data-xml-align=\"left\">Chronic obstructive pulmonary disease</td><td class=\"xxxx-borders shading\">10,121 (1)</td><td class=\"xxxx-borders shading\">11,498 (1)</td><td class=\"xxxx-borders shading\">1,791 (1)</td><td class=\"xxxr-borders shading\">2,212 (1)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12\" data-xml-align=\"left\">Heart disease</td><td class=\"xxxx-borders\">31,836 (4)</td><td class=\"xxxx-borders\">31,596 (4)</td><td class=\"xxxx-borders\">5,653 (3)</td><td class=\"xxxr-borders\">5,880 (3)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12 shading\" data-xml-align=\"left\">Solid-organ transplantation</td><td class=\"xxxx-borders shading\">351 (&lt;1)</td><td class=\"xxxx-borders shading\">370 (&lt;1)</td><td class=\"xxxx-borders shading\">148 (&lt;1)</td><td class=\"xxxr-borders shading\">136 (&lt;1)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12\" data-xml-align=\"left\">Obesity: BMI, 30 to 40</td><td class=\"xxxx-borders\">129,148 (15)</td><td class=\"xxxx-borders\">125,120 (14)</td><td class=\"xxxx-borders\">30,558 (18)</td><td class=\"xxxr-borders\">28,580 (17)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12 shading\" data-xml-align=\"left\">Severe obesity: BMI, ≥40</td><td class=\"xxxx-borders shading\">11,861 (1)</td><td class=\"xxxx-borders shading\">12,568 (1)</td><td class=\"xxxx-borders shading\">3,478 (2)</td><td class=\"xxxr-borders shading\">3,107 (2)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12\" data-xml-align=\"left\">Pregnancy</td><td class=\"xxxx-borders\">6,082 (1)</td><td class=\"xxxx-borders\">6,082 (1)</td><td class=\"xxxx-borders\">4,959 (3)</td><td class=\"xxxr-borders\">4,959 (3)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12 shading\" data-xml-align=\"left\">Sickle cell disease</td><td class=\"xxxx-borders shading\">140 (&lt;1)</td><td class=\"xxxx-borders shading\">182 (&lt;1)</td><td class=\"xxxx-borders shading\">50 (&lt;1)</td><td class=\"xxxr-borders shading\">55 (&lt;1)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12\" data-xml-align=\"left\">Smoking</td><td class=\"xxxx-borders\">157,803 (18)</td><td class=\"xxxx-borders\">187,822 (21)</td><td class=\"xxxx-borders\">18,899 (11)</td><td class=\"xxxr-borders\">30,376 (18)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12 shading\" data-xml-align=\"left\">Type 2 diabetes mellitus</td><td class=\"xxxx-borders shading\">61,865 (7)</td><td class=\"xxxx-borders shading\">61,093 (7)</td><td class=\"xxxx-borders shading\">12,448 (7)</td><td class=\"xxxr-borders shading\">12,396 (7)</td></tr><tr><td class=\"xxlx-borders hanging02\">CDC “possible” risk criteria — no. (%)</td><td class=\"xxxx-borders\"> </td><td class=\"xxxx-borders\"> </td><td class=\"xxxx-borders\"> </td><td class=\"xxxr-borders\"> </td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12 shading\" data-xml-align=\"left\">Asthma</td><td class=\"xxxx-borders shading\">46,836 (5)</td><td class=\"xxxx-borders shading\">47,151 (5)</td><td class=\"xxxx-borders shading\">10,079 (6)</td><td class=\"xxxr-borders shading\">10,413 (6)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12\" data-xml-align=\"left\">Cerebrovascular disease</td><td class=\"xxxx-borders\">14,296 (2)</td><td class=\"xxxx-borders\">14,919 (2)</td><td class=\"xxxx-borders\">2,661 (2)</td><td class=\"xxxr-borders\">2,738 (2)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12 shading\" data-xml-align=\"left\">Other respiratory disease</td><td class=\"xxxx-borders shading\">1,884 (&lt;1)</td><td class=\"xxxx-borders shading\">1,961 (&lt;1)</td><td class=\"xxxx-borders shading\">322 (&lt;1)</td><td class=\"xxxr-borders shading\">362 (&lt;1)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12\" data-xml-align=\"left\">Hypertension</td><td class=\"xxxx-borders\">94,819 (11)</td><td class=\"xxxx-borders\">93,357 (11)</td><td class=\"xxxx-borders\">15,514 (9)</td><td class=\"xxxr-borders\">15,682 (9)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12 shading\" data-xml-align=\"left\">Immunosuppression</td><td class=\"xxxx-borders shading\">15,430 (2)</td><td class=\"xxxx-borders shading\">15,433 (2)</td><td class=\"xxxx-borders shading\">4,346 (2)</td><td class=\"xxxr-borders shading\">4,457 (3)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12\" data-xml-align=\"left\">Neurologic disease</td><td class=\"xxxx-borders\">26,340 (3)</td><td class=\"xxxx-borders\">28,421 (3)</td><td class=\"xxxx-borders\">5,194 (3)</td><td class=\"xxxr-borders\">5,455 (3)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12 shading\" data-xml-align=\"left\">Liver disease</td><td class=\"xxxx-borders shading\">10,491 (1)</td><td class=\"xxxx-borders shading\">12,558 (1)</td><td class=\"xxxx-borders shading\">2,391 (1)</td><td class=\"xxxr-borders shading\">2,600 (2)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12\" data-xml-align=\"left\">Overweight: BMI, 25 to 30</td><td class=\"xxxx-borders\">284,904 (32)</td><td class=\"xxxx-borders\">271,335 (31)</td><td class=\"xxxx-borders\">53,374 (31)</td><td class=\"xxxr-borders\">50,038 (29)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging12 shading\" data-xml-align=\"left\">Thalassemia</td><td class=\"xxxx-borders shading\">5,884 (1)</td><td class=\"xxxx-borders shading\">5,644 (1)</td><td class=\"xxxx-borders shading\">1,599 (1)</td><td class=\"xxxr-borders shading\">1,595 (1)</td></tr><tr data-xml-align=\"center\"><td class=\"xblx-borders hanging12\" data-xml-align=\"left\">Type 1 diabetes mellitus</td><td class=\"xbxx-borders\">2,797 (&lt;1)</td><td class=\"xbxx-borders\">2,648 (&lt;1)</td><td class=\"xbxx-borders\">694 (&lt;1)</td><td class=\"xbxr-borders\">763 (&lt;1)</td></tr></tbody></table></div><figcaption><div class=\"caption\">Baseline Characteristics of the Study Populations According to Vaccination Status and SARS-CoV-2 Infection Status.<a href=\"#t1fn1\" role=\"doc-noteref\">*</a></div><div class=\"notes\"><div role=\"doc-footnote\" data-has=\"label\"><div class=\"label\">*</div><div id=\"t1fn1\" role=\"paragraph\">Statistics are based on means and distributions from a pool of all the adverse event–specific cohorts. Characteristics of the various study populations after application of all eligibility criteria and the matching process are listed. BMI denotes body-mass index (the weight in kilograms divided by the square of the height in meters), CDC Centers for Disease Control and Prevention, IQR interquartile range, RT-PCR reverse-transcriptase polymerase chain reaction, and SARS-CoV-2 severe acute respiratory syndrome coronavirus 2.</div></div></div></figcaption></figure></div><div role=\"paragraph\">The effect of vaccination on the various potential adverse events included in this study is presented in <a href=\"#t2\">Table 2</a>. The risk was substantially higher on either the multiplicative (risk ratio) or additive (risk difference) scales in the vaccinated group than in the unvaccinated group for myocarditis (risk ratio, 3.24; 95% confidence interval [CI], 1.55 to 12.44; risk difference, 2.7 events per 100,000 persons; 95% CI, 1.0 to 4.6), lymphadenopathy (risk ratio, 2.43; 95% CI, 2.05 to 2.78; risk difference, 78.4 events per 100,000 persons; 95% CI, 64.1 to 89.3), appendicitis (risk ratio, 1.40; 95% CI, 1.02 to 2.01; risk difference, 5.0 events per 100,000 persons; 95% CI, 0.3 to 9.9), and herpes zoster infection (risk ratio, 1.43; 95% CI, 1.20 to 1.73; risk difference, 15.8 events per 100,000 persons; 95% CI, 8.2 to 24.2). Vaccination was substantially protective against adverse events such as anemia, acute kidney injury, intracranial hemorrhage, and lymphopenia.</div><div class=\"figure-wrap\" data-presentation=\"diminished-in-flow\"><header><div class=\"label\">Table 2</div></header><figure id=\"t2\" class=\"table\"><div class=\"graphic-wrap\" data-presentation=\"suppressed-in-viewer\"><img src=\"/cms/10.1056/NEJMoa2110475/asset/7591f5c4-9026-47f3-8f22-be6cedd96bbf/assets/images/large/nejmoa2110475_t2.jpg\" height=\"1472\" width=\"1500\" loading=\"lazy\" /></div><div class=\"table-wrap catalyst-standard\" data-presentation=\"suppressed-in-flow\"><table data-shading=\"custom\"><thead><tr class=\"head1\"><th class=\"txlx-borders\" data-xml-align=\"left\">Event</th><th class=\"txxx-borders\">Adverse-Event Cohort in Each Group</th><th class=\"txxx-borders\">Vaccinated<br /> Group</th><th class=\"txxx-borders\">Control<br /> Group</th><th class=\"txxx-borders\">Risk Ratio<br /> (95% CI)</th><th class=\"txxr-borders\">Risk Difference<br /> (95% CI)</th></tr><tr class=\"head3\"><td class=\"xxlx-borders\"> </td><th class=\"xxxx-borders\">no. of persons</th><th class=\"xxxx-borders\" colspan=\"2\"><span>no. of events</span></th><td class=\"xxxx-borders\"> </td><th class=\"xxxr-borders\">no. of events/100,000 persons</th></tr></thead><tbody><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging01 shading\" data-xml-align=\"left\">Acute kidney injury</td><td class=\"xxxx-borders shading\">912,019</td><td class=\"xxxx-borders shading\">20</td><td class=\"xxxx-borders shading\">45</td><td class=\"xxxx-borders shading\">0.44 (0.23 to 0.73)</td><td class=\"xxxr-borders shading\">−4.6 (−7.8 to −1.8)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging01\" data-xml-align=\"left\">Anemia</td><td class=\"xxxx-borders\">709,267</td><td class=\"xxxx-borders\">298</td><td class=\"xxxx-borders\">378</td><td class=\"xxxx-borders\">0.79 (0.67 to 0.93)</td><td class=\"xxxr-borders\">−18.7 (−32.1 to −6.1)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging01 shading\" data-xml-align=\"left\">Appendicitis</td><td class=\"xxxx-borders shading\">900,289</td><td class=\"xxxx-borders shading\">95</td><td class=\"xxxx-borders shading\">66</td><td class=\"xxxx-borders shading\">1.40 (1.02 to 2.01)</td><td class=\"xxxr-borders shading\">5.0 (0.3 to 9.9)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging01\" data-xml-align=\"left\">Arrhythmia</td><td class=\"xxxx-borders\">856,152</td><td class=\"xxxx-borders\">254</td><td class=\"xxxx-borders\">284</td><td class=\"xxxx-borders\">0.89 (0.74 to 1.04)</td><td class=\"xxxr-borders\">−6.1 (−14.7 to 1.8)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging01 shading\" data-xml-align=\"left\">Arthritis or arthropathy</td><td class=\"xxxx-borders shading\">731,340</td><td class=\"xxxx-borders shading\">64</td><td class=\"xxxx-borders shading\">70</td><td class=\"xxxx-borders shading\">0.95 (0.65 to 1.34)</td><td class=\"xxxr-borders shading\">−0.8 (−6.3 to 4.2)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging01\" data-xml-align=\"left\">Bell’s palsy</td><td class=\"xxxx-borders\">923,692</td><td class=\"xxxx-borders\">81</td><td class=\"xxxx-borders\">59</td><td class=\"xxxx-borders\">1.32 (0.92 to 1.86)</td><td class=\"xxxr-borders\">3.5 (−1.1 to 7.8)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging01 shading\" data-xml-align=\"left\">Cerebrovascular accident</td><td class=\"xxxx-borders shading\">917,598</td><td class=\"xxxx-borders shading\">45</td><td class=\"xxxx-borders shading\">55</td><td class=\"xxxx-borders shading\">0.84 (0.54 to 1.27)</td><td class=\"xxxr-borders shading\">−1.6 (−5.3 to 2.0)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging01\" data-xml-align=\"left\">Deep-vein thrombosis</td><td class=\"xxxx-borders\">925,380</td><td class=\"xxxx-borders\">39</td><td class=\"xxxx-borders\">47</td><td class=\"xxxx-borders\">0.87 (0.55 to 1.40)</td><td class=\"xxxr-borders\">−1.1 (−4.5 to 2.7)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging01 shading\" data-xml-align=\"left\">Herpes simplex infection</td><td class=\"xxxx-borders shading\">876,328</td><td class=\"xxxx-borders shading\">219</td><td class=\"xxxx-borders shading\">205</td><td class=\"xxxx-borders shading\">1.13 (0.95 to 1.38)</td><td class=\"xxxr-borders shading\">4.8 (−1.9 to 12.4)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging01\" data-xml-align=\"left\">Herpes zoster infection</td><td class=\"xxxx-borders\">888,647</td><td class=\"xxxx-borders\">283</td><td class=\"xxxx-borders\">204</td><td class=\"xxxx-borders\">1.43 (1.20 to 1.73)</td><td class=\"xxxr-borders\">15.8 (8.2 to 24.2)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging01 shading\" data-xml-align=\"left\">Intracranial hemorrhage</td><td class=\"xxxx-borders shading\">933,130</td><td class=\"xxxx-borders shading\">13</td><td class=\"xxxx-borders shading\">30</td><td class=\"xxxx-borders shading\">0.48 (0.20 to 0.89)</td><td class=\"xxxr-borders shading\">−2.9 (−5.6 to −0.5)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging01\" data-xml-align=\"left\">Lymphadenopathy</td><td class=\"xxxx-borders\">823,006</td><td class=\"xxxx-borders\">660</td><td class=\"xxxx-borders\">279</td><td class=\"xxxx-borders\">2.43 (2.05 to 2.78)</td><td class=\"xxxr-borders\">78.4 (64.1 to 89.3)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging01 shading\" data-xml-align=\"left\">Lymphopenia</td><td class=\"xxxx-borders shading\">938,939</td><td class=\"xxxx-borders shading\">2</td><td class=\"xxxx-borders shading\">7</td><td class=\"xxxx-borders shading\">0.26 (0.00 to 1.03)</td><td class=\"xxxr-borders shading\">−0.9 (−2.0 to &lt;0.1)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging01\" data-xml-align=\"left\">Myocardial infarction</td><td class=\"xxxx-borders\">892,785</td><td class=\"xxxx-borders\">59</td><td class=\"xxxx-borders\">60</td><td class=\"xxxx-borders\">1.07 (0.74 to 1.60)</td><td class=\"xxxr-borders\">0.8 (−3.3 to 5.2)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging01 shading\" data-xml-align=\"left\">Myocarditis</td><td class=\"xxxx-borders shading\">938,812</td><td class=\"xxxx-borders shading\">21</td><td class=\"xxxx-borders shading\">6</td><td class=\"xxxx-borders shading\">3.24 (1.55 to 12.44)</td><td class=\"xxxr-borders shading\">2.7 (1.0 to 4.6)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging01\" data-xml-align=\"left\">Neutropenia</td><td class=\"xxxx-borders\">919,291</td><td class=\"xxxx-borders\">20</td><td class=\"xxxx-borders\">22</td><td class=\"xxxx-borders\">0.87 (0.46 to 1.66)</td><td class=\"xxxr-borders\">−0.5 (−2.8 to 1.8)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging01 shading\" data-xml-align=\"left\">Other thrombosis<a href=\"#t2fn2\" role=\"doc-noteref\">†</a></td><td class=\"xxxx-borders shading\">932,469</td><td class=\"xxxx-borders shading\">12</td><td class=\"xxxx-borders shading\">22</td><td class=\"xxxx-borders shading\">0.46 (0.19 to 0.91)</td><td class=\"xxxr-borders shading\">−2.2 (−4.6 to −0.3)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging01\" data-xml-align=\"left\">Paresthesia</td><td class=\"xxxx-borders\">827,478</td><td class=\"xxxx-borders\">552</td><td class=\"xxxx-borders\">496</td><td class=\"xxxx-borders\">1.12 (0.98 to 1.24)</td><td class=\"xxxr-borders\">10.8 (−1.8 to 21.4)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging01 shading\" data-xml-align=\"left\">Pericarditis</td><td class=\"xxxx-borders shading\">936,197</td><td class=\"xxxx-borders shading\">27</td><td class=\"xxxx-borders shading\">18</td><td class=\"xxxx-borders shading\">1.27 (0.68 to 2.31)</td><td class=\"xxxr-borders shading\">1.0 (−1.6 to 3.4)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging01\" data-xml-align=\"left\">Pulmonary embolism</td><td class=\"xxxx-borders\">937,116</td><td class=\"xxxx-borders\">10</td><td class=\"xxxx-borders\">17</td><td class=\"xxxx-borders\">0.56 (0.21 to 1.15)</td><td class=\"xxxr-borders\">−1.5 (−3.6 to 0.4)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging01 shading\" data-xml-align=\"left\">Seizure</td><td class=\"xxxx-borders shading\">913,091</td><td class=\"xxxx-borders shading\">36</td><td class=\"xxxx-borders shading\">35</td><td class=\"xxxx-borders shading\">0.99 (0.62 to 1.64)</td><td class=\"xxxr-borders shading\">−0.4 (−3.0 to 3.1)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging01\" data-xml-align=\"left\">Syncope</td><td class=\"xxxx-borders\">858,068</td><td class=\"xxxx-borders\">326</td><td class=\"xxxx-borders\">267</td><td class=\"xxxx-borders\">1.12 (0.94 to 1.34)</td><td class=\"xxxr-borders\">6.2 (−3.2 to 15.4)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging01 shading\" data-xml-align=\"left\">Thrombocytopenia</td><td class=\"xxxx-borders shading\">923,123</td><td class=\"xxxx-borders shading\">56</td><td class=\"xxxx-borders shading\">60</td><td class=\"xxxx-borders shading\">0.94 (0.63 to 1.27)</td><td class=\"xxxr-borders shading\">−0.6 (−4.6 to 2.3)</td></tr><tr data-xml-align=\"center\"><td class=\"xxlx-borders hanging01\" data-xml-align=\"left\">Uveitis</td><td class=\"xxxx-borders\">933,217</td><td class=\"xxxx-borders\">26</td><td class=\"xxxx-borders\">20</td><td class=\"xxxx-borders\">1.27 (0.68 to 2.67)</td><td class=\"xxxr-borders\">1.0 (−1.5 to 3.8)</td></tr><tr data-xml-align=\"center\"><td class=\"xblx-borders hanging01 shading\" data-xml-align=\"left\">Vertigo</td><td class=\"xbxx-borders shading\">773,263</td><td class=\"xbxx-borders shading\">433</td><td class=\"xbxx-borders shading\">395</td><td class=\"xbxx-borders shading\">1.12 (0.97 to 1.28)</td><td class=\"xbxr-borders shading\">9.3 (−2.5 to 20.0)</td></tr></tbody></table></div><figcaption><div class=\"caption\">Adverse Events Associated with SARS-CoV-2 Vaccination.<a href=\"#t2fn1\" role=\"doc-noteref\">*</a></div><div class=\"notes\"><div role=\"doc-footnote\" data-has=\"label\"><div class=\"label\">*</div><div id=\"t2fn1\" role=\"paragraph\">Estimates were calculated with the use of the Kaplan–Meier estimator 42 days after vaccination or SARS-CoV-2 infection. Confidence intervals (CIs) were estimated with the use of the percentile bootstrap method with 500 repetitions.</div></div><div role=\"doc-footnote\" data-has=\"label\"><div class=\"label\">†</div><div id=\"t2fn2\" role=\"paragraph\">The “other thrombosis” category is a composite diagnosis that includes arterial embolism and thrombosis, venous embolism and thrombosis, vascular insufficiency of the intestine, portal-vein thrombosis, or cranial venous sinus thrombosis.</div></div></div></figcaption></figure></div><div role=\"paragraph\">Figure S1 shows the cumulative incidence (risk) curves for each specific adverse event. Spikes in the incidence of lymphadenopathy were seen after both the first and second doses of vaccine, whereas the incidence of myocarditis spiked mainly after the second dose of vaccine.</div></section><section id=\"sec-2-2\"><h3>SARS-CoV-2 Infection Analysis</h3><div role=\"paragraph\">A total of 233,392 persons (median age, 36 years) were eligible to be included in the SARS-CoV-2 infection cohort (<a href=\"#f2\">Figure 2</a>). On average, across the adverse event–specific cohorts, 75.8% of the eligible persons were successfully matched. <a href=\"#t1\">Table 1</a> shows the average distribution of characteristics in these cohorts, across the two study groups (infected and noninfected). The characteristics of each adverse event–specific cohort are provided in Table S5. The cohorts for the analysis of SARS-CoV-2 infection comprised a mean of 173,106 SARS-CoV-2–infected persons (median age, 34 years). A total of 54% of these persons were female.</div><div class=\"figure-wrap\" data-presentation=\"diminished-in-flow\"><header><div class=\"label\">Figure 2</div></header><figure id=\"f2\" class=\"graphic\"><img src=\"/cms/10.1056/NEJMoa2110475/asset/938326b3-ed95-4627-9316-17222e41f18f/assets/images/large/nejmoa2110475_f2.jpg\" height=\"1500\" width=\"1075\" aria-labelledby=\"f2\" loading=\"lazy\" /><figcaption><div class=\"caption\">Study Population for the SARS-CoV-2 Analysis.</div><div class=\"notes\"><div role=\"doc-footnote\">Absolute numbers and percentage changes are shown for each inclusion and exclusion criterion. The chart focuses on the SARS-CoV-2–infected population. The derivation group includes the entire population, including uninfected persons. The shaded boxes indicate the two study groups. The same exclusion criteria were applied to the uninfected persons for each index date on which they were considered for matching. Covid-19 denotes coronavirus disease 2019.</div></div></figcaption></figure></div><div role=\"paragraph\">Table S6 shows the effect of SARS-CoV-2 infection on the incidence of various adverse events. Infection substantially increased the risk of many different adverse events, including myocarditis (risk ratio, 18.28; 95% CI, 3.95 to 25.12; risk difference, 11.0 events per 100,000 persons; 95% CI, 5.6 to 15.8), acute kidney injury (risk ratio, 14.83; 95% CI, 9.24 to 28.75; risk difference, 125.4 events per 100,000 persons; 95% CI, 107.0 to 142.6), pulmonary embolism (risk ratio, 12.14; 95% CI, 6.89 to 29.20; risk difference, 61.7 events per 100,000 persons; 95% CI, 48.5 to 75.4), intracranial hemorrhage (risk ratio, 6.89; 95% CI, 1.90 to 19.16; risk difference, 7.6 events per 100,000 persons; 95% CI, 2.7 to 12.6), pericarditis (risk ratio, 5.39; 95% CI, 2.22 to 23.58; risk difference, 10.9 events per 100,000 persons; 95% CI, 4.9 to 16.9), myocardial infarction (risk ratio, 4.47; 95% CI, 2.47 to 9.95; risk difference, 25.1 events per 100,000 persons; 95% CI, 16.2 to 33.9), deep-vein thrombosis (risk ratio, 3.78; 95% CI, 2.50 to 6.59; risk difference, 43.0 events per 100,000 persons; 95% CI, 29.9 to 56.6), and arrhythmia (risk ratio, 3.83; 95% CI, 3.07 to 4.95; risk difference, 166.1 events per 100,000 persons; 95% CI, 139.6 to 193.2).</div></section><section id=\"sec-2-3\"><h3>Both Analyses</h3><div role=\"paragraph\"><a href=\"#f3\">Figure 3</a> shows estimated risk ratios in both the vaccination and SARS-CoV-2 infection analyses for adverse events in which vaccination or infection substantially increased the risk. <a href=\"#f4\">Figure 4</a> shows the absolute risk associated with vaccination, alongside the absolute risk associated with SARS-CoV-2 infection, for the same adverse events.</div><div class=\"figure-wrap\" data-presentation=\"diminished-in-flow\"><header><div class=\"label\">Figure 3</div></header><figure id=\"f3\" class=\"graphic\"><img src=\"/cms/10.1056/NEJMoa2110475/asset/6bb7e88d-d03d-48d4-8d70-ef4adb4ff49f/assets/images/large/nejmoa2110475_f3.jpg\" height=\"1139\" width=\"1500\" aria-labelledby=\"f3\" loading=\"lazy\" /><figcaption><div class=\"caption\">Risk Ratios for Adverse Events after Vaccination or SARS-CoV-2 Infection.</div><div class=\"notes\"><div role=\"doc-footnote\">Estimated risk ratios for adverse events after vaccination or SARS-CoV-2 infection are shown. The risk ratio on the y axis is presented on a logarithmic scale to facilitate comparison of both increased and decreased risk. 𝙸 bars indicate 95% confidence intervals.</div></div></figcaption></figure></div><div class=\"figure-wrap\" data-presentation=\"diminished-in-flow\"><header><div class=\"label\">Figure 4</div></header><figure id=\"f4\" class=\"graphic\"><img src=\"/cms/10.1056/NEJMoa2110475/asset/29e40d5c-aa86-45bd-9439-5b174b45d147/assets/images/large/nejmoa2110475_f4.jpg\" height=\"943\" width=\"1500\" aria-labelledby=\"f4\" loading=\"lazy\" /><figcaption><div class=\"caption\">Absolute Excess Risk of Various Adverse Events after Vaccination or SARS-CoV-2 Infection.</div><div class=\"notes\"><div role=\"doc-footnote\">Point estimates of the risk differences for selected adverse events are shown. Estimates were derived 42 days after vaccination or SARS-CoV-2 infection with the use of the Kaplan–Meier estimator. Risk differences are shown per 100,000 persons and rounded to the nearest integer. Negative differences (decreased risk) are represented as negative values on the y axis, and positive differences (increased risk) are represented as positive values on the y axis. The abbreviation mRNA denotes messenger RNA.</div></div></figcaption></figure></div></section></section><section id=\"sec-3\" data-type=\"discussion\"><h2>Discussion</h2><div role=\"paragraph\">We used a data set involving more than 2.4 million vaccinated persons from an integrated health care organization to evaluate the safety profile of the BNT162b2 mRNA Covid-19 vaccine. The main potential adverse events identified included an excess risk of lymphadenopathy (78.4 events per 100,000 persons), herpes zoster infection (15.8 events), appendicitis (5.0 events), and myocarditis (2.7 events).</div><div role=\"paragraph\">To place these risks in context, we also examined data on more than 240,000 infected persons to estimate the effects of a documented SARS-CoV-2 infection on the incidence of the same adverse events. SARS-CoV-2 infection was not estimated to have a meaningful effect on the incidence of lymphadenopathy, herpes zoster infection, or appendicitis, but it was estimated to result in a substantial excess risk of myocarditis (11.0 events per 100,000 persons). SARS-CoV-2 infection was also estimated to substantially increase the risk of several adverse events for which vaccination was not found to increase the risk, including an estimated excess risk of arrhythmia (166.1 events per 100,000 persons), acute kidney injury (125.4 events), pulmonary embolism (61.7 events), deep-vein thrombosis (43.0 events), myocardial infarction (25.1 events), pericarditis (10.9 events), and intracranial hemorrhage (7.6 events).</div><div role=\"paragraph\">An association between Covid-19 vaccination and myocarditis has been previously reported.<sup><a href=\"#r20\" role=\"doc-biblioref\" data-xml-rid=\"r20\">20</a></sup> Although no cases of myocarditis were reported in the BNT162b2 (Pfizer–BioNTech),<sup><a href=\"#r2\" role=\"doc-biblioref\" data-xml-rid=\"r2\">2</a></sup> mRNA-1273 (Moderna),<sup><a href=\"#r3\" role=\"doc-biblioref\" data-xml-rid=\"r3\">3</a></sup> or ChAdOx1 nCoV-19 (AstraZeneca)<sup><a href=\"#r4\" role=\"doc-biblioref\" data-xml-rid=\"r4\">4</a></sup> phase 3 clinical trials, multiple cases of myocarditis after Covid-19 vaccination have recently been reported in the literature,<sup><a href=\"#r21\" role=\"doc-biblioref\" data-xml-rid=\"r21 r22 r23 r24 r25\">21-25</a></sup> and both the Israeli Ministry of Health<sup><a href=\"#r26\" role=\"doc-biblioref\" data-xml-rid=\"r26\">26</a></sup> and the CDC have investigated this association.<sup><a href=\"#r27\" role=\"doc-biblioref\" data-xml-rid=\"r27\">27</a></sup> The risk appears to be highest among young men.<sup><a href=\"#r26\" role=\"doc-biblioref\" data-xml-rid=\"r26 r27\">26,27</a></sup> We found that the risk of myocarditis increased by a factor of three after vaccination, which translated to approximately 3 excess events per 100,000 persons; the 95% confidence interval indicated that values between 1 and 5 excess events per 100,000 persons were compatible with our data. Among the 21 persons with myocarditis in the vaccinated group, the median age was 25 years (interquartile range, 20 to 34), and 90.9% were male.</div><div role=\"paragraph\">Another vaccine-related adverse event that has recently received attention in the medical literature is Bell’s palsy. In a recent article based on publicly available data from the BNT162b2 and mRNA-1273 vaccine trials, Ozonoff et al.<sup><a href=\"#r28\" role=\"doc-biblioref\" data-xml-rid=\"r28\">28</a></sup> suggested a possible association between these vaccines and Bell’s palsy and estimated a rate ratio of approximately 7.0. This conclusion differed from the Food and Drug Administration briefing on these vaccines in December 2020; that briefing considered the incidence of Bell’s palsy to be similar to the background incidence.<sup><a href=\"#r5\" role=\"doc-biblioref\" data-xml-rid=\"r5\">5</a></sup> A small number of cases of Bell’s palsy after Covid-19 vaccination have also been reported in the literature.<sup><a href=\"#r29\" role=\"doc-biblioref\" data-xml-rid=\"r29 r30\">29,30</a></sup> In the current study, the effect estimate was consistent with a potentially mild increase in the risk of Bell’s palsy after vaccination, with a risk ratio of 1.32 (95% CI, 0.92 to 1.86). The absolute effect was small, with up to 8 excess events per 100,000 persons being highly compatible with our data according to the 95% confidence interval. Herpes zoster infection, the incidence of which we found to be increased after vaccination, is one of the potential causes of facial-nerve palsy.<sup><a href=\"#r31\" role=\"doc-biblioref\" data-xml-rid=\"r31\">31</a></sup></div><div role=\"paragraph\">Another particularly notable class of adverse events that has been reported in the context of Covid-19 vaccines is thromboembolic events. These adverse events, which primarily affect young women, have been linked with the ChAdOx1 nCoV-19<sup><a href=\"#r32\" role=\"doc-biblioref\" data-xml-rid=\"r32\">32</a></sup> and Ad26.COV2.S (Johnson &amp; Johnson–Janssen) Covid-19 vaccines,<sup><a href=\"#r33\" role=\"doc-biblioref\" data-xml-rid=\"r33\">33</a></sup> both of which are adenoviral vector vaccines. However, we did not find an association between the BNT162b2 vaccine and various thromboembolic events in this study.</div><div role=\"paragraph\">Some initially unexpected effects were seen in the results of the current study. The BNT162b2 vaccine appears to be protective against certain conditions such as anemia and intracranial hemorrhage. These same adverse events are also identified in this study as complications of SARS-CoV-2 infection, so it appears likely that the protective effect of the vaccine is mediated through its protection against undiagnosed SARS-CoV-2 infection, which may be undiagnosed either because of a lack of testing or because of false negative PCR results.</div><div role=\"paragraph\">This study has several limitations. First, persons in the study were not randomly assigned according to exposures (vaccinations and SARS-CoV-2 infections); this may have introduced confounding at baseline and selection bias at censoring, especially since a single set of confounders was used for adjustment in the assessment of many disparate adverse events. Second, the matching process that was necessary to attain exchangeability between the study groups resulted in a study population with a different composition than the eligible population (e.g., median age, 38 years rather than 43 years). Because this different composition changes the population over which the causal effect is being estimated, different estimates might be found for adverse events for which the incidence may differ substantially between subgroups (e.g., myocarditis). Also, we excluded certain populations (such as health care workers and persons residing in long-term care facilities) that could be at particularly high risk for certain adverse events. Both of these issues should be taken into account when considering the generalizability of the findings.</div><div role=\"paragraph\">Third, some diagnoses that were recorded in out-of-network hospitals, which were delayed in being reported to the insurer and were not entered by the person’s general practitioner from the hospital discharge notes into the outpatient medical record, could have been missed. Fourth, it is possible that persons are more likely to increase their levels of clinical awareness, concern, or both after vaccination or SARS-CoV-2 infection, and thus they may be more likely to report or seek medical care for their symptoms, resulting in a spuriously increased incidence of the various adverse events in the vaccinated or infected groups. Similarly, among persons with SARS-CoV-2 infection, the spike in the incidence of certain adverse events in the first day of follow-up could indicate the initial clinical manifestation of the infection, but it could also be related to active testing for SARS-CoV-2. Fifth, all the effect measures that we presented are based only on a new incidence of the specific adverse event under study; thus, less light was shed on the potential additional risk among persons with a medical history of each of these adverse events. However, this choice was necessary to distinguish between true new diagnoses of a given adverse event and recoding of past diagnoses and to ensure the accuracy of the adverse-event labels.</div><div role=\"paragraph\">In this study, we sought to place the increased risk of adverse events caused by the BNT162b2 vaccine in context by contrasting this risk with that of the same adverse events after documented infection with SARS-CoV-2. We thought that this was necessary because vaccination and its potential risks do not occur in a void but rather in the context of an ongoing pandemic. Although the general risks of hospitalization, severe disease, and death from Covid-19 are widely recognized, secondary complications of infection are less well known. Therefore, in this analysis, we sought to estimate the effects of SARS-CoV-2 infection on the incidence of the same list of adverse events examined in the vaccination analysis. Because the cohorts that we used to study the vaccine and infection effects were different in composition, care should be taken when comparing the resulting risk estimates. In addition, knowledge of these risks alone is insufficient for a complete decision-theoretic analysis. When a person decides to become vaccinated, this choice results in a probability of 100% for the vaccination, whereas the alternative of contracting SARS-CoV-2 infection is an event with uncertain probability that depends on the person, place, and time. Moreover, infection with SARS-CoV-2 has many other adverse effects beyond those considered here, including the risk of transmission to family members and others.</div><div role=\"paragraph\">We estimated that the BNT162b2 vaccine resulted in an increased incidence of a few adverse events over a 42-day follow-up period. Although most of these events were mild, some of them, such as myocarditis, could be potentially serious. However, our results indicate that SARS-CoV-2 infection is itself a very strong risk factor for myocarditis, and it also substantially increases the risk of multiple other serious adverse events. These findings help to shed light on the short- and medium-term risks of the vaccine and place them in clinical context. Further studies will be needed to estimate the potential of long-term adverse events.</div></section>\n\n\n\n        \n        \n</div></section><section id=\"backmatter\" data-extent=\"backmatter\" data-location=\"articleTab_article\"><div class=\"core-container\"><section id=\"backnotes\" data-location=\"notes_article\"><h2>Notes</h2><div data-type=\"disclaimer\" role=\"paragraph\">Because of data privacy regulations, the raw data for this study cannot be shared.</div><div data-type=\"published/updated\" role=\"paragraph\">This article was published on August 25, 2021, at NEJM.org.</div><div role=\"paragraph\">Supported by the Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at <span class=\"named-content\" data-type=\"funder\">Harvard Medical School</span> and <span class=\"named-content\" data-type=\"funder\">Clalit Research Institute</span>. Dr. Lipsitch receives support from the <span class=\"named-content\" data-type=\"funder\">Morris–Singer Foundation</span>.</div><div role=\"paragraph\"><a href=\"#ap2\">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role=\"paragraph\">We thank Oren Miron for his valuable advice.</div></section><section id=\"supplementary-materials\" class=\"core-supplementary-materials\"><h2>Supplementary Material</h2><div role=\"list\"><div id=\"ap1\" class=\"core-supplementary-material\" role=\"listitem\"><div class=\"core-description\"><span class=\"core-label\">Supplementary Appendix</span> <span class=\"core-filename\">(nejmoa2110475_appendix.pdf)</span></div><div class=\"core-link\"><ul><li><a href=\"/doi/suppl/10.1056/NEJMoa2110475/suppl_file/nejmoa2110475_appendix.pdf\" download=\"nejmoa2110475_appendix.pdf\" data-interactiontype=\"multimedia_download\" data-multimedia-type=\"Supplementary Material\"data-behavior=\"trackDownloadEvent\" data-multimedia-filename=\"nejmoa2110475_appendix.pdf\" data-doi=\"10.1056/NEJMoa2110475\">Download</a></li><li>4.32 MB</li></ul></div></div><div id=\"ap2\" class=\"core-supplementary-material\" role=\"listitem\"><div class=\"core-description\"><span class=\"core-label\">Disclosure Forms</span> <span class=\"core-filename\">(nejmoa2110475_disclosures.pdf)</span></div><div class=\"core-link\"><ul><li><a href=\"/doi/suppl/10.1056/NEJMoa2110475/suppl_file/nejmoa2110475_disclosures.pdf\" download=\"nejmoa2110475_disclosures.pdf\" data-interactiontype=\"multimedia_download\" data-multimedia-type=\"Supplementary Material\"data-behavior=\"trackDownloadEvent\" data-multimedia-filename=\"nejmoa2110475_disclosures.pdf\" data-doi=\"10.1056/NEJMoa2110475\">Download</a></li><li>447.73 KB</li></ul></div></div></div></section><section id=\"bibliography\" class=\"core-reference-list\" role=\"doc-bibliography\" data-location=\"references_article\"><h2>References</h2><div role=\"list\"><div role=\"listitem\" data-has=\"label\"><div class=\"label\">1.</div><div id=\"r1\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Our World in Data. Coronavirus (COVID-19) vaccinations. Statistics and research (<a href=\"https://ourworldindata.org/covid-vaccinations#source-information-country-by-country\">https://ourworldindata.org/covid-vaccinations#source-information-country-by-country</a>).</div><div class=\"external-links\"><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=Coronavirus+%28COVID-19%29+vaccinations.+Statistics+and+research\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">2.</div><div id=\"r2\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. <em>N Engl J Med</em> 2020;383:2603-2615.</div><div class=\"external-links\"><div class=\"core-xlink-crossref\"><a href=\"https://doi.org/10.1056/NEJMoa2034577\" target=\"_blank\">Crossref</a></div><div class=\"core-xlink-pubmed\"><a href=\"https://pubmed.ncbi.nlm.nih.gov/33301246/\" target=\"_blank\">PubMed</a></div><div class=\"core-xlink-isi\"><a href=\"https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000605648000010\" target=\"_blank\">ISI</a></div><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+the+BNT162b2+mRNA+Covid-19+vaccine.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=2603-2615&amp;doi=10.1056%2FNEJMoa2034577&amp;pmid=33301246\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">3.</div><div id=\"r3\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. <em>N Engl J Med</em> 2021;384:403-416.</div><div class=\"external-links\"><div class=\"core-xlink-crossref\"><a href=\"https://doi.org/10.1056/NEJMoa2035389\" target=\"_blank\">Crossref</a></div><div class=\"core-xlink-pubmed\"><a href=\"https://pubmed.ncbi.nlm.nih.gov/33378609/\" target=\"_blank\">PubMed</a></div><div class=\"core-xlink-isi\"><a href=\"https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000629333200009\" target=\"_blank\">ISI</a></div><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+the+mRNA-1273+SARS-CoV-2+vaccine.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=403-416&amp;doi=10.1056%2FNEJMoa2035389&amp;pmid=33378609\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">4.</div><div id=\"r4\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <em>Lancet</em> 2021;397:99-111.</div><div class=\"external-links\"><div class=\"core-xlink-crossref\"><a href=\"https://doi.org/10.1016/S0140-6736(20)32661-1\" target=\"_blank\">Crossref</a></div><div class=\"core-xlink-pubmed\"><a href=\"https://pubmed.ncbi.nlm.nih.gov/33306989/\" target=\"_blank\">PubMed</a></div><div class=\"core-xlink-isi\"><a href=\"https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000607269000027\" target=\"_blank\">ISI</a></div><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+the+ChAdOx1+nCoV-19+vaccine+%28AZD1222%29+against+SARS-CoV-2%3A+an+interim+analysis+of+four+randomised+controlled+trials+in+Brazil%2C+South+Africa%2C+and+the+UK.&amp;publication_year=2021&amp;journal=Lancet&amp;pages=99-111&amp;doi=10.1016%2FS0140-6736%2820%2932661-1&amp;pmid=33306989\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">5.</div><div id=\"r5\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee: December 10, 2020 meeting announcement. December 2020 (<a href=\"https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-december-10-2020-meeting-announcement\">https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-december-10-2020-meeting-announcement</a>).</div><div class=\"external-links\"><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=Vaccines+and+Related+Biological+Products+Advisory+Committee%3A+December+10%2C+2020+meeting+announcement&amp;publication_year=2020\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">6.</div><div id=\"r6\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Vaccine Adverse Event Reporting System. Report an adverse event to VAERS (<a href=\"https://vaers.hhs.gov/reportevent.html\">https://vaers.hhs.gov/reportevent.html</a>).</div><div class=\"external-links\"><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=Report+an+adverse+event+to+VAERS\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">7.</div><div id=\"r7\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">World Health Organization. Background paper on Covid-19 disease and vaccines: prepared by the Strategic Advisory Group of Experts (SAGE) on immunization working group on COVID-19 vaccines. December 22, 2020 (<a href=\"https://apps.who.int/iris/handle/10665/338095\">https://apps.who.int/iris/handle/10665/338095</a>).</div><div class=\"external-links\"><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=Background+paper+on+Covid-19+disease+and+vaccines%3A+prepared+by+the+Strategic+Advisory+Group+of+Experts+%28SAGE%29+on+immunization+working+group+on+COVID-19+vaccines&amp;publication_year=2020\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">8.</div><div id=\"r8\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Law B, Sturkenboom M. SPEAC — Safety Platform for Emergency vACcines D2.3 priority list of adverse events of special interest: COVID-19. May 25, 2020 (<a href=\"https://brightoncollaboration.us/wp-content/uploads/2020/06/SPEAC_D2.3_V2.0_COVID-19_20200525_public.pdf\">https://brightoncollaboration.us/wp-content/uploads/2020/06/SPEAC_D2.3_V2.0_COVID-19_20200525_public.pdf</a>).</div><div class=\"external-links\"><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=SPEAC+%E2%80%94+Safety+Platform+for+Emergency+vACcines+D2.3+priority+list+of+adverse+events+of+special+interest%3A+COVID-19&amp;publication_year=2020\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">9.</div><div id=\"r9\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Biologics Effectiveness and Safety (BEST) Initiative home page (<a href=\"https://www.bestinitiative.org\">https://www.bestinitiative.org</a>).</div><div class=\"external-links\"><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar?q=Biologics+Effectiveness+and+Safety+%28BEST%29+Initiative+home+page+%28https%3A%2F%2Fwww.bestinitiative.org%29.\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">10.</div><div id=\"r10\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. <em>N Engl J Med</em> 2021;384:1412-1423.</div><div class=\"external-links\"><div class=\"core-xlink-crossref\"><a href=\"https://doi.org/10.1056/NEJMoa2101765\" target=\"_blank\">Crossref</a></div><div class=\"core-xlink-pubmed\"><a href=\"https://pubmed.ncbi.nlm.nih.gov/33626250/\" target=\"_blank\">PubMed</a></div><div class=\"core-xlink-isi\"><a href=\"https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000640554500008\" target=\"_blank\">ISI</a></div><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=BNT162b2+mRNA+Covid-19+vaccine+in+a+nationwide+mass+vaccination+setting.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=1412-1423&amp;doi=10.1056%2FNEJMoa2101765&amp;pmid=33626250\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">11.</div><div id=\"r11\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Hall VJ, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. <em>Lancet</em> 2021;397:1725-1735.</div><div class=\"external-links\"><div class=\"core-xlink-crossref\"><a href=\"https://doi.org/10.1016/S0140-6736(21)00790-X\" target=\"_blank\">Crossref</a></div><div class=\"core-xlink-pubmed\"><a href=\"https://pubmed.ncbi.nlm.nih.gov/33901423/\" target=\"_blank\">PubMed</a></div><div class=\"core-xlink-isi\"><a href=\"https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000647813600027\" target=\"_blank\">ISI</a></div><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=COVID-19+vaccine+coverage+in+health-care+workers+in+England+and+effectiveness+of+BNT162b2+mRNA+vaccine+against+infection+%28SIREN%29%3A+a+prospective%2C+multicentre%2C+cohort+study.&amp;publication_year=2021&amp;journal=Lancet&amp;pages=1725-1735&amp;doi=10.1016%2FS0140-6736%2821%2900790-X&amp;pmid=33901423\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">12.</div><div id=\"r12\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. <em>Lancet Infect Dis</em> 2021;21:939-949.</div><div class=\"external-links\"><div class=\"core-xlink-crossref\"><a href=\"https://doi.org/10.1016/S1473-3099(21)00224-3\" target=\"_blank\">Crossref</a></div><div class=\"core-xlink-pubmed\"><a href=\"https://pubmed.ncbi.nlm.nih.gov/33930320/\" target=\"_blank\">PubMed</a></div><div class=\"core-xlink-isi\"><a href=\"https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000669688900033\" target=\"_blank\">ISI</a></div><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=Vaccine+side-effects+and+SARS-CoV-2+infection+after+vaccination+in+users+of+the+COVID+Symptom+Study+app+in+the+UK%3A+a+prospective+observational+study.&amp;publication_year=2021&amp;journal=Lancet+Infect+Dis&amp;pages=939-949&amp;doi=10.1016%2FS1473-3099%2821%2900224-3&amp;pmid=33930320\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">13.</div><div id=\"r13\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Mathioudakis AG, Ghrew M, Ustianowski A, et al. Self-reported real-world safety and reactogenicity of COVID-19 vaccines: a vaccine recipient survey. <em>Life (Basel)</em> 2021;11:249-249.</div><div class=\"external-links\"><div class=\"core-xlink-pubmed\"><a href=\"https://pubmed.ncbi.nlm.nih.gov/33803014/\" target=\"_blank\">PubMed</a></div><div class=\"core-xlink-isi\"><a href=\"https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000633818300001\" target=\"_blank\">ISI</a></div><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=Self-reported+real-world+safety+and+reactogenicity+of+COVID-19+vaccines%3A+a+vaccine+recipient+survey.&amp;publication_year=2021&amp;journal=Life+%28Basel%29&amp;pages=249-249&amp;pmid=33803014\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">14.</div><div id=\"r14\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Song JY, Cheong HJ, Kim SR, et al. Early safety monitoring of COVID-19 vaccines in healthcare workers. <em>J Korean Med Sci</em> 2021;36(15):e110-e110.</div><div class=\"external-links\"><div class=\"core-xlink-crossref\"><a href=\"https://doi.org/10.3346/jkms.2021.36.e110\" target=\"_blank\">Crossref</a></div><div class=\"core-xlink-pubmed\"><a href=\"https://pubmed.ncbi.nlm.nih.gov/33876589/\" target=\"_blank\">PubMed</a></div><div class=\"core-xlink-isi\"><a href=\"https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000646716500006\" target=\"_blank\">ISI</a></div><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=Early+safety+monitoring+of+COVID-19+vaccines+in+healthcare+workers.&amp;publication_year=2021&amp;journal=J+Korean+Med+Sci&amp;pages=e110-e110&amp;doi=10.3346%2Fjkms.2021.36.e110&amp;pmid=33876589\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">15.</div><div id=\"r15\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Chen G, Li X, Sun M, et al. COVID-19 mRNA vaccines are generally safe in the short term: a vaccine vigilance real-world study says. <em>Front Immunol</em> 2021;12:669010-669010.</div><div class=\"external-links\"><div class=\"core-xlink-crossref\"><a href=\"https://doi.org/10.3389/fimmu.2021.669010\" target=\"_blank\">Crossref</a></div><div class=\"core-xlink-pubmed\"><a href=\"https://pubmed.ncbi.nlm.nih.gov/34093567/\" target=\"_blank\">PubMed</a></div><div class=\"core-xlink-isi\"><a href=\"https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000657642000001\" target=\"_blank\">ISI</a></div><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=COVID-19+mRNA+vaccines+are+generally+safe+in+the+short+term%3A+a+vaccine+vigilance+real-world+study+says.&amp;publication_year=2021&amp;journal=Front+Immunol&amp;pages=669010-669010&amp;doi=10.3389%2Ffimmu.2021.669010&amp;pmid=34093567\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">16.</div><div id=\"r16\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Bardenheier BH, Gravenstein S, Blackman C, et al. Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents. <em>Vaccine</em> 2021;39:3844-3851.</div><div class=\"external-links\"><div class=\"core-xlink-crossref\"><a href=\"https://doi.org/10.1016/j.vaccine.2021.05.088\" target=\"_blank\">Crossref</a></div><div class=\"core-xlink-pubmed\"><a href=\"https://pubmed.ncbi.nlm.nih.gov/34092431/\" target=\"_blank\">PubMed</a></div><div class=\"core-xlink-isi\"><a href=\"https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000663773600010\" target=\"_blank\">ISI</a></div><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=Adverse+events+following+mRNA+SARS-CoV-2+vaccination+among+U.S.+nursing+home+residents&amp;publication_year=2021&amp;journal=Vaccine&amp;pages=3844-3851&amp;doi=10.1016%2Fj.vaccine.2021.05.088&amp;pmid=34092431\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">17.</div><div id=\"r17\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Cohen R, Rabin H. National Insurance Institute of Israel. Membership in sick funds 2016. August 2017. (In Hebrew) (<a href=\"https://www.btl.gov.il/Publications/survey/Documents/seker289/seker_289.pdf\">https://www.btl.gov.il/Publications/survey/Documents/seker289/seker_289.pdf</a>).</div><div class=\"external-links\"><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=Membership+in+sick+funds+2016&amp;publication_year=2017\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">18.</div><div id=\"r18\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Centers for Disease Control and Prevention. People with certain medical conditions. May 2021 (<a href=\"https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html\">https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html</a>).</div><div class=\"external-links\"><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=People+with+certain+medical+conditions&amp;publication_year=2021\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">19.</div><div id=\"r19\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. <em>J Am Stat Assoc</em> 1958;53:457-481.</div><div class=\"external-links\"><div class=\"core-xlink-crossref\"><a href=\"https://doi.org/10.1080/01621459.1958.10501452\" target=\"_blank\">Crossref</a></div><div class=\"core-xlink-pubmed\"><a href=\"NOT_FOUND/\" target=\"_blank\">PubMed</a></div><div class=\"core-xlink-isi\"><a href=\"https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1958WX09300012\" target=\"_blank\">ISI</a></div><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=Nonparametric+estimation+from+incomplete+observations.&amp;publication_year=1958&amp;journal=J+Am+Stat+Assoc&amp;pages=457-481&amp;doi=10.1080%2F01621459.1958.10501452&amp;pmid=NOT_FOUND\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">20.</div><div id=\"r20\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Castiello T, Georgiopoulos G, Finocchiaro G, et al. COVID-19 and myocarditis: a systematic review and overview of current challenges. <em>Heart Fail Rev</em> 2021 March 24 (Epub ahead of print).</div><div class=\"external-links\"><div class=\"core-xlink-crossref\"><a href=\"https://doi.org/10.1007/s10741-021-10087-9\" target=\"_blank\">Crossref</a></div><div class=\"core-xlink-pubmed\"><a href=\"https://pubmed.ncbi.nlm.nih.gov/33761041/\" target=\"_blank\">PubMed</a></div><div class=\"core-xlink-isi\"><a href=\"https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000632306400001\" target=\"_blank\">ISI</a></div><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=COVID-19+and+myocarditis%3A+a+systematic+review+and+overview+of+current+challenges.&amp;publication_year=2021&amp;journal=Heart+Fail+Rev&amp;doi=10.1007%2Fs10741-021-10087-9&amp;pmid=33761041\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">21.</div><div id=\"r21\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Ammirati E, Cavalotti C, Milazzo A, et al. Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection. <em>Int J Cardiol Heart Vasc</em> 2021;34:100774-100774.</div><div class=\"external-links\"><div class=\"core-xlink-crossref\"><a href=\"https://doi.org/10.1016/j.ijcha.2021.100774\" target=\"_blank\">Crossref</a></div><div class=\"core-xlink-pubmed\"><a href=\"https://pubmed.ncbi.nlm.nih.gov/33821210/\" target=\"_blank\">PubMed</a></div><div class=\"core-xlink-isi\"><a href=\"https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000667480400011\" target=\"_blank\">ISI</a></div><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=Temporal+relation+between+second+dose+BNT162b2+mRNA+Covid-19+vaccine+and+cardiac+involvement+in+a+patient+with+previous+SARS-COV-2+infection.&amp;publication_year=2021&amp;journal=Int+J+Cardiol+Heart+Vasc&amp;pages=100774-100774&amp;doi=10.1016%2Fj.ijcha.2021.100774&amp;pmid=33821210\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">22.</div><div id=\"r22\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Abu Mouch S, Roguin A, Hellou E, et al. Myocarditis following COVID-19 mRNA vaccination. <em>Vaccine</em> 2021;39:3790-3793.</div><div class=\"external-links\"><div class=\"core-xlink-crossref\"><a href=\"https://doi.org/10.1016/j.vaccine.2021.05.087\" target=\"_blank\">Crossref</a></div><div class=\"core-xlink-pubmed\"><a href=\"https://pubmed.ncbi.nlm.nih.gov/34092429/\" target=\"_blank\">PubMed</a></div><div class=\"core-xlink-isi\"><a href=\"https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000663773600003\" target=\"_blank\">ISI</a></div><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=Myocarditis+following+COVID-19+mRNA+vaccination.&amp;publication_year=2021&amp;journal=Vaccine&amp;pages=3790-3793&amp;doi=10.1016%2Fj.vaccine.2021.05.087&amp;pmid=34092429\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">23.</div><div id=\"r23\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Marshall M, Ferguson ID, Lewis P, et al. Symptomatic acute myocarditis in seven adolescents following Pfizer-BioNTech COVID-19 vaccination. <em>Pediatrics</em> 2021 June 4 (Epub ahead of print).</div><div class=\"external-links\"><div class=\"core-xlink-crossref\"><a href=\"https://doi.org/10.1542/peds.2021-052478\" target=\"_blank\">Crossref</a></div><div class=\"core-xlink-pubmed\"><a href=\"https://pubmed.ncbi.nlm.nih.gov/34088762/\" target=\"_blank\">PubMed</a></div><div class=\"core-xlink-isi\"><a href=\"https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000755048000072\" target=\"_blank\">ISI</a></div><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=Symptomatic+acute+myocarditis+in+seven+adolescents+following+Pfizer-BioNTech+COVID-19+vaccination.&amp;publication_year=2021&amp;journal=Pediatrics&amp;doi=10.1542%2Fpeds.2021-052478&amp;pmid=34088762\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">24.</div><div id=\"r24\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Albert E, Aurigemma G, Saucedo J, Gerson DS. Myocarditis following COVID-19 vaccination. <em>Radiol Case Rep</em> 2021;16:2142-2145.</div><div class=\"external-links\"><div class=\"core-xlink-crossref\"><a href=\"https://doi.org/10.1016/j.radcr.2021.05.033\" target=\"_blank\">Crossref</a></div><div class=\"core-xlink-pubmed\"><a href=\"https://pubmed.ncbi.nlm.nih.gov/34025885/\" target=\"_blank\">PubMed</a></div><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=Myocarditis+following+COVID-19+vaccination.&amp;publication_year=2021&amp;journal=Radiol+Case+Rep&amp;pages=2142-2145&amp;doi=10.1016%2Fj.radcr.2021.05.033&amp;pmid=34025885\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">25.</div><div id=\"r25\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Bautista García J, Peña Ortega P, Bonilla Fernández JA, Cárdenes León A, Ramírez Burgos L, Caballero Dorta E. Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19. <em>Rev Esp Cardiol (Engl Ed)</em> 2021 April 27 (Epub ahead of print).</div><div class=\"external-links\"><div class=\"core-xlink-pubmed\"><a href=\"https://pubmed.ncbi.nlm.nih.gov/33994339/\" target=\"_blank\">PubMed</a></div><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=Acute+myocarditis+after+administration+of+the+BNT162b2+vaccine+against+COVID-19&amp;publication_year=2021&amp;pmid=33994339\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">26.</div><div id=\"r26\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Surveillance of myocarditis (inflammation of the heart muscle) cases between December 2020 and May 2021 (including). <em>Press release of the Israeli Ministry of Health</em>, February 6, 2021 (<a href=\"https://www.gov.il/en/departments/news/01062021-03\">https://www.gov.il/en/departments/news/01062021-03</a>).</div><div class=\"external-links\"><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=Surveillance+of+myocarditis+%28inflammation+of+the+heart+muscle%29+cases+between+December+2020+and+May+2021+%28including%29&amp;publication_year=2021\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">27.</div><div id=\"r27\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Centers for Disease Control and Prevention. Myocarditis and pericarditis following mRNA COVID-19 vaccination. June 23, 2021 (<a href=\"https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html\">https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html</a>).</div><div class=\"external-links\"><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=Myocarditis+and+pericarditis+following+mRNA+COVID-19+vaccination\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">28.</div><div id=\"r28\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Ozonoff A, Nanishi E, Levy O. Bell’s palsy and SARS-CoV-2 vaccines. <em>Lancet Infect Dis</em> 2021;21:450-452.</div><div class=\"external-links\"><div class=\"core-xlink-crossref\"><a href=\"https://doi.org/10.1016/S1473-3099(21)00076-1\" target=\"_blank\">Crossref</a></div><div class=\"core-xlink-pubmed\"><a href=\"https://pubmed.ncbi.nlm.nih.gov/33639103/\" target=\"_blank\">PubMed</a></div><div class=\"core-xlink-isi\"><a href=\"https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000637956500006\" target=\"_blank\">ISI</a></div><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=Bell%E2%80%99s+palsy+and+SARS-CoV-2+vaccines.&amp;publication_year=2021&amp;journal=Lancet+Infect+Dis&amp;pages=450-452&amp;doi=10.1016%2FS1473-3099%2821%2900076-1&amp;pmid=33639103\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">29.</div><div id=\"r29\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Repajic M, Lai XL, Xu P, Liu A. Bell’s palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell’s palsy. <em>Brain Behav Immun Health</em> 2021;13:100217-100217.</div><div class=\"external-links\"><div class=\"core-xlink-crossref\"><a href=\"https://doi.org/10.1016/j.bbih.2021.100217\" target=\"_blank\">Crossref</a></div><div class=\"core-xlink-pubmed\"><a href=\"https://pubmed.ncbi.nlm.nih.gov/33594349/\" target=\"_blank\">PubMed</a></div><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=Bell%E2%80%99s+palsy+after+second+dose+of+Pfizer+COVID-19+vaccination+in+a+patient+with+history+of+recurrent+Bell%E2%80%99s+palsy.&amp;publication_year=2021&amp;journal=Brain+Behav+Immun+Health&amp;pages=100217-100217&amp;doi=10.1016%2Fj.bbih.2021.100217&amp;pmid=33594349\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">30.</div><div id=\"r30\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Colella G, Orlandi M, Cirillo N. Bell’s palsy following COVID-19 vaccination. <em>J Neurol</em> 2021 February 21 (Epub ahead of print).</div><div class=\"external-links\"><div class=\"core-xlink-crossref\"><a href=\"https://doi.org/10.1007/s00415-021-10462-4\" target=\"_blank\">Crossref</a></div><div class=\"core-xlink-pubmed\"><a href=\"https://pubmed.ncbi.nlm.nih.gov/33611630/\" target=\"_blank\">PubMed</a></div><div class=\"core-xlink-isi\"><a href=\"https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000620102200003\" target=\"_blank\">ISI</a></div><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=Bell%E2%80%99s+palsy+following+COVID-19+vaccination.&amp;publication_year=2021&amp;journal=J+Neurol&amp;doi=10.1007%2Fs00415-021-10462-4&amp;pmid=33611630\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">31.</div><div id=\"r31\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Peitersen E. Bell’s palsy: the spontaneous course of 2,500 peripheral facial nerve palsies of different etiologies. <em>Acta Otolaryngol Suppl</em> 2002;549:4-30.</div><div class=\"external-links\"><div class=\"core-xlink-crossref\"><a href=\"https://doi.org/10.1080/000164802760370736\" target=\"_blank\">Crossref</a></div><div class=\"core-xlink-pubmed\"><a href=\"https://pubmed.ncbi.nlm.nih.gov/12482166/\" target=\"_blank\">PubMed</a></div><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=Bell%E2%80%99s+palsy%3A+the+spontaneous+course+of+2%2C500+peripheral+facial+nerve+palsies+of+different+etiologies.&amp;publication_year=2002&amp;journal=Acta+Otolaryngol+Suppl&amp;pages=4-30&amp;doi=10.1080%2F000164802760370736&amp;pmid=12482166\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">32.</div><div id=\"r32\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. <em>N Engl J Med</em> 2021;384:2092-2101.</div><div class=\"external-links\"><div class=\"core-xlink-crossref\"><a href=\"https://doi.org/10.1056/NEJMoa2104840\" target=\"_blank\">Crossref</a></div><div class=\"core-xlink-pubmed\"><a href=\"https://pubmed.ncbi.nlm.nih.gov/33835769/\" target=\"_blank\">PubMed</a></div><div class=\"core-xlink-isi\"><a href=\"https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000640363200001\" target=\"_blank\">ISI</a></div><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=Thrombotic+thrombocytopenia+after+ChAdOx1+nCov-19+vaccination.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=2092-2101&amp;doi=10.1056%2FNEJMoa2104840&amp;pmid=33835769\" target=\"_blank\">Google Scholar</a></div></div></div></div></div><div role=\"listitem\" data-has=\"label\"><div class=\"label\">33.</div><div id=\"r33\" class=\"citations\"><div class=\"citation\"><div class=\"citation-content\">Centers for Disease Control and Prevention, Health Alert Network. Emergency preparedness and response: cases of cerebral venous sinus thrombosis with thrombocytopenia after receipt of the Johnson &amp; Johnson COVID-19 vaccine. April 13, 2021 (<a href=\"https://emergency.cdc.gov/han/2021/han00442.asp\">https://emergency.cdc.gov/han/2021/han00442.asp</a>).</div><div class=\"external-links\"><div class=\"core-xlink-google-scholar\"><a href=\"https://scholar.google.com/scholar_lookup?title=Emergency+preparedness+and+response%3A+cases+of+cerebral+venous+sinus+thrombosis+with+thrombocytopenia+after+receipt+of+the+Johnson+%26+Johnson+COVID-19+vaccine&amp;publication_year=2021\" target=\"_blank\">Google Scholar</a></div></div></div></div></div></div></section></div></section><div class=\"core-collateral\"><div id=\"core-collateral-info\" role=\"tabpanel\"><header><h2><i class=\"icon-info\" aria-hidden=\"true\"></i>Information &amp; Authors</h2></header><section id=\"tab-information\" aria-labelledby=\"information\" role=\"tabpanel\"><h3>Information</h3><section class=\"core-self-citation\"><h4>Published In</h4><div class=\"core-journal-presentation\"><div class=\"core-journal-description\"><div property=\"isPartOf\" typeof=\"Periodical\"><span property=\"name\">New England Journal of Medicine</span></div><div class=\"core-enumeration\"><a href=\"/toc/nejm/385/12\"><span property=\"isPartOf\" typeof=\"PublicationVolume\">Volume <span property=\"volumeNumber\">385</span></span> • <span property=\"isPartOf\" typeof=\"PublicationIssue\">Number <span property=\"issueNumber\">12</span></span> • <span property=\"datePublished\">September 16, 2021</span></a></div><div class=\"core-pagination\"><span class=\"heading\">Pages</span>: <span class=\"content\"><span property=\"pageStart\">1078</span>-<span property=\"pageEnd\">1090</span></span></div></div></div></section><section class=\"core-copyright\"><h4>Copyright</h4><div role=\"paragraph\">Copyright © 2021 Massachusetts Medical Society. All rights reserved.</div></section><section data-translation=\"YXQYoa2110475\" class=\"core-component-translation hidden\"><h4>Translation</h4><div role=\"paragraph\"><a target=\"_blank\">Chinese Translation 中文翻译</a></div></section><section class=\"core-history\"><h4>History</h4><div><b class=\"core-label\">Published online</b>: August 25, 2021</div><div><b class=\"core-label\">Published in issue</b>: September 16, 2021</div></section><section data-location=\"recirc_topics_article\" class=\"core-classifications\"><h4>Topics</h4><div class=\"keywords\"><ol><li><a href=\"/browse/topic/cardiomyopathy-myocarditis-pericarditis\" alt=\"View article keyword Cardiomyopathy/Myocarditis/Pericarditis\" data-interactiontype=\"article_recirculation_click\">Cardiomyopathy/Myocarditis/Pericarditis</a></li><li role=\"presentation\" aria-hidden=\"true\" class=\"list-line-break\"></li><li><a href=\"/browse/topic/coronavirus\" alt=\"View article keyword Coronavirus\" data-interactiontype=\"article_recirculation_click\">Coronavirus</a></li><li role=\"presentation\" aria-hidden=\"true\" class=\"list-line-break\"></li><li><a href=\"/browse/topic/vaccines\" alt=\"View article keyword Vaccines\" data-interactiontype=\"article_recirculation_click\">Vaccines</a></li><li role=\"presentation\" aria-hidden=\"true\" class=\"list-line-break\"></li></ol></div></section></section><section id=\"tab-contributors\" aria-labelledby=\"contributors\" role=\"tabpanel\"><h3>Authors</h3><section class=\"core-authors\"><h4>Authors</h4><div role=\"paragraph\"><span property=\"author\" typeof=\"Person\"><span property=\"givenName\">Noam</span> <span property=\"familyName\">Barda</span>, <span property=\"honorificSuffix\">M.D.</span></span>, <span property=\"author\" typeof=\"Person\"><span property=\"givenName\">Noa</span> <span property=\"familyName\">Dagan</span>, <span property=\"honorificSuffix\">M.D.</span> <a class=\"orcid-id\" href=\"https://orcid.org/0000-0001-8811-7825\" property=\"identifier\" aria-label=\"ORCID identifier\" target=\"_blank\">https://orcid.org/0000-0001-8811-7825</a></span>, <span property=\"author\" typeof=\"Person\"><span property=\"givenName\">Yatir</span> <span property=\"familyName\">Ben-Shlomo</span>, <span property=\"honorificSuffix\">B.Sc.</span></span>, <span property=\"author\" typeof=\"Person\"><span property=\"givenName\">Eldad</span> <span property=\"familyName\">Kepten</span>, <span property=\"honorificSuffix\">Ph.D.</span></span>, <span property=\"author\" typeof=\"Person\"><span property=\"givenName\">Jacob</span> <span property=\"familyName\">Waxman</span>, <span property=\"honorificSuffix\">M.D.</span></span>, <span property=\"author\" typeof=\"Person\"><span property=\"givenName\">Reut</span> <span property=\"familyName\">Ohana</span>, <span property=\"honorificSuffix\">M.Sc.</span></span>, <span property=\"author\" typeof=\"Person\"><span property=\"givenName\">Miguel A.</span> <span property=\"familyName\">Hernán</span>, <span property=\"honorificSuffix\">M.D.</span> <a class=\"orcid-id\" href=\"https://orcid.org/0000-0003-1619-8456\" property=\"identifier\" aria-label=\"ORCID identifier\" target=\"_blank\">https://orcid.org/0000-0003-1619-8456</a></span>, <span property=\"author\" typeof=\"Person\"><span property=\"givenName\">Marc</span> <span property=\"familyName\">Lipsitch</span>, <span property=\"honorificSuffix\">D.Phil.</span> <a class=\"orcid-id\" href=\"https://orcid.org/0000-0003-1504-9213\" property=\"identifier\" aria-label=\"ORCID identifier\" target=\"_blank\">https://orcid.org/0000-0003-1504-9213</a></span>, <span property=\"author\" typeof=\"Person\"><span property=\"givenName\">Isaac</span> <span property=\"familyName\">Kohane</span>, <span property=\"honorificSuffix\">M.D.</span></span>, <span property=\"author\" typeof=\"Person\"><span property=\"givenName\">Doron</span> <span property=\"familyName\">Netzer</span>, <span property=\"honorificSuffix\">M.D.</span></span>, <span property=\"author\" typeof=\"Person\"><span property=\"givenName\">Ben Y.</span> <span property=\"familyName\">Reis</span>, <span property=\"honorificSuffix\">Ph.D.</span></span>, and <span property=\"author\" typeof=\"Person\"><span property=\"givenName\">Ran D.</span> <span property=\"familyName\">Balicer</span>, <span property=\"honorificSuffix\">M.D.</span></span></div></section><section class=\"core-affiliations\"><h4>Affiliations</h4><div property=\"affiliation\" typeof=\"Organization\"><span property=\"name\">From the Clalit Research Institute, Innovation Division (N.B., N.D., Y.B.-S., E.K., J.W., R.O., R.D.B.), and the Community Medical Services Division (D.N.), Clalit Health Services, Tel Aviv, and Software and Information Systems Engineering (N.B., N.D.) and the School of Public Health, Faculty of Health Sciences (R.D.B.), Ben-Gurion University of the Negev, Be’er Sheva — both in Israel; the Department of Biomedical Informatics (N.B., N.D., I.K.), and the Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute (N.B., N.D., I.K., B.Y.R., R.D.B.), Harvard Medical School (B.Y.R.), the Departments of Epidemiology and Biostatistics (M.A.H.), CAUSALab (M.A.H.), and the Center for Communicable Disease Dynamics, Departments of Epidemiology and Immunology and Infectious Diseases (M.L.), Harvard T.H. Chan School of Public Health, and the Predictive Medicine Group, Computational Health Informatics Program, Boston Children’s Hospital (B.Y.R.) — all in Boston.</span></div></section><section class=\"core-authors-notes\"><h4>Notes</h4><div role=\"doc-footnote\">Address reprint requests to Dr. Balicer at the Clalit Research Institute, Innovation Division, Clalit Health Services, 101 Arlozorov St., Tel Aviv, Israel, or at <a href=\"/cdn-cgi/l/email-protection#ccbeaeada0a5afa9be8cafa0ada0a5b8e2a3beabe2a5a0\"><span class=\"__cf_email__\" data-cfemail=\"7e0c1c1f12171d1b0c3e1d121f12170a50110c19501712\">[email&#160;protected]</span></a>.</div><div role=\"doc-footnote\"><div id=\"fn1\" role=\"paragraph\">Drs. Barda and Dagan and Drs. Reis and Balicer contributed equally to this article.</div></div></section></section></div><div id=\"core-collateral-metrics\" role=\"tabpanel\"><header><h2><i class=\"icon-timeline\" aria-hidden=\"true\"></i>Metrics &amp; Citations</h2></header><section id=\"tab-metrics-inner\" aria-labelledby=\"metrics-inner\" role=\"tabpanel\"><h3>Metrics</h3><section></section><section>\n\n\n\n\n\n\n\n\n\n    \n    \n        <div data-widget-def=\"UX3HTMLWidget\" data-widget-id=\"95ea9f58-ec0e-4db2-b2ab-280fc876af53\" data-location=\"article_metrics_article\">\n        \n\n\n\n        \n            <h4 class=\"\">\n                Altmetrics\n            </h4>\n        \n        <div data-badge-details=\"right\" data-badge-type=\"large-donut\" data-doi=\"10.1056/NEJMoa2110475\" data-hide-no-mentions=\"true\" data-link-target=\"_blank\" class=\"altmetric-embed\">\n</div>\n<script data-cfasync=\"false\" src=\"/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js\"></script><script async type='text/javascript' src='https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js'></script>\n\n        </div>\n    \n\n</section></section><section id=\"tab-citations\" aria-labelledby=\"citations\" role=\"tabpanel\"><h3>Citations</h3><section>\n\n\n\n        \n            <h4 class=\"\">\n                Export citation\n            </h4>\n        \n        <div class=\"citation-download\">\n  <p class=\"citation-download_msg\">Select the format you want to export the citation of this publication.</p>\n  <form action=\"/action/downloadCitation\" name=\"frmCitmgr\" method=\"post\" target=\"_self\" class=\"citation-download_form\">\n    <input type=\"hidden\" name=\"doi\" value=\"10.1056/NEJMoa2110475\"/>\n    <input type=\"hidden\" name=\"downloadFileName\" value=\"csp_385_\"/>\n    <input type=\"hidden\" name=\"include\" value=\"abs\"/>\n    <div class=\"citation-download_select\">\n      <label for=\"slct_format\" class=\"form-label\">Format*</label>\n      <select id=\"slct_format\" name=\"format\" required=\"required\" class=\"form-control\">\n        <option value=\"\">Please select</option>\n        <option value=\"ris\">RIS (ProCite, Reference Manager)</option>\n        <option value=\"endnote\">EndNote</option>\n        <option value=\"bibtex\">BibTex</option>\n        <option value=\"medlars\">Medlars</option>\n        <option value=\"refworks\">RefWorks</option>\n      </select>\n    </div>\n    <div class=\"citation-download_checkbox\">\n      <label class=\"checkbox--primary\">\n        <input type=\"checkbox\" name=\"direct\" value=\"true\"/>\n        <span class=\"checkbox--primary-icons\">\n          <span class=\"checkbox--primary-unchecked\">\n            <span class=\"icon-component\">\n              <svg aria-hidden=\"true\">\n                <use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked\"></use>\n              </svg>\n            </span>\n          </span>\n          <span class=\"checkbox--primary-checked\">\n            <span class=\"icon-component\">\n              <svg aria-hidden=\"true\">\n                <use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked\"></use>\n              </svg>\n            </span>\n          </span>\n        </span>\n        <span class=\"checkbox--primary-label\">\n          <span class=\"checkbox--primary-label-text\">Direct Import</span>\n        </span>\n      </label>\n    </div>\n    <div class=\"citation-download_btn\">\n      <button type=\"submit\" name=\"submit\" value=\"Download\" class=\"ng-btn_default ng-btn_iconLeft\" data-interactiontype=\"article_tools_citation_download\" data-multimedia-type =\"Citation\">\n        <span class=\"icon-component\">\n          <svg aria-hidden=\"true\">\n            <use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations\"></use>\n          </svg>\n        </span>\n        <span class=\"ng-btn_text\">Export citation</span>\n      </button>\n    </div>\n  </form>\n</div>\n</section><section>\n\n\n\n\n\n\n\n\n\n    \n    \n        <div data-widget-def=\"UX3CitedByWidget\" data-widget-id=\"efb4df9a-8e1a-47f9-bfb7-271959277a9f\" data-location=\"citedby_article\">\n        \n\n\n\n        \n            <h4 class=\"\">\n                Cited by\n            </h4>\n        \n        <section id=\"cited-by\" class=\"cited-by\"><div class=\"cited-by__wrapper\"><div id=\"cited-by__content\" class=\"cited-by__content\"><ol data-source=\"/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.385.issue-12%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2110475%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms\" data-lazyload=\"false\" data-total='665' class=\"cited-by__list list-unstyled\"><li class=\"cited-by__entry border-bottom pb-16 mb-24\"><ul class=\"cited-by__entry__authors list-inline\"><li class=\"list-inline-item cited-by__entry__author\">Nelson Luis Cahuapaza-Gutierrez, </li><li class=\"list-inline-item cited-by__entry__author\">Renzo Pajuelo-Vasquez, </li><li class=\"list-inline-item cited-by__entry__author\">Cristina Quiroz-Narvaez, </li><li class=\"list-inline-item cited-by__entry__author\">Flavia Rioja-Torres, </li><li class=\"list-inline-item cited-by__entry__author\">María Quispe-Andahua, </li><li class=\"list-inline-item cited-by__entry__author\">Fernando M. Runzer-Colmenares, </li></ul><span class=\"cited-by__entry__title\">Acute abdomen following COVID-19 vaccination: a systematic review, </span><span class=\"cited-by__entry__series-title\">Clinical and Experimental Vaccine Research, </span><span class=\"cited-by__entry__volume\"><strong>13</strong>, </span><span class=\"cited-by__entry__issue\">1, </span><span class=\"cited-by__entry__page-range\">(42), </span><span class=\"cited-by__entry__pub-date\">(2024).</span><a href=\"https://doi.org/10.7774/cevr.2024.13.1.42\" title=\"Crossref\" target=\"_blank\" class=\"cited-by__entry__doi\">https://doi.org/10.7774/cevr.2024.13.1.42</a><div class=\"cited-by__entry__extra-links\"><a href=\"https://doi.org/10.7774/cevr.2024.13.1.42\" target=\"_blank\" class=\"cited-by__entry__visitable\">Crossref</a></div></li><li class=\"cited-by__entry border-bottom pb-16 mb-24\"><ul class=\"cited-by__entry__authors list-inline\"><li class=\"list-inline-item cited-by__entry__author\">Qiong Wu, </li><li class=\"list-inline-item cited-by__entry__author\">Jiayi Tong, </li><li class=\"list-inline-item cited-by__entry__author\">Bingyu Zhang, </li><li class=\"list-inline-item cited-by__entry__author\">Dazheng Zhang, </li><li class=\"list-inline-item cited-by__entry__author\">Jiajie Chen, </li><li class=\"list-inline-item cited-by__entry__author\">Yuqing Lei, </li><li class=\"list-inline-item cited-by__entry__author\">Yiwen Lu, </li><li class=\"list-inline-item cited-by__entry__author\">Yudong Wang, </li><li class=\"list-inline-item cited-by__entry__author\">Lu Li, </li><li class=\"list-inline-item cited-by__entry__author\">Yishan Shen, </li><li class=\"list-inline-item cited-by__entry__author\">Jie Xu, </li><li class=\"list-inline-item cited-by__entry__author\">L. Charles Bailey, </li><li class=\"list-inline-item cited-by__entry__author\">Jiang Bian, </li><li class=\"list-inline-item cited-by__entry__author\">Dimitri A. Christakis, </li><li class=\"list-inline-item cited-by__entry__author\">Megan L. Fitzgerald, </li><li class=\"list-inline-item cited-by__entry__author\">Kathryn Hirabayashi, </li><li class=\"list-inline-item cited-by__entry__author\">Ravi Jhaveri, </li><li class=\"list-inline-item cited-by__entry__author\">Alka Khaitan, </li><li class=\"list-inline-item cited-by__entry__author\">Tianchen Lyu, </li><li class=\"list-inline-item cited-by__entry__author\">Suchitra Rao, </li><li class=\"list-inline-item cited-by__entry__author\">Hanieh Razzaghi, </li><li class=\"list-inline-item cited-by__entry__author\">Hayden T. Schwenk, </li><li class=\"list-inline-item cited-by__entry__author\">Fei Wang, </li><li class=\"list-inline-item cited-by__entry__author\">Margot I. Gage Witvliet, </li><li class=\"list-inline-item cited-by__entry__author\">Eric J. Tchetgen Tchetgen, </li><li class=\"list-inline-item cited-by__entry__author\">Jeffrey S. Morris, </li><li class=\"list-inline-item cited-by__entry__author\">Christopher B. Forrest, </li><li class=\"list-inline-item cited-by__entry__author\">Yong Chen, </li></ul><span class=\"cited-by__entry__title\">Real-World Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and Adolescents, </span><span class=\"cited-by__entry__series-title\">Annals of Internal Medicine, </span><span class=\"cited-by__entry__volume\"><strong>177</strong>, </span><span class=\"cited-by__entry__issue\">2, </span><span class=\"cited-by__entry__page-range\">(165-176), </span><span class=\"cited-by__entry__pub-date\">(2024).</span><a href=\"https://doi.org/10.7326/M23-1754\" title=\"Crossref\" target=\"_blank\" class=\"cited-by__entry__doi\">https://doi.org/10.7326/M23-1754</a><div class=\"cited-by__entry__extra-links\"><a href=\"https://doi.org/10.7326/M23-1754\" target=\"_blank\" class=\"cited-by__entry__visitable\">Crossref</a></div></li><li class=\"cited-by__entry border-bottom pb-16 mb-24\"><ul class=\"cited-by__entry__authors list-inline\"><li class=\"list-inline-item cited-by__entry__author\">Henry Krasner, </li><li class=\"list-inline-item cited-by__entry__author\">Nicolette Harmon, </li><li class=\"list-inline-item cited-by__entry__author\">Jeffrey Martin, </li><li class=\"list-inline-item cited-by__entry__author\">Crysty-Ann Olaco, </li><li class=\"list-inline-item cited-by__entry__author\">Dale M. Netski, </li><li class=\"list-inline-item cited-by__entry__author\">Kavita Batra, </li></ul><span class=\"cited-by__entry__title\">Community Level Correlates of COVID-19 Booster Vaccine Hesitancy in the United States: A Cross-Sectional Analysis, </span><span class=\"cited-by__entry__series-title\">Vaccines, </span><span class=\"cited-by__entry__volume\"><strong>12</strong>, </span><span class=\"cited-by__entry__issue\">2, </span><span class=\"cited-by__entry__page-range\">(167), </span><span class=\"cited-by__entry__pub-date\">(2024).</span><a href=\"https://doi.org/10.3390/vaccines12020167\" title=\"Crossref\" target=\"_blank\" class=\"cited-by__entry__doi\">https://doi.org/10.3390/vaccines12020167</a><div class=\"cited-by__entry__extra-links\"><a href=\"https://doi.org/10.3390/vaccines12020167\" target=\"_blank\" class=\"cited-by__entry__visitable\">Crossref</a></div></li><li class=\"cited-by__entry border-bottom pb-16 mb-24\"><ul class=\"cited-by__entry__authors list-inline\"><li class=\"list-inline-item cited-by__entry__author\">Tal Gazitt, </li><li class=\"list-inline-item cited-by__entry__author\">Noa Hayat, </li><li class=\"list-inline-item cited-by__entry__author\">Nili Stein, </li><li class=\"list-inline-item cited-by__entry__author\">Amir Haddad, </li><li class=\"list-inline-item cited-by__entry__author\">Ilan Feldhamer, </li><li class=\"list-inline-item cited-by__entry__author\">Arnon Dov Cohen, </li><li class=\"list-inline-item cited-by__entry__author\">Walid Saliba, </li><li class=\"list-inline-item cited-by__entry__author\">Devy Zisman, </li></ul><span class=\"cited-by__entry__title\">The Risk of Herpes Zoster Events in Patients with Spondyloarthritis and the Effect of BNT162b2 mRNA COVID-19 Vaccine, </span><span class=\"cited-by__entry__series-title\">Vaccines, </span><span class=\"cited-by__entry__volume\"><strong>12</strong>, </span><span class=\"cited-by__entry__issue\">1, </span><span class=\"cited-by__entry__page-range\">(85), </span><span class=\"cited-by__entry__pub-date\">(2024).</span><a href=\"https://doi.org/10.3390/vaccines12010085\" title=\"Crossref\" target=\"_blank\" class=\"cited-by__entry__doi\">https://doi.org/10.3390/vaccines12010085</a><div class=\"cited-by__entry__extra-links\"><a href=\"https://doi.org/10.3390/vaccines12010085\" target=\"_blank\" class=\"cited-by__entry__visitable\">Crossref</a></div></li><li class=\"cited-by__entry border-bottom pb-16 mb-24\"><ul class=\"cited-by__entry__authors list-inline\"><li class=\"list-inline-item cited-by__entry__author\">Jung Yoon Choi, </li><li class=\"list-inline-item cited-by__entry__author\">Yongjoon Lee, </li><li class=\"list-inline-item cited-by__entry__author\">Nam Gi Park, </li><li class=\"list-inline-item cited-by__entry__author\">Mi Sung Kim, </li><li class=\"list-inline-item cited-by__entry__author\">Sandy Jeong Rhie, </li></ul><span class=\"cited-by__entry__title\">Serious Safety Signals and Prediction Features Following COVID-19 mRNA Vaccines Using the Vaccine Adverse Event Reporting System, </span><span class=\"cited-by__entry__series-title\">Pharmaceuticals, </span><span class=\"cited-by__entry__volume\"><strong>17</strong>, </span><span class=\"cited-by__entry__issue\">3, </span><span class=\"cited-by__entry__page-range\">(356), </span><span class=\"cited-by__entry__pub-date\">(2024).</span><a href=\"https://doi.org/10.3390/ph17030356\" title=\"Crossref\" target=\"_blank\" class=\"cited-by__entry__doi\">https://doi.org/10.3390/ph17030356</a><div class=\"cited-by__entry__extra-links\"><a href=\"https://doi.org/10.3390/ph17030356\" target=\"_blank\" class=\"cited-by__entry__visitable\">Crossref</a></div></li><li class=\"cited-by__entry border-bottom pb-16 mb-24\"><ul class=\"cited-by__entry__authors list-inline\"><li class=\"list-inline-item cited-by__entry__author\">Martin Heil, </li></ul><span class=\"cited-by__entry__title\">Self-DNA driven inflammation in COVID-19 and after mRNA-based vaccination: lessons for non-COVID-19 pathologies, </span><span class=\"cited-by__entry__series-title\">Frontiers in Immunology, </span><span class=\"cited-by__entry__volume\"><strong>14</strong>, </span><span class=\"cited-by__entry__pub-date\">(2024).</span><a href=\"https://doi.org/10.3389/fimmu.2023.1259879\" title=\"Crossref\" target=\"_blank\" class=\"cited-by__entry__doi\">https://doi.org/10.3389/fimmu.2023.1259879</a><div class=\"cited-by__entry__extra-links\"><a href=\"https://doi.org/10.3389/fimmu.2023.1259879\" target=\"_blank\" class=\"cited-by__entry__visitable\">Crossref</a></div></li><li class=\"cited-by__entry border-bottom pb-16 mb-24\"><ul class=\"cited-by__entry__authors list-inline\"><li class=\"list-inline-item cited-by__entry__author\">Shir Azrielant, </li><li class=\"list-inline-item cited-by__entry__author\">Yair Levin, </li><li class=\"list-inline-item cited-by__entry__author\">Alon Peled, </li><li class=\"list-inline-item cited-by__entry__author\">Liat Samuelov, </li><li class=\"list-inline-item cited-by__entry__author\">Eli Sprecher, </li><li class=\"list-inline-item cited-by__entry__author\">Mor Pavlovsky, </li></ul><span class=\"cited-by__entry__title\">BioNTech COVID-19 (BNT162b2) Vaccination and Varicella Zoster Reactivation: A Comprehensive Cross-sectional Study, </span><span class=\"cited-by__entry__series-title\">Acta Dermato-Venereologica, </span><span class=\"cited-by__entry__volume\"><strong>104</strong>, </span><span class=\"cited-by__entry__page-range\">(adv18389), </span><span class=\"cited-by__entry__pub-date\">(2024).</span><a href=\"https://doi.org/10.2340/actadv.v104.18389\" title=\"Crossref\" target=\"_blank\" class=\"cited-by__entry__doi\">https://doi.org/10.2340/actadv.v104.18389</a><div class=\"cited-by__entry__extra-links\"><a href=\"https://doi.org/10.2340/actadv.v104.18389\" target=\"_blank\" class=\"cited-by__entry__visitable\">Crossref</a></div></li><li class=\"cited-by__entry border-bottom pb-16 mb-24\"><ul class=\"cited-by__entry__authors list-inline\"><li class=\"list-inline-item cited-by__entry__author\">Jin Kyun Park, </li><li class=\"list-inline-item cited-by__entry__author\">Eun Bong Lee, </li><li class=\"list-inline-item cited-by__entry__author\">Kevin L Winthrop, </li></ul><span class=\"cited-by__entry__title\">What rheumatologists need to know about mRNA vaccines: current status and future of mRNA vaccines in autoimmune inflammatory rheumatic diseases, </span><span class=\"cited-by__entry__series-title\">Annals of the Rheumatic Diseases, </span><span class=\"cited-by__entry__page-range\">(ard-2024-225492), </span><span class=\"cited-by__entry__pub-date\">(2024).</span><a href=\"https://doi.org/10.1136/ard-2024-225492\" title=\"Crossref\" target=\"_blank\" class=\"cited-by__entry__doi\">https://doi.org/10.1136/ard-2024-225492</a><div class=\"cited-by__entry__extra-links\"><a href=\"https://doi.org/10.1136/ard-2024-225492\" target=\"_blank\" class=\"cited-by__entry__visitable\">Crossref</a></div></li><li class=\"cited-by__entry border-bottom pb-16 mb-24\"><ul class=\"cited-by__entry__authors list-inline\"><li class=\"list-inline-item cited-by__entry__author\">Fabrizio Martora, </li><li class=\"list-inline-item cited-by__entry__author\">Matteo Megna, </li><li class=\"list-inline-item cited-by__entry__author\">Teresa Battista, </li><li class=\"list-inline-item cited-by__entry__author\">Massimiliano Scalvenzi, </li><li class=\"list-inline-item cited-by__entry__author\">Alessia Villani, </li><li class=\"list-inline-item cited-by__entry__author\">Sara Cacciapuoti, </li><li class=\"list-inline-item cited-by__entry__author\">Luca Potestio, </li></ul><span class=\"cited-by__entry__title\">Viral reactivation following COVID-19 vaccination: a review of the current literature, </span><span class=\"cited-by__entry__series-title\">Clinical and Experimental Dermatology, </span><span class=\"cited-by__entry__pub-date\">(2024).</span><a href=\"https://doi.org/10.1093/ced/llae061\" title=\"Crossref\" target=\"_blank\" class=\"cited-by__entry__doi\">https://doi.org/10.1093/ced/llae061</a><div class=\"cited-by__entry__extra-links\"><a href=\"https://doi.org/10.1093/ced/llae061\" target=\"_blank\" class=\"cited-by__entry__visitable\">Crossref</a></div></li><li class=\"cited-by__entry border-bottom pb-16 mb-24\"><ul class=\"cited-by__entry__authors list-inline\"><li class=\"list-inline-item cited-by__entry__author\">Chunhua Zhou, </li><li class=\"list-inline-item cited-by__entry__author\">Yuanzheng Qiu, </li><li class=\"list-inline-item cited-by__entry__author\">Jianxin Wang, </li><li class=\"list-inline-item cited-by__entry__author\">Xiang Zhong, </li><li class=\"list-inline-item cited-by__entry__author\">Xiufang Zhu, </li><li class=\"list-inline-item cited-by__entry__author\">Xiaojing Huang, </li><li class=\"list-inline-item cited-by__entry__author\">Lan Yang, </li><li class=\"list-inline-item cited-by__entry__author\">Qiaolei Ji, </li><li class=\"list-inline-item cited-by__entry__author\">Feifei Zhou, </li><li class=\"list-inline-item cited-by__entry__author\">Shunquan Wu, </li><li class=\"list-inline-item cited-by__entry__author\">Mengjie Yang, </li><li class=\"list-inline-item cited-by__entry__author\">Jing Zhang, </li><li class=\"list-inline-item cited-by__entry__author\">Kaili Liu, </li><li class=\"list-inline-item cited-by__entry__author\">Li Ji, </li><li class=\"list-inline-item cited-by__entry__author\">Hanyu Yang, </li><li class=\"list-inline-item cited-by__entry__author\">Chunlei Li, </li><li class=\"list-inline-item cited-by__entry__author\">Yuanyuan Zhao, </li></ul><span class=\"cited-by__entry__title\">The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial, </span><span class=\"cited-by__entry__series-title\">Emerging Microbes & Infections, </span><span class=\"cited-by__entry__volume\"><strong>13</strong>, </span><span class=\"cited-by__entry__issue\">1, </span><span class=\"cited-by__entry__pub-date\">(2024).</span><a href=\"https://doi.org/10.1080/22221751.2024.2320913\" title=\"Crossref\" target=\"_blank\" class=\"cited-by__entry__doi\">https://doi.org/10.1080/22221751.2024.2320913</a><div class=\"cited-by__entry__extra-links\"><a href=\"https://doi.org/10.1080/22221751.2024.2320913\" target=\"_blank\" class=\"cited-by__entry__visitable\">Crossref</a></div></li><li class=\"cited-by__entry--see-more\"><a href=\"javascript:void(0)\" data-source=\"/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.385.issue-12%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2110475%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms\" class=\"cited-by__see-more\">See more</a></li></ol></div><div class=\"cited-by__spinner justify-content-center align-items-center d-none\"><div role=\"status\" class=\"spinner-border text-gray\"><span class=\"sr-only\">Loading...</span></div></div></div></section>\n\n        </div>\n    \n\n</section></section></div><div id=\"core-collateral-fulltext-options\" role=\"tabpanel\"><header><h2><i class=\"icon-eye\" aria-hidden=\"true\"></i>View Options</h2></header><div tabindex=\"0\" class=\"section--wrapper\"><h3>View options</h3><section class=\"format--pdf\"><h4> <abbr title=\"Portable Document Format\">PDF</abbr></h4><a href=\"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2110475\" title=\"View PDF\" data-toggle=\"tooltip\" aria-label=\"View PDF\" class=\"btn btn--pdf\" data-behavior=\"trackDownloadEvent\" data-doi=\"10.1056/NEJMoa2110475\" data-interactiontype=\"article_tools_download_pdf\" data-multimedia-type=\"Article PDF\" data-multimedia-filename=\"nejmoa2110475.pdf\"><i aria-hidden=\"true\" class=\"icon-pdf\"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--><div tabindex=\"-1\" class=\"section--wrapper\"></div></div><div id=\"core-collateral-media\" role=\"tabpanel\"><header><h2><i class=\"icon-photo\" aria-hidden=\"true\"></i>Media</h2></header><section id=\"tab-figures\" aria-labelledby=\"figures\" role=\"tabpanel\"><h3>Figures</h3></section><section id=\"tab-other\" aria-labelledby=\"other\" role=\"tabpanel\"><h3>Other</h3></section></div><div id=\"core-collateral-tables\" role=\"tabpanel\"><header><h2><i class=\"icon-tables\" aria-hidden=\"true\"></i>Tables</h2></header><!-- There is no content. --></div><div id=\"core-collateral-share\" role=\"tabpanel\"><header><h2><i class=\"icon-share\" aria-hidden=\"true\"></i>Share</h2></header><h3>Share</h3><div class=\"section--wrapper\"><section><h4>CONTENT LINK</h4><div id=\"share-self\"><p data-id=\"article-share-self-link\" class=\"share-self__source\"></p><button data-id=\"article-share-access\" class=\"share-self__action btn btn--inverse\"><i aria-hidden=\"true\" class=\"icon-copy-o\"></i><span>Copy Link</span></button><div aria-live=\"polite\" class=\"share-self__status\"><p class=\"share-self__success\"><i aria-hidden=\"true\" class=\"icon-check_circle\"></i><span>Copied!</span></p><p class=\"share-self__failed\"><i aria-hidden=\"true\" class=\"icon-x_btnclose\"></i><span>Copying failed.</span></p></div></div></section><section data-location=\"share_tools_article\"><h4>Share</h4><div class=\"share-buttons a2a a2a_kit\"><a href=\"#\" aria-label=\"Share on Facebook\" data-id=\"article-share-facebook\" rel=\"nofollow noopener\" role=\"link\" target=\"_blank\" title=\"Share on Facebook\" class=\"btn btn--facebook a2a_button_facebook\" data-interactiontype=\"social\"><i aria-hidden=\"true\" class=\"icon-facebook\"></i><span>Facebook</span></a><a href=\"#\" aria-label=\"Share on X (formerly Twitter)\" data-id=\"article-share-twitter\" rel=\"nofollow noopener\" role=\"link\" target=\"_blank\" title=\"Share on X (formerly Twitter)\" class=\"btn btn--twitter a2a_button_twitter\" data-interactiontype=\"social\"><i aria-hidden=\"true\" class=\"icon-twitter\"></i><span>X (formerly Twitter)</span></a><a href=\"#\" aria-label=\"Share on Linkedin\" data-id=\"article-share-linkedin\" rel=\"nofollow noopener\" role=\"link\" target=\"_blank\" title=\"Share on Linkedin\" class=\"btn btn--linkedin a2a_button_linkedin\" data-interactiontype=\"social\"><i aria-hidden=\"true\" class=\"icon-linkedin\"></i><span>Linkedin</span></a><a href=\"#\" aria-label=\"Share on email\" data-id=\"article-share-email\" rel=\"nofollow noopener\" role=\"link\" target=\"_blank\" title=\"Share on email\" class=\"btn btn--email a2a_button_email\" data-interactiontype=\"content_email_click\"><i aria-hidden=\"true\" class=\"icon-mail\"></i><span>email</span></a></div></section></div></div></div><aside data-core-aside=\"right-rail\">\n\n\n\n        \n        <div id=\"DTM_Position_MedRectangle\" class=\"ad\"></div>\n\n\n\n\n        \n        <div class=\"ng-page_layout-sidebarSpacing\"></div>\n\n\n\n\n\n\n\n\n\n\n    \n    \n        <div data-widget-def=\"relatedArticlesWidget\" data-widget-id=\"8206d5cd-cb8c-4ff9-8c46-3d22e0dee215\" data-location=\"recirc_curatedRelated_article\">\n        \n\n\n\n        \n        <div class=\"ng-related-articles\"><h3 class=\"ng-subsection-title\"><span class=\"ng-subsection-title_text\">Related articles</span></h3><ul class=\"ng-related-articles_list\"><li class=\"ng-related-articles_item\"><div class=\"issue-item issue-item_sm\"><div class=\"issue-item_meta\"><ul class=\"issue-item_meta-list clearfix\"><li class=\"issue-item_meta-item\"><a href=\"/browse/nejm-article-type/editorial\" class=\"issue-item_type\">Editorial</a></li><li class=\"issue-item_meta-item\"><span class=\"issue-item_date\">Aug 25, 2021</span></li></ul></div><div class=\"issue-item_row\"><div class=\"issue-item_left\"><div class=\"issue-item_content clearfix\"><h4 class=\"issue-item_title\"><a href=\"/doi/full/10.1056/NEJMe2112543\" data-interactiontype=\"article_recirculation_click\" class=\"issue-item_title-link animation-underline\">The Importance of Context in Covid-19 Vaccine Safety</a></h4><div class=\"issue-item_authors-and-text\"><span class=\"issue-item_authors\">G.M. Lee</span></div></div></div></div></div></li></ul></div>\n\n        </div>\n    \n\n\n\n\n\n        \n        <div class=\"ng-page_layout-sidebarSpacing\"></div>\n\n\n\n\n        \n        <div id=\"nejm_jobs\" class=\"nejm_jobs\"></div><script src=\"https://apps1.nejmcareercenter.org/?width=300&amp;sp=all\"></script>\n\n\n\n\n        \n        <div class=\"ng-page_layout-sidebarSpacing\"></div>\n\n\n\n\n\n\n\n\n\n\n    \n    \n        <div data-widget-def=\"literatumAd\" data-widget-id=\"001e4aa7-b6fe-4b21-9d5b-5bde81227c67\" id=\"ad-article-right-rail-300x250-1\">\n        \n\n\n\n        \n        \n\n\n\n    \n        <div class=\"pb-house-message adplaceholder exists\">\n            <a href=\"/action/clickThrough?id=127766&url=https%3A%2F%2Fwww.nejm.org%2Fcme-ce%2Fobesity%3Fpromo%3DONFQCE01%26query%3Dcm_rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dcme_ce_obesity&loc=%2Fdoi%2Ffull%2F10.1056%2Fnejmoa2110475&pubId=41290331&placeholderId=101337&productId=1007\"><img src=\"/sda/127766/obesitySeminar-300x250-nodate2X.jpg\" width=\"300\" height=\"250\"></a>\n            \n        </div>\n    \n\n    \n\n    \n\n\n\n        </div>\n    \n\n\n\n\n\n        \n        <div class=\"ng-page_layout-sidebarSpacing\"></div>\n\n\n\n\n\n\n\n\n\n\n    \n    \n        <div data-widget-def=\"oneSearchMultiSearch\" data-widget-id=\"60d16923-fa2a-4094-9a10-bdfe581427cf\" data-location=\"recirc_artType_railA_article\">\n        \n\n\n\n        \n        <div class=\"os-ms os-ms-more-article-type\"><h3 class=\"ng-subsection-title\"><a href=\"/browse/nejm-article-type/original-article\" class=\"ng-subsection-title_link animation-icon-shift\"><span class=\"ng-subsection-title_text\">More Original Articles</span><span class=\"ng-subsection-title_icon\"><span class=\"icon-component \"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-a5d5b6d8a6cc46cb61c3d16941f26e75.spritemap.svg#arrows-longArrowRight\"></use></svg></span></span></a></h3><ul class=\"os-ms-more-article-type_list\"><li class=\"os-ms-more-article-type_item\"><div class=\"issue-item issue-item_sm\"><div class=\"issue-item_meta\"><ul class=\"issue-item_meta-list clearfix\"><li class=\"issue-item_meta-item\"><a href=\"/browse/nejm-article-type/original-article\" class=\"issue-item_type\">Original Article</a></li><li class=\"issue-item_meta-item\"><span class=\"issue-item_date\">Oct 10, 2024</span></li><li class=\"issue-item_meta-item\"><span class=\"issue-item_cme\">CME</span></li><li data-toggle=\"tooltip\" data-original-title=\"Video\" class=\"issue-item_meta-item\"><span aria-label=\"Video\" class=\"issue-item_video\"><span class=\"icon-component \"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-a5d5b6d8a6cc46cb61c3d16941f26e75.spritemap.svg#tooltip-video\"></use></svg></span></span></li></ul></div><div class=\"issue-item_row\"><div class=\"issue-item_left\"><div class=\"issue-item_content clearfix\"><h4 class=\"issue-item_title\"><a href=\"/doi/full/10.1056/NEJMoa2404873\" data-interactiontype=\"article_recirculation_click\" class=\"issue-item_title-link animation-underline\">Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer</a></h4><div class=\"issue-item_authors-and-text\"><span class=\"issue-item_authors\">Y. Cheng and Others</span></div></div></div></div></div></li><li class=\"os-ms-more-article-type_item\"><div class=\"issue-item issue-item_sm\"><div class=\"issue-item_meta\"><ul class=\"issue-item_meta-list clearfix\"><li class=\"issue-item_meta-item\"><a href=\"/browse/nejm-article-type/original-article\" class=\"issue-item_type\">Original Article</a></li><li class=\"issue-item_meta-item\"><span class=\"issue-item_date\">Oct 10, 2024</span></li></ul></div><div class=\"issue-item_row\"><div class=\"issue-item_left\"><div class=\"issue-item_content clearfix\"><h4 class=\"issue-item_title\"><a href=\"/doi/full/10.1056/NEJMoa2405541\" data-interactiontype=\"article_recirculation_click\" class=\"issue-item_title-link animation-underline\">Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy</a></h4><div class=\"issue-item_authors-and-text\"><span class=\"issue-item_authors\">C.N. Duncan and Others</span></div></div></div></div></div></li><li class=\"os-ms-more-article-type_item\"><div class=\"issue-item issue-item_sm\"><div class=\"issue-item_meta\"><ul class=\"issue-item_meta-list clearfix\"><li class=\"issue-item_meta-item\"><a href=\"/browse/nejm-article-type/original-article\" class=\"issue-item_type\">Original Article</a></li><li class=\"issue-item_meta-item\"><span class=\"issue-item_date\">Oct 10, 2024</span></li><li class=\"issue-item_meta-item\"><span class=\"issue-item_cme\">CME</span></li><li data-toggle=\"tooltip\" data-original-title=\"Video\" class=\"issue-item_meta-item\"><span aria-label=\"Video\" class=\"issue-item_video\"><span class=\"icon-component \"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-a5d5b6d8a6cc46cb61c3d16941f26e75.spritemap.svg#tooltip-video\"></use></svg></span></span></li></ul></div><div class=\"issue-item_row\"><div class=\"issue-item_left\"><div class=\"issue-item_content clearfix\"><h4 class=\"issue-item_title\"><a href=\"/doi/full/10.1056/NEJMoa2404204\" data-interactiontype=\"article_recirculation_click\" class=\"issue-item_title-link animation-underline\">Beta-Blocker Interruption or Continuation after Myocardial Infarction</a></h4><div class=\"issue-item_authors-and-text\"><span class=\"issue-item_authors\">J. Silvain and Others</span></div></div></div></div></div></li></ul></div>\n\n        </div>\n    \n\n\n\n\n\n        \n        <div><div class=\"pb-dropzone\" data-pb-dropzone=\"col-0\" title=\"col-0\"></div></div>\n\n\n\n\n\n\n\n\n\n\n    \n    \n        <div data-widget-def=\"UX3HTMLWidget\" data-widget-id=\"ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1\" id=\"bc-web-rec\">\n        \n\n\n\n        \n        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->\n\n        </div>\n    \n\n</aside></article><div data-extent=\"article-wrapper\"><div class=\"core-container\"></div><div class=\"after-credits\"><div class=\"core-container\"><a href=\"/doi/pdf/10.1056/NEJMoa2110475?download=true\" data-behavior=\"trackDownloadEvent\" data-doi=\"10.1056/NEJMoa2110475\" data-interactiontype=\"article_tools_download_pdf\" data-multimedia-type=\"Article PDF\" data-multimedia-filename=\"nejmoa2110475.pdf\"><span>Download PDF</span></a></div></div></div><script id=\"contribution-meta\" type=\"application/json\">{\n    \"doi\": \"10.1056/NEJMoa2110475\"\n}\n</script><script type=\"text/javascript\" defer=\"defer\" src=\"https://static.addtoany.com/menu/page.js\" class=\"optanon-category-C0004 ot-vscat-C0004\"></script><script id=\"book-title\" type=\"application/json\">{\n    \"bookTitle\": \"\"\n}\n</script><div class=\"articles-nav\"></div><div role=\"navigation\" aria-label=\"Sticky Navigation\" class=\"st-header\"><div class=\"st-header__content\"><div class=\"st-header__item st-header__menu\"></div><div class=\"st-header__current st-header__item\"><div class=\"st-header__label\">Now Reading:</div><div class=\"st-header__title\"></div></div><div class=\"st-header__share st-header__item\"><div title=\"Share options\" data-toggle=\"tooltip\" class=\"share-dropblock dropdown\"><a id=\"sticky-header-dropBlock\" href=\"#\" role=\"button\" data-toggle=\"dropdown\" aria-haspopup=\"true\" aria-expanded=\"false\" class=\"dropdown-toggle\"><span class=\"sr-only\">Share</span><i aria-hidden=\"true\" class=\"icon-share\"></i></a><div aria-labelledby=\"sticky-header-dropBlock\" data-location=\"share_tools_article\" class=\"dropdown-menu\"><ul class=\"rlist--inline a2a a2a_kit\"><li><a href=\"#\" aria-label=\"Share on Facebook\" data-id=\"article-share-facebook\" rel=\"nofollow noopener\" role=\"link\" target=\"_blank\" title=\"Share on Facebook\" class=\"btn btn--facebook a2a_button_facebook\" data-interactiontype=\"social\"><i aria-hidden=\"true\" class=\"icon-facebook\"></i></a></li><li><a href=\"#\" aria-label=\"Share on X (formerly Twitter)\" data-id=\"article-share-twitter\" rel=\"nofollow noopener\" role=\"link\" target=\"_blank\" title=\"Share on X (formerly Twitter)\" class=\"btn btn--twitter a2a_button_twitter\" data-interactiontype=\"social\"><i aria-hidden=\"true\" class=\"icon-twitter\"></i></a></li><li><a href=\"#\" aria-label=\"Share on Linkedin\" data-id=\"article-share-linkedin\" rel=\"nofollow noopener\" role=\"link\" target=\"_blank\" title=\"Share on Linkedin\" class=\"btn btn--linkedin a2a_button_linkedin\" data-interactiontype=\"social\"><i aria-hidden=\"true\" class=\"icon-linkedin\"></i></a></li><li><a href=\"#\" aria-label=\"Share on email\" data-id=\"article-share-email\" rel=\"nofollow noopener\" role=\"link\" target=\"_blank\" title=\"Share on email\" class=\"btn btn--email a2a_button_email\" data-interactiontype=\"content_email_click\"><i aria-hidden=\"true\" class=\"icon-mail\"></i></a></li></ul></div></div></div><div class=\"st-header__nav st-header__item\"><div role=\"menu\" class=\"content-navigation\"><a href=\"/doi/full/10.1056/NEJMoa2105675\" role=\"menuitem\" aria-label=\"Previous article\" class=\"content-navigation__prev\"><div aria-hidden=\"true\" class=\"content-navigation__hint\"><div class=\"content-navigation__hint__content\"><h6>PREVIOUS ARTICLE</h6><div>Effect of Salt Substitution on Cardiovascular Events and Death</div></div></div><i aria-hidden=\"true\" class=\"icon-arrow-left\"></i><span>Previous</span></a><a href=\"/doi/full/10.1056/NEJMoa2107322\" role=\"menuitem\" aria-label=\"Next article\" class=\"content-navigation__next\"><div aria-hidden=\"true\" class=\"content-navigation__hint\"><div class=\"content-navigation__hint__content\"><h6>NEXT ARTICLE</h6><div>Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer</div></div></div><span>Next</span><i aria-hidden=\"true\" class=\"icon-arrow-right\"></i></a></div></div></div><div class=\"st-header__track\"><div id=\"progress-tracker\" class=\"st-header__tracker\"></div></div></div><template id=\"figure_nav_template\"><nav><a href=\"#\" title=\"Open in viewer\" class=\"open-in-viewer\"><i aria-hidden=\"true\" class=\"icon-expand\"></i></a></nav></template><template id=\"fv_panel_template\" data-shareSocial=\"Share\"><div class=\"fv__panel js--hidden\"><div class=\"fv__panel__text\"><div class=\"fv__panel__contentTitle\"></div><div class=\"fv__panel__contentText\"></div></div></div></template>\n<template id=\"fv_directory_template\" data-overlay=\"View figure\"><div class=\"fv__directory\"><div class=\"fv__header\"><nav class=\"tab__nav\"></nav><a href=\"#\" title=\"Close figure viewer\" class=\"fv__close\"><i aria-hidden=\"true\" class=\"icon-close\"></i></a></div><div class=\"fv__content tab__content\"></div></div></template><template id=\"fv_directory_tabItem_template\" data-figures=\"Figures\" data-others=\"Others\" data-tables=\"Tables\"><button role=\"tab\" data-toggle=\"tab\" class=\"tab__nav__item\"></button></template>\n<template id=\"fv_lightbox_template\" data-sr-back=\"Go to figure location within the article\" data-sr-closeAlt=\"Close\" data-sr-download=\"Toggle download panel\" data-sr-download-pptx=\"Download PPT\" data-sr-info=\"Toggle information panel\" data-sr-panel=\"Close panel\" data-sr-share=\"Toggle share panel\" data-sr-zoom=\"Zoom\" data-text-close=\"Back to article\" data-text-nav-figures=\"All figures\" data-text-nav-others=\"All others\" data-text-nav-tables=\"All tables\" data-text-viewAll=\"View all material\" data-title-back=\"Back to article\" data-title-closeAlt=\"Close\" data-title-download=\"Download\" data-title-download-pptx=\"Download PPT\" data-title-info=\"Info\" data-title-share=\"Share\" data-title-zoom=\"Zoom\"></template>\n<template id=\"fv_toolbar_template\"><div class=\"fv__toolbar__info\"><strong class=\"fv__toolbar__contentTitle uppercase\"></strong><p class=\"fv__toolbar__contentText\"></p></div></template><template id=\"toCitationLink\" data-citation=\"Citation\" data-footnote=\"Footnote\"><div class=\"to-citation__wrapper\"><a class=\"to-citation\"><i aria-hidden=\"true\" class=\"icon-return\"></i><span>Go to</span></a></div></template><template id=\"toCitationButton\" data-citation=\"Citation\" data-footnote=\"Footnote\"><div class=\"to-citation__wrapper\"><button class=\"to-citation\"><i aria-hidden=\"true\" class=\"icon-return\"></i><span>Go to</span></button></div></template><template id=\"toCitationAccordion\" data-collapse-citation=\"Hide Citations\" data-expand-citation=\"Show Citations\" data-collapse-footnote=\"Hide Footnotes\" data-expand-footnote=\"Show Footnotes\"><div class=\"to-citation__wrapper\"><button aria-controls=\"aria-controls\" aria-expanded=\"false\" aria-haspopup=\"true\" aria-label=\"Toggle citations menu\" class=\"to-citation__toggle\"><i aria-hidden=\"true\" class=\"icon-plus\"></i><span data-expand-title=\"data-expand-title\" data-collapsed-title=\"data-collapsed-title\" class=\"accordion__toggle__title\"></span></button><div role=\"menu\" aria-label=\"links\" class=\"to-citation__accordion no-separator\"><ul></ul></div></div></template><template id=\"toCitationAccordionItem\"><li><a class=\"to-citation\"><i aria-hidden=\"true\" class=\"icon-return\"></i><span></span></a></li></template><template id=\"citations_truncate_template\"><div class=\"citations-truncation\"><button data-label-expand=\"Show all references\" data-label-collapse=\"Show fewer\" data-label-remaining=\"references remaining\" class=\"btn btn--secondary\"><span>Show all references</span></button></div></template><template id=\"collateral_texts_template\" data-references=\"References\" data-figure=\"Go to Figure\" data-media=\"Go to Media\" data-more=\"More\" data-original=\"Go to original\" data-table=\"Go to Table\" data-inViewer=\"Open in Viewer\" data-allInViewer=\"Open all in viewer\"><svg data-tags=\"copyright\" viewBox=\"0 0 24 24\"><path d=\"M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z\"/></svg><span>Request permissions</span><i aria-hidden=\"true\" class=\"icon-open_in_new\"></i></template><template id=\"collapsible_authors_template\"><button aria-expanded=\"false\" data-expandable=\"all\" data-label-expand=\"Expand All\" data-label-collapse=\"Collapse All\" class=\"collateral-contributors-control\"><span>Expand All</span></button></template>\n<template id=\"collapsible_tables_collapse_template\"><div class=\"collapsible-figure-btn__wrapper expanded\"><button aria-expanded=\"true\" class=\"btn collapsible-figure-btn btn--inverse\"><i aria-hidden=\"true\" class=\"icon-arrow-up\"></i><span class=\"text-uppercase\">Collapse</span></button></div></template>\n<template id=\"collapsible_tables_expand_template\"><div class=\"collapsible-figure-btn__wrapper collapsed\"><button aria-expanded=\"false\" class=\"btn collapsible-figure-btn btn--inverse\"><i aria-hidden=\"true\" class=\"icon-arrow-down\"></i><span class=\"text-uppercase\">Expand Table</span></button></div></template><template id=\"authorsAffiliationsLink\"><a href=\"#tab-contributors\" class=\"to-authors-affiliations\">Authors Info & Affiliations</a></template>\n\n        </main>\n    \n\n</div>\n\n\n\n\n        \n        <div class=\"ng-page_layout ng-page_layout-fullWidth\"><div class=\"container-fluid\"><div class=\"row\"><div class=\"col-12\">\n\n\n\n        \n        \n\n\n\n\n        \n        <div class=\"ng-page_layout-contentSpacing\"></div>\n\n\n\n\n\n\n\n\n\n\n    \n    \n        <div data-widget-def=\"oneSearchMultiSearch\" data-widget-id=\"778b3ad8-1a8d-43d8-8196-63b03df4a138\" data-location=\"recirc_inIssue_bottom_article\">\n        \n\n\n\n        \n        <div class=\"os-ms os-ms-more-from-issue\"><h3 class=\"ng-subsection-title\"><a href=\"/toc/nejm/385/12\" class=\"ng-subsection-title_link animation-icon-shift\"><span class=\"ng-subsection-title_text\">More from Vol. 385 No. 12</span><span class=\"ng-subsection-title_icon\"><span class=\"icon-component \"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-a5d5b6d8a6cc46cb61c3d16941f26e75.spritemap.svg#arrows-longArrowRight\"></use></svg></span></span></a></h3><ul class=\"os-ms-more-from-issue_list\"><li class=\"os-ms-more-from-issue_item\"><div class=\"issue-item issue-item_sm\"><div class=\"issue-item_meta\"><ul class=\"issue-item_meta-list clearfix\"><li class=\"issue-item_meta-item\"><a href=\"/browse/nejm-article-type/original-article\" class=\"issue-item_type\">Original Article</a></li><li class=\"issue-item_meta-item\"><span class=\"issue-item_date\">Sep 16, 2021</span></li><li class=\"issue-item_meta-item\"><span class=\"issue-item_free\">FREE</span></li></ul></div><div class=\"issue-item_row\"><div class=\"issue-item_left\"><div class=\"issue-item_content clearfix\"><h4 class=\"issue-item_title\"><a href=\"/doi/full/10.1056/NEJMoa1708120\" data-interactiontype=\"article_recirculation_click\" class=\"issue-item_title-link animation-underline\">Safety and Immunogenicity of an Anti–Zika Virus DNA Vaccine</a></h4><div class=\"issue-item_authors-and-text\"><span class=\"issue-item_authors\">P. Tebas and Others</span></div></div></div></div></div></li><li class=\"os-ms-more-from-issue_item\"><div class=\"issue-item issue-item_sm\"><div class=\"issue-item_meta\"><ul class=\"issue-item_meta-list clearfix\"><li class=\"issue-item_meta-item\"><a href=\"/browse/nejm-article-type/original-article\" class=\"issue-item_type\">Original Article</a></li><li class=\"issue-item_meta-item\"><span class=\"issue-item_date\">Sep 16, 2021</span></li><li data-toggle=\"tooltip\" data-original-title=\"Video\" class=\"issue-item_meta-item\"><span aria-label=\"Video\" class=\"issue-item_video\"><span class=\"icon-component \"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-a5d5b6d8a6cc46cb61c3d16941f26e75.spritemap.svg#tooltip-video\"></use></svg></span></span></li><li class=\"issue-item_meta-item\"><span class=\"issue-item_free\">FREE</span></li></ul></div><div class=\"issue-item_row\"><div class=\"issue-item_left\"><div class=\"issue-item_content clearfix\"><h4 class=\"issue-item_title\"><a href=\"/doi/full/10.1056/NEJMoa2105675\" data-interactiontype=\"article_recirculation_click\" class=\"issue-item_title-link animation-underline\">Effect of Salt Substitution on Cardiovascular Events and Death</a></h4><div class=\"issue-item_authors-and-text\"><span class=\"issue-item_authors\">B. Neal and Others</span></div></div></div></div></div></li><li class=\"os-ms-more-from-issue_item\"><div class=\"issue-item issue-item_sm\"><div class=\"issue-item_meta\"><ul class=\"issue-item_meta-list clearfix\"><li class=\"issue-item_meta-item\"><a href=\"/browse/nejm-article-type/original-article\" class=\"issue-item_type\">Original Article</a></li><li class=\"issue-item_meta-item\"><span class=\"issue-item_date\">Sep 16, 2021</span></li><li data-toggle=\"tooltip\" data-original-title=\"Visual Abstract\" class=\"issue-item_meta-item\"><span aria-label=\"Visual Abstract\" class=\"issue-item_visualAbstract\"><span class=\"icon-component \"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-a5d5b6d8a6cc46cb61c3d16941f26e75.spritemap.svg#tooltip-visual\"></use></svg></span></span></li><li class=\"issue-item_meta-item\"><span class=\"issue-item_free\">FREE</span></li></ul></div><div class=\"issue-item_row\"><div class=\"issue-item_left\"><div class=\"issue-item_content clearfix\"><h4 class=\"issue-item_title\"><a href=\"/doi/full/10.1056/NEJMoa2035916\" data-interactiontype=\"article_recirculation_click\" class=\"issue-item_title-link animation-underline\">Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children</a></h4><div class=\"issue-item_authors-and-text\"><span class=\"issue-item_authors\">P.D. Patel and Others</span></div></div></div></div></div></li></ul></div>\n\n        </div>\n    \n\n</div></div></div></div>\n\n\n\n\n        \n        <div class=\"ng-page_layout-bottomAd\"><div class=\"container-fluid\"><div class=\"row\"><div class=\"col-12\">\n\n\n\n\n\n\n\n\n\n    \n    \n        <div data-widget-def=\"literatumAd\" data-widget-id=\"7e022d0d-4a48-44a7-af66-033cf5c13eb8\" id=\"ad-article-bottom-FULLx320-1\">\n        \n\n\n\n        \n        \n\n\n\n    \n        <div class=\"pb-house-message adplaceholder exists\">\n            <!-- START: Circulation Footer 3 -->\n<aside class=\"g-cta-subscribe\">\n\t<style>\n.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:\" \";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}\n\t</style>\n\t<div class=\"bads_footer-banner24-ONJQNRF1\">\n\t  <div class=\"bads_footer-banner24-ONJQNRF1-inner bads_clearfix\">\n\t\t <div class=\"bads_subs-btn\">\n\t\t\t<h5 class=\"bads_h5\">Discount Resident Offer</h5>\n\t\t\t<p class=\"g-cta-subscribe__title\">Tap into groundbreaking research and clinically relevant insights</p>\n\t\t\t<ul class=\"g-cta-subscribe__actions\">\n\t\t\t\t<li class=\"g-cta-subscribe__actions-primary\">\n\t\t\t\t  <a href=\"/action/clickThrough?id=127716&url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252Fnejmoa2110475%26promo%3DONFQNRF1&loc=%2Fdoi%2Ffull%2F10.1056%2Fnejmoa2110475&pubId=41290331&placeholderId=101336&productId=1035\" class=\"ng-btn_primary ng-btn_iconRight\"><span class=\"ng-btn_text\">Subscribe </span><span class=\"icon-component\"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight\"></use></svg></span></a>\n\t\t\t\t</li>\n\t\t\t</ul>\n\t\t\t<p class=\"g-cta-subscribe__login\">Already a subscriber? <a href=\"/action/clickThrough?id=127716&url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252Fnejmoa2110475%26promo%3DONFQANR4&loc=%2Fdoi%2Ffull%2F10.1056%2Fnejmoa2110475&pubId=41290331&placeholderId=101336&productId=1035\">Activate</a> your online access.</p>\n\t\t </div>\n\n\t\t<div class=\"bads_device-img\">\n\t\t   <img src=\"/sda/127716/footer-devices-2x.png\" alt=\"Devices\">\n\t\t</div>\n\t   </div>\n\t</div>\n</aside>\n<!--/END: Circulation Footer 3 -->\n            \n        </div>\n    \n\n    \n\n    \n\n\n\n        </div>\n    \n\n</div></div></div></div>\n\n\n\n\n        \n        <footer class=\"ng-footer footer__top\"><div data-location=\"footer\" class=\"ng-footer_columns\"><div class=\"container-fluid\"><div class=\"row\"><div class=\"col-lg-4 col-md-6 col-sm-12 ng-footer_column\"><div class=\"row\"><div class=\"col-6 ng-footer_column-nested\">\n\n\n\n        \n        <h4 class=\"ng-footer_column-title\">ARTICLE CATEGORIES</h4>\n<ul class=\"ng-footer_column-list\">\n    <li class=\"ng-footer_column-list-item\">\n        <a href=\"/browse/nejm-article-category/research\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Research</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/browse/nejm-article-category/review\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Reviews</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/browse/nejm-article-category/clinical-cases\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Clinical Cases</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/browse/nejm-article-category/perspective\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Perspective</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/browse/nejm-article-category/commentary\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Commentary</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/browse/nejm-article-category/other\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Other</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/medical-article-index\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Browse all Articles</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/toc/nejm/current\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Current Issue</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/loi/nejm\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Issue Index</span></a></li>\n</ul>\n</div><div class=\"col-6 ng-footer_column-nested\">\n\n\n\n        \n        <h4 class=\"ng-footer_column-title\">RESOURCES</h4>\n<ul class=\"ng-footer_column-list\">\n    <li class=\"ng-footer_column-list-item\"><a href=\"/author-center/home\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Authors &amp; Reviewers</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/author-center/home\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Submit a Manuscript</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/about-nejm/products-and-services\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Subscribers</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"https://tools.ovid.com/ovidtools/nejm.html\" target=\"_blank\" rel=\"noopener\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Institutional Administrators</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/media\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Media</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/about-nejm/how-to-advertise\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Advertisers</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/information-for-subscription-agents\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Agents</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/about-nejm/permissions\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Permissions & Licensing</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/about-nejm/reprints\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Reprints</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"https://www.nejmcareercenter.org\" target=\"_blank\" rel=\"noopener\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">NEJM CareerCenter</span></a>\n    </li>\n</ul>\n</div></div></div><div class=\"col-lg-4 col-md-6 col-sm-12 ng-footer_column\"><div class=\"row\"><div class=\"col-6 ng-footer_column-nested\">\n\n\n\n        \n        <h4 class=\"ng-footer_column-title\">ABOUT US</h4>\n<ul class=\"ng-footer_column-list\">\n    <li class=\"ng-footer_column-list-item\"><a href=\"/about-nejm/about-nejm\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">About NEJM</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"https://www.nejmgroup.org/\" target=\"_blank\" rel=\"noopener\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">NEJM Group</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/about-nejm/products-and-services\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Products &amp; Services</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/about-nejm/editors-and-publishers\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Editors &amp; Publishers</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/about-nejm/advertising-policies\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Advertising Policies</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/contact-nejm\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Contact Us</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/about-nejm/frequently-asked-questions?#Accessibility\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Accessibility</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/about-nejm/frequently-asked-questions\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">FAQs</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/about-nejm/help\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Help</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/cdn-cgi/l/email-protection#6013091405060505040201030b200e050a0d4e0f1207\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Site Feedback</span></a></li>\n</ul>\n</div><div class=\"col-6 ng-footer_column-nested\">\n\n\n\n        \n        <h4 class=\"ng-footer_column-title\">SUBSCRIPTIONS</h4>\n<ul class=\"ng-footer_column-list\">\n    <li class=\"ng-footer_column-list-item\"><a href=\"/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3\" class=\"ng-footer_column-link animation-underline ro-mode_disabled\"><span class=\"ng-footer_column-link-text\">Subscribe</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52\" class=\"ng-footer_column-link animation-underline ro-mode_disabled\"><span class=\"ng-footer_column-link-text\">Renew</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/action/storeProxy?action=activate&amp;promo=ONFLNAA1\" class=\"ng-footer_column-link animation-underline ro-mode_disabled\"><span class=\"ng-footer_column-link-text\">Activate Subscription</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/action/storeProxy?action=register&amp;promo=ONFLNRC4\" class=\"ng-footer_column-link animation-underline ro-mode_disabled\"><span class=\"ng-footer_column-link-text\">Create Account</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"https://myaccount.nejm.org\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Manage Account</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1\" class=\"ng-footer_column-link animation-underline ro-mode_disabled\"><span class=\"ng-footer_column-link-text\">Pay Bill</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"https://info.lww.com/Request-NEJM-for-your-institution.html\" target=\"_blank\" rel=\"noopener\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Institution Subscriptions</span></a></li>    \n    <li class=\"ng-footer_column-list-item\"><a href=\"https://myaccount.nejm.org/special-content\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Special Content</span></a></li>\n</ul>\n</div></div></div><div class=\"col-lg-4 col-md-12 ng-footer_column\"><div class=\"row\"><div class=\"col-6 ng-footer_column-nested\">\n\n\n\n        \n        <h4 class=\"ng-footer_column-title\">STAY CONNECTED</h4>\n<ul class=\"ng-footer_column-list\">\n    <li class=\"ng-footer_column-list-item\"><a href=\"https://myaccount.nejm.org/emails?section=NEJM\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Email Alerts</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/action/storeProxy?action=register&amp;promo=ONFLNRC3\" class=\"ng-footer_column-link animation-underline ro-mode_disabled\"><span class=\"ng-footer_column-link-text\">Create Account</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/about-nejm/products-and-services\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Apps</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"https://www.nejmcareercenter.org\" target=\"_blank\" rel=\"noopener\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">NEJM CareerCenter</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/rss-feed/\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Podcasts</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/rss-feed/\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">RSS Feed</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"/about-nejm/institutional-access\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-text\">Remote Access</span></a></li>\n</ul>\n</div><div class=\"col-6 ng-footer_column-nested\">\n\n\n\n        \n        <h4 class=\"ng-footer_column-title\">FOLLOW US</h4>\n<ul class=\"ng-footer_column-list\">\n    <li class=\"ng-footer_column-list-item\"><a href=\"https://www.facebook.com/TheNewEnglandJournalofMedicine\" target=\"_blank\" rel=\"noopener\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-icon\"><span class=\"icon-component\"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook\"></use></svg></span></span><span class=\"ng-footer_column-link-text\">Facebook</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"https://twitter.com/nejm\" target=\"_blank\" rel=\"noopener\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-icon\"><span class=\"icon-component\"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter\"></use></svg></span></span><span class=\"ng-footer_column-link-text\">X (formerly Twitter)</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"https://www.instagram.com/nejm/\" target=\"_blank\" rel=\"noopener\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-icon\"><span class=\"icon-component\"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram\"></use></svg></span></span><span class=\"ng-footer_column-link-text\">Instagram</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"https://www.youtube.com/user/NEJMvideo\" target=\"_blank\" rel=\"noopener\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-icon\"><span class=\"icon-component\"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube\"></use></svg></span></span><span class=\"ng-footer_column-link-text\">Youtube</span></a></li>\n    <li class=\"ng-footer_column-list-item\"><a href=\"https://www.linkedin.com/company/nejm-group\" target=\"_blank\" rel=\"noopener\" class=\"ng-footer_column-link animation-underline\"><span class=\"ng-footer_column-link-icon\"><span class=\"icon-component\"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin\"></use></svg></span></span><span class=\"ng-footer_column-link-text\">LinkedIn</span></a></li>\n</ul>\n</div></div></div></div></div></div><div data-location=\"footer\" class=\"ng-footer_journals\"><div class=\"container-fluid\"><div class=\"row\"><div class=\"col-12\">\n\n\n\n        \n        <h4 class=\"ng-footer_journals-label\">JOURNALS</h4>\n<ul class=\"ng-footer_journals-list\">\n    <li class=\"ng-footer_journals-item\"><a href=\"https://www.nejm.org/\" target=\"_blank\" rel=\"noopener\" class=\"ng-footer_journals-link\">The New England Journal of Medicine</a></li>\n    <li class=\"ng-footer_journals-item\"><a href=\"https://catalyst.nejm.org/\" target=\"_blank\" rel=\"noopener\" class=\"ng-footer_journals-link\">NEJM Catalyst Innovations in Care Delivery</a></li>\n    <li class=\"ng-footer_journals-item\"><a href=\"https://evidence.nejm.org/\" target=\"_blank\" rel=\"noopener\" class=\"ng-footer_journals-link\">NEJM Evidence</a></li>\n    <li class=\"ng-footer_journals-item\"><a href=\"https://ai.nejm.org/\" target=\"_blank\" rel=\"noopener\" class=\"ng-footer_journals-link\">NEJM AI</a></li>\n</ul>\n</div></div></div></div><div data-location=\"legal\" class=\"ng-footer_bottom\"><div class=\"container-fluid\"><div class=\"row\"><div class=\"col-lg-7 col-md-6 ng-footer_bottom-left\">\n\n\n\n        \n        <p>Copyright &#169; 2024 <a href=\"https://www.massmed.org/\" target=\"_blank\" rel=\"noopener\" class=\"ng-footer_bottom-link\">Massachusetts Medical Society</a>. All rights reserved. Electronic ISSN 1533-4406. Print ISSN 0028-4793.</p>\n<p>The content of this site is intended for health care professionals.</p>\n</div><div class=\"col-lg-5 col-md-6 ng-footer_bottom-right\">\n\n\n\n        \n        <style>\n  #teconsent a {\n    color: #666;\n    text-decoration: none;\n  }\n  #teconsent a:hover {\n    color: #666;\n    text-decoration: underline;\n  }\n</style>\n<ul class=\"ng-footer_bottom-list\">\n     <li class=\"ng-footer_bottom-list-item\"><a href=\"https://www.nejmgroup.org/legal/copyright-information.htm\" target=\"_blank\" rel=\"noopener\" class=\"ng-footer_bottom-link\">Copyright</a></li>\n    <li class=\"ng-footer_bottom-list-item\"><a href=\"https://www.nejmgroup.org/legal/terms-of-use.htm\"  target=\"_blank\" rel=\"noopener\" class=\"ng-footer_bottom-link\">Terms</a></li>\n    <li class=\"ng-footer_bottom-list-item\"><a href=\"https://www.nejmgroup.org/legal/privacy-policy.htm\"  target=\"_blank\" rel=\"noopener\" class=\"ng-footer_bottom-link\">Privacy Policy</a></li>\n    <li class=\"ng-footer_bottom-list-item\"><span id=\"teconsent\"></span></li>\n    </ul>\n    <a href=\"https://www.nejmgroup.org/\" title=\"NEJM Group\" target=\"_blank\" rel=\"noopener\" class=\"ng-footer_logo-link\"><img src=\"/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg\" alt=\"NEJM Group logo\" class=\"ng-footer_logo\"></a>\n</div></div></div></div><div data-show-after=\"400\" class=\"back-to-top back-to-top--align-right  \"><button data-snap=\"footer__top\" class=\"back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center\"><svg viewBox=\"0 0 36 36\" class=\"position-relative\"><path d=\"M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831\" class=\"back-to-top__action__ring-bg\"></path><path d=\"M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831\" stroke-dasharray=\"0, 100\" class=\"back-to-top__action__ring\"></path></svg><span class=\"back-to-top__action-icon position-absolute d-flex\"><span class=\"icon-component \"><svg aria-hidden=\"true\"><use xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-a5d5b6d8a6cc46cb61c3d16941f26e75.spritemap.svg#arrows-up\"></use></svg></span></span><span class=\"sr-only\">Back to top</span></button></div></footer>\n\n\n\n\n        \n        <!-- TrustArc: Banner -->\n<div id=\"consent_blackbar\"></div>\n<!-- /TrustArc: Banner -->\n\n\n\n\n        \n        <link rel=\"stylesheet\" href=\"https://cssjs.nejm.org/mmsWidgets.css\"><script data-cfasync=\"false\" src=\"/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js\"></script><script type=\"text/javascript\" src=\"https://cssjs.nejm.org/mmsWidgets.js\"></script><script type=\"text/javascript\">var litSSO = {\n    \"ucid\": null,\n    \"accessToken\": null,\n    \"authState\": null\n};\n\nvar loginUri = '/action/doSsoLogin';\nvar logoutUri = '/action/doLogout';\n\ndisplayAuthenticatedMessage();\n\nmmsWidgets.init({\n    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',\n    origin: 'NEJM',\n    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',\n    isFullPageSignIn: isSignInPage(),\n    debug: true,\n\n    onReady: function (e) {\n        console.log('<<<<<<<<<< client: received onReady event.');\n        $(\"A.litSsoLogin\").click(function (e) {\n            if (!$(e.currentTarget).hasClass(\"noMd\") || $(e.currentTarget).parents(\".header_sm-login\").length === 0) {\n                mmsWidgets.signIn(e);\n                return false;\n            }\n        });\n        $(\"A.litSsoLogout\").click(function (e) {\n            mmsWidgets.signOut(e);\n            return false;\n        });\n        $(\"A.litSsoCreate\").click(function (e) {\n            mmsWidgets.showRegModal(e);\n            return false;\n        });\n        $(\"A.litSsoSubscribe\").click(function (e) {\n            if (!$(e.currentTarget).hasClass(\"noMd\") || $(e.currentTarget).parents(\".header_sm-login\").length === 0)\n                location.assign(e.currentTarget.href);\n            return false;\n        });\n        if (window.doSSOLogin) {\n            window.setTimeout(function () {\n                mmsWidgets.signIn();\n            }, 500);\n        }\n        ;\n    },\n    onLoginSuccess: function (e) {\n        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));\n\n        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, \"\"));\n        document.cookie = \"skipSso=; expires=; path=/\";\n        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {\n            location.assign(loginUri + \"?ucid=\" + e.profile.ucid\n                + \"&accessToken=\" + e.accessToken\n                + \"&authState=\" + e.authState\n                + \"&email=\" + encodeURIComponent(e.profile.email)\n                + \"&givenNames=\" + e.profile.givenName\n                + \"&surname=\" + e.profile.familyName\n                + \"&redirectUri=\" + redirectUrl\n                + \"&uccLastUpdatedDate=\" + encodeURIComponent(e.profile.uccLastUpdatedDate)\n                + \"&rememberMe=\" + e.rememberMe);\n        }\n    },\n    onAuthStateReady: function (e) {\n        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))\n\n        var isMmsSsoAuthenticated = (e.authState && e.authState !== \"anonymous\" && e.authState !== \"lead\" && e.ucid && e.accessToken) ? true : false;\n        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;\n        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);\n\n        if (isMmsSsoAuthenticated) {\n            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {\n                if (window.skipSso)\n                    document.cookie = \"skipSso=\" + encodeURIComponent(e.ucid) + \"; expires=; path=/\";\n\n                if (!window.skipSso && document.cookie.indexOf(\"skipSso=\" + encodeURIComponent(e.ucid)) == -1) {\n                    location.assign(loginUri + \"?ucid=\" + e.profile.ucid\n                        + \"&accessToken=\" + e.accessToken\n                        + \"&authState=\" + e.authState\n                        + \"&email=\" + encodeURIComponent(e.profile.email)\n                        + \"&givenNames=\" + e.profile.givenName\n                        + \"&surname=\" + e.profile.familyName\n                        + \"&redirectUri=\" + location.href.replace(window.location.origin, \"\")\n                        + \"&uccLastUpdatedDate=\" + encodeURIComponent(e.profile.uccLastUpdatedDate)\n                        + \"&rememberMe=\" + e.rememberMe);\n                } else\n                    console.log('**** client: Skip SSO ****');\n            } else if (e.accessToken !== litSSO.accessToken)\n                updateLitSession(e.ucid, e.accessToken);\n        } else if (isLitSsoAuthenticated)\n            location.assign(logoutUri + \"?redirectUri=\" + encodeURIComponent(location.href.replace(window.location.origin, \"\")));\n\n        if (document.getElementById(\"ssoerr-ucid\"))\n            document.getElementById(\"ssoerr-ucid\").innerHTML = e.ucid;\n\n    },\n    onRegistrationSuccess: function (e) {\n        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))\n        document.cookie = \"skipSso=; expires=; path=/\";\n        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';\n        location.assign(loginUri + \"?ucid=\" + e.profile.ucid\n            + \"&accessToken=\" + e.accessToken\n            + \"&authState=\" + e.authState\n            + \"&email=\" + encodeURIComponent(e.profile.email)\n            + \"&givenNames=\" + e.profile.givenName\n            + \"&surname=\" + e.profile.familyName\n            + \"&redirectUri=\" + location.href.replace(window.location.origin, \"\")\n            + \"&uccLastUpdatedDate=\" + encodeURIComponent(uccLastUpdatedDate)\n            + \"&rememberMe=\" + e.rememberMe);\n    },\n    onLogoutSuccess: function (e) {\n        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))\n\n        document.cookie = \"skipSso=; expires=; path=/\";\n        location.assign(logoutUri);\n    },\n});\n\nfunction updateLitSession(ucid, accessToken) {\n    $.ajax({\n        method: \"GET\",\n        url: \"/action/doSsoSessionUpdate\",\n        data: {ucid: ucid, accessToken: accessToken},\n        success: function (callData, textStatus) {\n            console.log(\"Session accessToken updated\")\n            litSSO.accessToken = accessToken\n        },\n        error: function (jqXHR, textStatus, errorThrown) {\n            alert(\"Your website session has expired and will now be reset.\")\n            console.log(\"Session update failed: \" + jqXHR.responseText)\n            location.assign(logoutUri + \"?redirectUri=\" + encodeURIComponent(location.href.replace(window.location.origin, \"\")));\n        }\n    });\n}\n\nfunction getRedirectUri(location, fallback) {\n    const urlParams = new URLSearchParams(location);\n    const uriUrlParam = urlParams.get('uri');\n    if (uriUrlParam)\n        return encodeURIComponent(uriUrlParam);\n    else\n        return encodeURIComponent(fallback);\n}\n\nfunction isSignInPage() {\n    return document.querySelector('meta[name=\"pbContext\"]').content.indexOf(\"customPage:string:/sign-in\") > -1;\n}\n\nfunction displayAuthenticatedMessage() {\n    if (isSignInPage()) {\n        var div = document.getElementById('authMsg');\n        if (\"\" === \"PersonUser\") {\n            div.innerHTML += \"You are already signed in to \" + window.location.origin.replace(\"https://\", \"\").replace(\"www.\", \"\") + \". If you would like to sign in with a different email address, please use the form below.\";\n        } else {\n            div.innerHTML = '';\n        }\n    }\n}</script>\n\n\n\n\n        \n        <script>\n    document.addEventListener('DOMContentLoaded', function() {\n        var metaTag = document.querySelector('meta[name=\"dc.Identifier\"]');\n        if (metaTag && metaTag.getAttribute('content').indexOf('10.1056/NEJMpv',0)==0) {\n            var footer = document.createElement('footer');\n            footer.classList.add('author-groups');\n\n            // Get the core-authors section\n            var coreAuthorsSection = document.querySelector('.core-authors');\n            if (coreAuthorsSection) {\n                var coreAuthorsClone = coreAuthorsSection.cloneNode(true);\n                coreAuthorsClone.classList.add('authors');\n                var h4Authors = coreAuthorsClone.querySelector('h4');\n                if (h4Authors) {\n                    h4Authors.classList.add('d-none');\n                }\n                var paragraphDiv = coreAuthorsClone.querySelector('div[role=\"paragraph\"]');\n                if (paragraphDiv) {\n                    paragraphDiv.classList.add('m-0');\n                }\n                footer.appendChild(coreAuthorsClone);\n            }\n\n            // Get the core-affiliations section\n            var coreAffiliationsSection = document.querySelector('.core-affiliations');\n            if (coreAffiliationsSection) {\n                var coreAffiliationsClone = coreAffiliationsSection.cloneNode(true);\n                coreAffiliationsClone.classList.add('affiliations');\n                var h4Affiliations = coreAffiliationsClone.querySelector('h4');\n                if (h4Affiliations) {\n                    h4Affiliations.classList.add('d-none');\n                }\n                footer.appendChild(coreAffiliationsClone);\n            }\n\n            var bodyMatterSection = document.getElementById('bodymatter');\n            if (bodyMatterSection && bodyMatterSection.parentNode) {\n                bodyMatterSection.parentNode.insertBefore(footer, bodyMatterSection.nextSibling);\n            }\n        }\n    });\n</script>\n\n\n\n\n        \n        <div><div class=\"pb-dropzone\" data-pb-dropzone=\"col-0\" title=\"col-0\"></div></div>\n        </div>\n    </div>\n\n\n\n        \n        \n\n            <script src=\"/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js\"></script>\n\n        <script src=\"/products/mms-nextgen/mms/releasedAssets/js/main.bundle-a6a18781b17ce59ac830.js\" ></script>\n        \n\n\n<div id=\"adModal\" tabindex=\"-1\" aria-labelledby=\"exampleModalCenterTitle\" class=\"ng-modal modal\"\n     style=\"display: none;\" aria-hidden=\"true\">\n    <div role=\"document\" class=\"ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer\">\n        <div class=\"ng-modal_content modal-content p-0\">\n            <div class=\"ng-modal_body modal-body m-0\">\n                <div class=\"ng-modal_header modal-header\">\n                    <button type=\"button\" data-dismiss=\"modal\" aria-label=\"Close\" class=\"ng-modal_close close\"><span\n                            aria-hidden=\"true\"><span class=\"icon-component \"><svg aria-hidden=\"true\"><use\n                            xlink:href=\"/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close\"></use></svg></span></span>\n                    </button>\n                </div>\n\n            </div>\n        </div>\n    </div>\n</div>\n<script type=\"text/javascript\" src=\"/wro/nlv6~product.js\"></script>\n\n\n\n\n\n\n\n\n<input id=\"showLayers\" type=\"hidden\" value=\"true\" />\n\n    <!-- placeholder id=null, description=ad-layer-config -->\n    <!-- placeholder id=null, description=ad-lauchLayer-1 -->\n    <!-- placeholder id=null, description=ad-layer-promo-1 -->\n\n    <input id=\"firstAd\" type=\"hidden\" value=\"\" />\n    <input id=\"secondAd\" type=\"hidden\" value=\"\" />\n\n    \n    \n    \n\n    \n    \n    <input id=\"IsInstitution\" type=\"hidden\" value=\"false\" />\n    <input id=\"IsSubscriber\" type=\"hidden\" value=\"true\" />\n    <input id=\"CustomerId\" type=\"hidden\" value=\"\" />\n\n\n<script type=\"text/javascript\">\n  jQuery.extend(jQuery.mmsLayers.config, {\n    rules: [{\n      \"name\": \"Launch Layer Ad\",\n      \"frequency\": 30,\n      \"showOnPage\": 5,\n      \"enabled\": false,\n      \"cookieName\": \"MarketingLaunchLayer\",\n      \"styleClass\": \"launchLayer\"\n    },\n    {\n      \"name\": \"Promo Layer Ad\",\n      \"frequency\": 14,\n      \"enabled\": true,\n      \"cookieName\": \"PromoLayer\",\n      \"styleClass\": \"promoLayer\"\n    },\n    {\n      \"name\": \"Interstitial Ad\",\n      \"frequency\": 7,\n      \"enabled\": false,\n      \"cookieName\": \"InterstitialAd\"\n    },\n    {\n      \"name\": \"Iperceptions - Ion Layer Ad\",\n      \"showOnPage\": 1,\n      \"enabled\": false,\n      \"test\": false,\n      \"cookieName\":\"Iperceptions\"\n    }]\n });\n</script>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n    <script type=\"text/javascript\">\n        $(document).ready(() => setTimeout(() => {\n            let _bnw=window,_bna=atob(\"bG9jYXRpb24=\"),_bnb=atob(\"b3JpZ2lu\"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(\" \"));\n            $.get(\"/resource/lodash?t=\"+_bnt);\n        },4000));\n    </script>\n\n\n\n\n\n\n\n\n    \n\n    \n    \n\n    \n    \n    \n    \n        \n            \n                <script type=\"text/javascript\" src=\"/wro/nlv6~article-metrics.js\"></script>\n            \n            \n            \n        \n    \n\n\n\n\n<script type=\"text/javascript\" src=\"/wro/nlv6~full-text-analytics.js\"></script>\n\n\n<script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML=\"window.__CF$cv$params={r:'8d07ba023f138ce6',t:'MTcyODU3NTAxMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);\";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><script defer src=\"https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015\" integrity=\"sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==\" data-cf-beacon='{\"rayId\":\"8d07ba023f138ce6\",\"serverTiming\":{\"name\":{\"cfExtPri\":true,\"cfL4\":true}},\"version\":\"2024.8.0\",\"token\":\"f55e150c7a5f4a4ab9ef82f4a1c9c43c\"}' crossorigin=\"anonymous\"></script>\n</body>\n</html>\n","oembed":false,"readabilityObject":{"title":"Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting","content":"<div id=\"readability-page-1\" class=\"page\"><article xmlns=\"http://www.w3.org/1999/xhtml\" data-design=\"pill\" data-has=\"right-rail\" data-type=\"research-article\" vocab=\"http://schema.org/\" typeof=\"ScholarlyArticle\" lang=\"en\" dir=\"ltr\"><header data-extent=\"frontmatter\" data-location=\"header_article\"><div><div><p><span><span>Authors</span>: <span role=\"list\"><span property=\"author\" typeof=\"Person\" role=\"listitem\"><span property=\"givenName\">Noam</span> <span property=\"familyName\">Barda</span>, <span property=\"honorificSuffix\">M.D.</span></span>, <span property=\"author\" typeof=\"Person\" role=\"listitem\"><span property=\"givenName\">Noa</span> <span property=\"familyName\">Dagan</span>, <span property=\"honorificSuffix\">M.D.</span> <a href=\"https://orcid.org/0000-0001-8811-7825\" property=\"identifier\" aria-label=\"ORCID identifier\" target=\"_blank\">https://orcid.org/0000-0001-8811-7825</a></span>, <span property=\"author\" typeof=\"Person\" role=\"listitem\"><span property=\"givenName\">Yatir</span> <span property=\"familyName\">Ben-Shlomo</span>, <span property=\"honorificSuffix\">B.Sc.</span></span>, <span property=\"author\" typeof=\"Person\" role=\"listitem\"><span property=\"givenName\">Eldad</span> <span property=\"familyName\">Kepten</span>, <span property=\"honorificSuffix\">Ph.D.</span></span>, <span property=\"author\" typeof=\"Person\" role=\"listitem\"><span property=\"givenName\">Jacob</span> <span property=\"familyName\">Waxman</span>, <span property=\"honorificSuffix\">M.D.</span></span>, <span property=\"author\" typeof=\"Person\" role=\"listitem\"><span property=\"givenName\">Reut</span> <span property=\"familyName\">Ohana</span>, <span property=\"honorificSuffix\">M.Sc.</span></span>, <span property=\"author\" typeof=\"Person\" role=\"listitem\"><span property=\"givenName\">Miguel A.</span> <span property=\"familyName\">Hernán</span>, <span property=\"honorificSuffix\">M.D.</span> <a href=\"https://orcid.org/0000-0003-1619-8456\" property=\"identifier\" aria-label=\"ORCID identifier\" target=\"_blank\">https://orcid.org/0000-0003-1619-8456</a></span>, <span property=\"author\" typeof=\"Person\" role=\"listitem\"><span property=\"givenName\">Marc</span> <span property=\"familyName\">Lipsitch</span>, <span property=\"honorificSuffix\">D.Phil.</span> <a href=\"https://orcid.org/0000-0003-1504-9213\" property=\"identifier\" aria-label=\"ORCID identifier\" target=\"_blank\">https://orcid.org/0000-0003-1504-9213</a></span>, <span property=\"author\" typeof=\"Person\" role=\"listitem\"><span property=\"givenName\">Isaac</span> <span property=\"familyName\">Kohane</span>, <span property=\"honorificSuffix\">M.D.</span></span>, <span property=\"author\" typeof=\"Person\" role=\"listitem\"><span property=\"givenName\">Doron</span> <span property=\"familyName\">Netzer</span>, <span property=\"honorificSuffix\">M.D.</span></span>, <span property=\"author\" typeof=\"Person\" role=\"listitem\"><span property=\"givenName\">Ben Y.</span> <span property=\"familyName\">Reis</span>, <span property=\"honorificSuffix\">Ph.D.</span></span>, and <span property=\"author\" typeof=\"Person\" role=\"listitem\"><span property=\"givenName\">Ran D.</span> <span property=\"familyName\">Balicer</span>, <span property=\"honorificSuffix\">M.D.</span></span></span></span></p></div><div><p>Published <span property=\"datePublished\">August 25, 2021</span></p><p><span property=\"name\">N Engl J Med</span> 2021<span property=\"isPartOf\" typeof=\"PublicationVolume\">;<span property=\"volumeNumber\">385</span></span>:<span property=\"pageStart\">1078</span>-<span property=\"pageEnd\">1090</span></p><p>DOI: 10.1056/NEJMoa2110475</p></div></div></header><section id=\"abstracts\" property=\"abstract\" typeof=\"Text\" role=\"doc-abstract\" data-extent=\"frontmatter\" data-location=\"articleTab_article\"><h2 property=\"name\">Abstract</h2><section id=\"abs-sec-1\"><h3>Background</h3><p>Preapproval trials showed that messenger RNA (mRNA)–based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet these trials were subject to size and patient-mix limitations. An evaluation of the safety of the BNT162b2 mRNA vaccine with respect to a broad range of potential adverse events is needed.</p></section><section id=\"abs-sec-2\"><h3>Methods</h3><p>We used data from the largest health care organization in Israel to evaluate the safety of the BNT162b2 mRNA vaccine. For each potential adverse event, in a population of persons with no previous diagnosis of that event, we individually matched vaccinated persons to unvaccinated persons according to sociodemographic and clinical variables. Risk ratios and risk differences at 42 days after vaccination were derived with the use of the Kaplan–Meier estimator. To place these results in context, we performed a similar analysis involving SARS-CoV-2–infected persons matched to uninfected persons. The same adverse events were studied in the vaccination and SARS-CoV-2 infection analyses.</p></section><section id=\"abs-sec-3\"><h3>Results</h3><p>In the vaccination analysis, the vaccinated and control groups each included a mean of 884,828 persons. Vaccination was most strongly associated with an elevated risk of myocarditis (risk ratio, 3.24; 95% confidence interval [CI], 1.55 to 12.44; risk difference, 2.7 events per 100,000 persons; 95% CI, 1.0 to 4.6), lymphadenopathy (risk ratio, 2.43; 95% CI, 2.05 to 2.78; risk difference, 78.4 events per 100,000 persons; 95% CI, 64.1 to 89.3), appendicitis (risk ratio, 1.40; 95% CI, 1.02 to 2.01; risk difference, 5.0 events per 100,000 persons; 95% CI, 0.3 to 9.9), and herpes zoster infection (risk ratio, 1.43; 95% CI, 1.20 to 1.73; risk difference, 15.8 events per 100,000 persons; 95% CI, 8.2 to 24.2). SARS-CoV-2 infection was associated with a substantially increased risk of myocarditis (risk ratio, 18.28; 95% CI, 3.95 to 25.12; risk difference, 11.0 events per 100,000 persons; 95% CI, 5.6 to 15.8) and of additional serious adverse events, including pericarditis, arrhythmia, deep-vein thrombosis, pulmonary embolism, myocardial infarction, intracranial hemorrhage, and thrombocytopenia.</p></section><section id=\"abs-sec-4\"><h3>Conclusions</h3><p>In this study in a nationwide mass vaccination setting, the BNT162b2 vaccine was not associated with an elevated risk of most of the adverse events examined. The vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse event and of many other serious adverse events was substantially increased after SARS-CoV-2 infection. (Funded by the Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute.)</p></section></section><div id=\"bodymatter\" data-extent=\"bodymatter\" property=\"articleBody\" typeof=\"Text\" data-location=\"articleTab_article\"><p>More than 1 year into the pandemic of coronavirus disease 2019 (Covid-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an unprecedented number of mass vaccination efforts are under way worldwide. Globally, nearly 3.4 billion doses of vaccine have been administered over the 6-month period since the first vaccines were approved.<sup><a href=\"#r1\" role=\"doc-biblioref\" data-xml-rid=\"r1\">1</a></sup></p><p>Phase 3 clinical trials showed that several Covid-19 vaccines were efficacious and had an acceptable safety profile.<sup><a href=\"#r2\" role=\"doc-biblioref\" data-xml-rid=\"r2 r3 r4\">2-4</a></sup> A number of potential adverse events were identified during these trials, including lymphadenopathy and idiopathic facial-nerve (Bell’s) palsy.<sup><a href=\"#r2\" role=\"doc-biblioref\" data-xml-rid=\"r2 r3\">2,3</a></sup> Trials of the BNT162b2 vaccine (Pfizer–BioNTech) also showed a mild imbalance between the vaccinated and placebo groups with respect to the number of cases of appendicitis, hypersensitivity reactions, acute myocardial infarction, and cerebrovascular accidents.<sup><a href=\"#r5\" role=\"doc-biblioref\" data-xml-rid=\"r5\">5</a></sup> However, phase 3 trials may have inherent limitations in assessing vaccine safety because of a small number of participants and a healthier-than-average sample population. Hence, they are often underpowered to identify less common adverse events. Postmarketing surveillance is required to monitor the safety of new vaccines in real-world settings.</p><p>Much effort is currently focused on characterizing the safety profiles of the recently approved Covid-19 vaccines. Passive surveillance systems such as the Vaccine Adverse Event Reporting System (VAERS)<sup><a href=\"#r6\" role=\"doc-biblioref\" data-xml-rid=\"r6\">6</a></sup> collect information about adverse events that are potentially related to vaccination. This information is voluntarily reported by health care providers and the public. These systems are useful for quickly identifying potential safety signals, which, along with the findings of phase 3 trials, can be translated to lists of adverse events of interest for further exploration (such as that provided by the Safety Platform for Emergency Vaccines [SPEAC]).<sup><a href=\"#r7\" role=\"doc-biblioref\" data-xml-rid=\"r7 r8\">7,8</a></sup> Active surveillance systems such as the Biologics Effectiveness and Safety (BEST) system (part of the Sentinel Initiative)<sup><a href=\"#r9\" role=\"doc-biblioref\" data-xml-rid=\"r9\">9</a></sup> aim to compare the incidence of adverse events of interest in large electronic health record databases with the background historical incidence. Although active surveillance can help highlight suspicious trends, the lack of a rigorously constructed comparable control group limits the ability of such surveillance to identify causal effects of vaccination.</p><p>The effectiveness of vaccines against SARS-CoV-2 has been confirmed in real-world studies,<sup><a href=\"#r10\" role=\"doc-biblioref\" data-xml-rid=\"r10 r11\">10,11</a></sup> but high-quality real-world safety data on the messenger RNA (mRNA)–based Covid-19 vaccines remain relatively sparse in the literature. The results of a study based on data reported by more than 600,000 vaccinated persons were recently published<sup><a href=\"#r12\" role=\"doc-biblioref\" data-xml-rid=\"r12\">12</a></sup>; that study mainly assessed common and mild side effects. Two additional studies, which were based on surveys of vaccinated participants, involved small cohorts,<sup><a href=\"#r13\" role=\"doc-biblioref\" data-xml-rid=\"r13 r14\">13,14</a></sup> and another study analyzed adverse events reported in the VAERS database.<sup><a href=\"#r15\" role=\"doc-biblioref\" data-xml-rid=\"r15\">15</a></sup> All these studies lacked controls. One study that did incorporate a control group included 8533 long-term care facility residents who had received the first dose of vaccine.<sup><a href=\"#r16\" role=\"doc-biblioref\" data-xml-rid=\"r16\">16</a></sup> The authors of this study concluded that the mRNA-based vaccines had an acceptable safety profile, and no notable adverse events were reported.</p><p>As of May 24, 2021, nearly 5 million people in Israel, comprising more than 55% of the population, had received two doses of the BNT162b2 vaccine.<sup><a href=\"#r1\" role=\"doc-biblioref\" data-xml-rid=\"r1\">1</a></sup> In this study, we used the integrated data repositories of the largest health care organization in Israel to evaluate the safety profile of the BNT162b2 vaccine. We compared the incidence of a broad set of potential short- and medium-term adverse events among vaccinated persons with the incidence among matched unvaccinated persons. Potential adverse events related to medical interventions are best understood in the context of the risks associated with the disease that these interventions aim to prevent or treat, so we also estimated the effects of SARS-CoV-2 infection on this same set of adverse events.</p><section id=\"sec-1\" data-type=\"methods\"><h2>Methods</h2><section id=\"sec-1-1\"><h3>Study Setting</h3><p>We analyzed observational data from Clalit Health Services (CHS) in order to emulate a target trial of the effects of the BNT162b2 vaccine on a broad range of potential adverse events in a population without SARS-CoV-2 infection. CHS is the largest of four integrated payer–provider health care organizations that offer mandatory health care coverage in Israel. CHS insures approximately 52% of the population of Israel (&gt;4.7 million of 9.0 million persons), and the CHS-insured population is approximately representative of the Israeli population at large.<sup><a href=\"#r17\" role=\"doc-biblioref\" data-xml-rid=\"r17\">17</a></sup> CHS directly provides outpatient care, and inpatient care is divided between CHS and out-of-network hospitals. CHS information systems are fully digitized and feed into a central data warehouse. Data regarding Covid-19, including the results of all SARS-CoV-2 polymerase-chain-reaction (PCR) tests, Covid-19 diagnoses and severity, and vaccinations, are collected centrally by the Israeli Ministry of Health and shared with each of the four national health care organizations daily.</p><p>This study was approved by the CHS institutional review board. The study was exempt from the requirement for informed consent.</p></section><section id=\"sec-1-2\"><h3>Eligibility Criteria</h3><p>Eligibility criteria included an age of 16 years or older, continuous membership in the health care organization for a full year, no previous SARS-CoV-2 infection, and no contact with the health care system in the previous 7 days (the latter criterion was included as an indicator of a health event not related to subsequent vaccination that could reduce the probability of receiving the vaccine). Because of difficulties in distinguishing the recoding of previous events from true new events, for each adverse event, persons with a previous diagnosis of that event were excluded.</p><p>As in our previous study of the effectiveness of the BNT162b2 vaccine,<sup><a href=\"#r10\" role=\"doc-biblioref\" data-xml-rid=\"r10\">10</a></sup> we also excluded persons from populations in which confounding could not be adequately addressed — long-term care facility residents, persons confined to their homes for medical reasons, health care workers, and persons for whom data on body-mass index or residential area were missing (missing data for these variables are rare in the CHS data). A complete definition of the study variables is included in Table S1 in the <a href=\"#ap1\">Supplementary Appendix</a>, available with the full text of this article at NEJM.org.</p></section><section id=\"sec-1-3\"><h3>Study Design and Oversight</h3><p>The target trial for this study would assign eligible persons to either vaccination or no vaccination. To emulate this trial, on each day from the beginning of the vaccination campaign in Israel (December 20, 2020) until the end of the study period (May 24, 2021), eligible persons who were vaccinated on that day were matched to eligible controls who had not been previously vaccinated. Since the matching process each day considered only information available on or before that day (and was thus unaffected by later vaccinations or SARS-CoV-2 infections), unvaccinated persons matched on a given day could be vaccinated on a future date, and on that future date they could become newly eligible for inclusion in the study as a vaccinated person.</p><p>In an attempt to emulate randomized assignment, vaccinated persons and unvaccinated controls were exactly matched on a set of baseline variables that were deemed to be potential confounders according to domain expertise — namely, variables that were potentially related to vaccination and to a tendency toward the development of a broad set of adverse clinical conditions. These matching criteria included the sociodemographic variables of age (categorized into 2-year age groups), sex (male or female), place of residence (at city- or town-level granularity), socioeconomic status (divided into seven categories), and population sector (general Jewish, Arab, or ultra-Orthodox Jewish). In addition, the matching criteria included clinical factors to account for general clinical condition and disease load, including the number of preexisting chronic conditions (those considered to be risk factors for severe Covid-19 by the Centers for Disease Control and Prevention [CDC] as of December 20, 2020,<sup><a href=\"#r18\" role=\"doc-biblioref\" data-xml-rid=\"r18\">18</a></sup> divided into four categories), the number of diagnoses documented in outpatient visits in the year before the index date (categorized into deciles within each age group), and pregnancy status.</p><p>All the authors designed the study and critically reviewed the manuscript. The first three authors collected and analyzed the data. A subgroup of the authors wrote the manuscript. The last author vouches for the accuracy and completeness of the data and for the fidelity of the study to the protocol. There was no commercial funding for this study, and no confidentiality agreements were in place.</p></section><section id=\"sec-1-4\"><h3>Adverse Events of Interest</h3><p>The set of potential adverse events for the target trial was drawn from several relevant sources, including the VAERS, BEST, and SPEAC frameworks, information provided by the vaccine manufacturer, and relevant scientific publications. We cast a wide net to capture a broad range of clinically meaningful short- and medium-term potential adverse events that would be likely to be documented in the electronic health record. Accordingly, mild adverse events such as fever, malaise, and local injection-site reactions were not included in this study. The study included 42 days of follow-up, which provided 21 days of follow-up after each of the first and second vaccine doses. A total of 42 days was deemed to be sufficient for identifying medium-term adverse events, without being so long as to dilute the incidence of short-term adverse events. Similarly, adverse events that could not plausibly be diagnosed within 42 days (e.g., chronic autoimmune disease) were not included.</p><p>Adverse events were defined according to diagnostic codes and short free-text phrases that accompany diagnoses in the CHS database. A complete list of the study outcomes (adverse events) and their definitions is provided in Table S2.</p><p>For each adverse event, persons were followed from the day of matching (time zero of follow-up) until the earliest of one of the following: documentation of the adverse event, 42 days, the end of the study calendar period, or death. We also ended the follow-up of a matched pair when the unvaccinated control received the first dose of vaccine or when either member of the matched pair received a diagnosis of SARS-CoV-2 infection.</p></section><section id=\"sec-1-5\"><h3>Risks of SARS-CoV-2 Infection</h3><p>To place the magnitude of the adverse effects of the vaccine in context, we also estimated the effects of SARS-CoV-2 infection on these same adverse events during the 42 days after diagnosis. We used the same design as the one that we used to study the adverse effects of vaccination, except that the analysis period started at the beginning of the Covid-19 pandemic in Israel (March 1, 2020) and persons who had had recent contact with the health care system were not excluded (because such contact may be expected in the days before diagnosis).</p><p>Each day in this SARS-CoV-2 analysis, persons with a new diagnosis of SARS-CoV-2 infection were matched to controls who were not previously infected. As in the vaccine safety analysis, persons could become infected with SARS-CoV-2 after they were already matched as controls on a previous day, in which case their data would be censored from the control group (along with their matched SARS-CoV-2–infected person) and they could then be included in the group of SARS-CoV-2–infected persons with a newly matched control. Follow-up of each matched pair started from the date of the positive PCR test result of the infected member and ended in an analogous manner to the main vaccination analysis, this time ending when the control member was infected or when either of the persons in the matched pair was vaccinated.</p><p>The effects of vaccination and of SARS-CoV-2 infection were estimated with different cohorts. Thus, they should be treated as separate sets of results rather than directly compared.</p></section><section id=\"sec-1-6\"><h3>Statistical Analysis</h3><p>Because a large proportion of the unvaccinated controls were vaccinated during the follow-up period, we opted to estimate the observational analogue of the per-protocol effect if all unvaccinated persons had remained unvaccinated during the follow-up. To do so, we censored data on the matched pair if and when the control member was vaccinated. Persons who were first matched as unvaccinated controls and then became vaccinated during the study period could be included again as vaccinated persons with a new matched control. The same procedure was followed in the SARS-CoV-2 infection analysis (i.e., persons who were first matched as uninfected controls and then became infected during the study period could be included again as infected persons with a new matched control).</p><p>We used the Kaplan–Meier estimator<sup><a href=\"#r19\" role=\"doc-biblioref\" data-xml-rid=\"r19\">19</a></sup> to construct cumulative incidence curves and to estimate the risk of each adverse event after 42 days in each group. The risks were compared with ratios and differences (per 100,000 persons).</p><p>In the vaccination analysis, so as not to attribute complications arising from SARS-CoV-2 infection to the vaccination (or lack thereof), we also censored data on the matched pair if and when either member received a diagnosis of SARS-CoV-2 infection. Similarly, in the SARS-CoV-2 infection analysis, we censored data on the matched pair if and when either member was vaccinated. Additional details are provided in the Supplementary Methods 1 section in the <a href=\"#ap1\">Supplementary Appendix</a>.</p><p>We calculated confidence intervals using the nonparametric percentile bootstrap method with 500 repetitions. As is standard practice for studies of safety outcomes, no adjustment for multiple comparisons was performed. Analyses were performed with the use of R software, version 4.0.4.</p></section></section><section id=\"sec-2\" data-type=\"results\"><h2>Results</h2><section id=\"sec-2-1\"><h3>Vaccination Analysis</h3><p>A total of 1,736,832 persons were eligible for inclusion in the vaccination cohort (<a href=\"#f1\">Figure 1</a>). The median age in the eligible cohort was 43 years (Table S3). The final size of the study population differed for each studied adverse event because of adverse event–specific exclusion of persons with a history of that event. On average, across the adverse event–specific cohorts, 72.4% of the eligible persons were successfully matched. <a href=\"#t1\">Table 1</a> shows the baseline characteristics of the total study population, with the mean distribution of characteristics across the various adverse event–specific cohorts. The characteristics of each adverse event–specific cohort are provided in Table S4. The vaccination cohorts included a mean of 884,828 vaccinated persons, with a median age of 38 years (5 years younger than the median age of the eligible cohort). A total of 48% of the population was female.</p><div data-presentation=\"diminished-in-flow\"><header><p>Figure 1</p></header><figure id=\"f1\"><img src=\"/cms/10.1056/NEJMoa2110475/asset/03921378-0cc4-472f-ac47-21060786e63e/assets/images/large/nejmoa2110475_f1.jpg\" height=\"1500\" width=\"988\" aria-labelledby=\"f1\" loading=\"lazy\"><figcaption><p>Study Population for the Vaccination Analysis.</p><div><p>Absolute numbers and percentage changes are shown for each inclusion and exclusion criterion. The chart focuses on the vaccinated population. The derivation group includes the entire population, including unvaccinated persons. The shaded boxes indicate the two study groups. The same exclusion criteria were applied to the unvaccinated persons for each index date on which they were considered for matching. BMI denotes body-mass index, CHS Clalit Health Services, and PCR polymerase chain reaction.</p></div></figcaption></figure></div><div data-presentation=\"diminished-in-flow\"><header><p>Table 1</p></header><figure id=\"t1\"><p><img src=\"/cms/10.1056/NEJMoa2110475/asset/9b324f0f-5d76-4651-bc5e-df6b37de5e06/assets/images/large/nejmoa2110475_t1.jpg\" height=\"1500\" width=\"982\" loading=\"lazy\"></p><div data-presentation=\"suppressed-in-flow\"><table data-shading=\"custom\"><thead><tr><th data-xml-align=\"left\">Characteristic</th><th colspan=\"2\"><span>Vaccination Analysis</span></th><th colspan=\"2\"><span>SARS-CoV-2 Analysis</span></th></tr><tr><td>&nbsp;</td><th>Vaccinated<br> Group<br>(N=884,828)</th><th>Control<br> Group<br>(N=884,828)</th><th>SARS-CoV-2–Infected Group<br>(N=173,106)</th><th>Control<br> Group<br>(N=173,106)</th></tr></thead><tbody><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Median age (IQR) — yr</td><td>38 (27–53)</td><td>38 (27–53)</td><td>34 (24–47)</td><td>34 (24–47)</td></tr><tr><td>Age group — no. (%)</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">16–39 yr</td><td>472,095 (53)</td><td>472,095 (53)</td><td>107,046 (62)</td><td>107,046 (62)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">40–49 yr</td><td>160,413 (18)</td><td>160,413 (18)</td><td>28,738 (17)</td><td>28,738 (17)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">50–59 yr</td><td>93,110 (11)</td><td>93,110 (11)</td><td>17,851 (10)</td><td>17,851 (10)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">60–69 yr</td><td>87,236 (10)</td><td>87,236 (10)</td><td>12,100 (7)</td><td>12,100 (7)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">70–79 yr</td><td>51,924 (6)</td><td>51,924 (6)</td><td>5,371 (3)</td><td>5,371 (3)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">≥80 yr</td><td>20,050 (2)</td><td>20,050 (2)</td><td>1,999 (1)</td><td>1,999 (1)</td></tr><tr><td>Sex — no. (%)</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Female</td><td>423,238 (48)</td><td>423,238 (48)</td><td>93,263 (54)</td><td>93,263 (54)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Male</td><td>461,590 (52)</td><td>461,590 (52)</td><td>79,843 (46)</td><td>79,843 (46)</td></tr><tr><td>Population sector — no. (%)</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">General Jewish</td><td>595,897 (67)</td><td>595,897 (67)</td><td>90,903 (53)</td><td>90,903 (53)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Ultra-Orthodox Jewish</td><td>24,343 (3)</td><td>24,343 (3)</td><td>20,864 (12)</td><td>20,864 (12)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Arab</td><td>264,588 (30)</td><td>264,588 (30)</td><td>61,339 (35)</td><td>61,339 (35)</td></tr><tr><td>No. of risk factors according to CDC criteria — no. (%)</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">0</td><td>571,604 (65)</td><td>571,604 (65)</td><td>108,980 (63)</td><td>108,980 (63)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">1</td><td>200,789 (23)</td><td>200,789 (23)</td><td>41,502 (24)</td><td>41,502 (24)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">2</td><td>61,924 (7)</td><td>61,924 (7)</td><td>11,976 (7)</td><td>11,976 (7)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">3</td><td>27,175 (3)</td><td>27,175 (3)</td><td>5,181 (3)</td><td>5,181 (3)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">≥4</td><td>23,335 (3)</td><td>23,335 (3)</td><td>5,467 (3)</td><td>5,467 (3)</td></tr><tr><td>CDC “certain” risk criteria — no. (%)</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Cancer</td><td>9,957 (1)</td><td>10,300 (1)</td><td>2,037 (1)</td><td>2,308 (1)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Chronic kidney disease</td><td>39,837 (4)</td><td>40,339 (5)</td><td>8,269 (5)</td><td>8,141 (5)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Chronic obstructive pulmonary disease</td><td>10,121 (1)</td><td>11,498 (1)</td><td>1,791 (1)</td><td>2,212 (1)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Heart disease</td><td>31,836 (4)</td><td>31,596 (4)</td><td>5,653 (3)</td><td>5,880 (3)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Solid-organ transplantation</td><td>351 (&lt;1)</td><td>370 (&lt;1)</td><td>148 (&lt;1)</td><td>136 (&lt;1)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Obesity: BMI, 30 to 40</td><td>129,148 (15)</td><td>125,120 (14)</td><td>30,558 (18)</td><td>28,580 (17)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Severe obesity: BMI, ≥40</td><td>11,861 (1)</td><td>12,568 (1)</td><td>3,478 (2)</td><td>3,107 (2)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Pregnancy</td><td>6,082 (1)</td><td>6,082 (1)</td><td>4,959 (3)</td><td>4,959 (3)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Sickle cell disease</td><td>140 (&lt;1)</td><td>182 (&lt;1)</td><td>50 (&lt;1)</td><td>55 (&lt;1)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Smoking</td><td>157,803 (18)</td><td>187,822 (21)</td><td>18,899 (11)</td><td>30,376 (18)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Type 2 diabetes mellitus</td><td>61,865 (7)</td><td>61,093 (7)</td><td>12,448 (7)</td><td>12,396 (7)</td></tr><tr><td>CDC “possible” risk criteria — no. (%)</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Asthma</td><td>46,836 (5)</td><td>47,151 (5)</td><td>10,079 (6)</td><td>10,413 (6)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Cerebrovascular disease</td><td>14,296 (2)</td><td>14,919 (2)</td><td>2,661 (2)</td><td>2,738 (2)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Other respiratory disease</td><td>1,884 (&lt;1)</td><td>1,961 (&lt;1)</td><td>322 (&lt;1)</td><td>362 (&lt;1)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Hypertension</td><td>94,819 (11)</td><td>93,357 (11)</td><td>15,514 (9)</td><td>15,682 (9)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Immunosuppression</td><td>15,430 (2)</td><td>15,433 (2)</td><td>4,346 (2)</td><td>4,457 (3)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Neurologic disease</td><td>26,340 (3)</td><td>28,421 (3)</td><td>5,194 (3)</td><td>5,455 (3)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Liver disease</td><td>10,491 (1)</td><td>12,558 (1)</td><td>2,391 (1)</td><td>2,600 (2)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Overweight: BMI, 25 to 30</td><td>284,904 (32)</td><td>271,335 (31)</td><td>53,374 (31)</td><td>50,038 (29)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Thalassemia</td><td>5,884 (1)</td><td>5,644 (1)</td><td>1,599 (1)</td><td>1,595 (1)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Type 1 diabetes mellitus</td><td>2,797 (&lt;1)</td><td>2,648 (&lt;1)</td><td>694 (&lt;1)</td><td>763 (&lt;1)</td></tr></tbody></table></div><figcaption><p>Baseline Characteristics of the Study Populations According to Vaccination Status and SARS-CoV-2 Infection Status.<a href=\"#t1fn1\" role=\"doc-noteref\">*</a></p><div role=\"doc-footnote\" data-has=\"label\"><p>*</p><p>Statistics are based on means and distributions from a pool of all the adverse event–specific cohorts. Characteristics of the various study populations after application of all eligibility criteria and the matching process are listed. BMI denotes body-mass index (the weight in kilograms divided by the square of the height in meters), CDC Centers for Disease Control and Prevention, IQR interquartile range, RT-PCR reverse-transcriptase polymerase chain reaction, and SARS-CoV-2 severe acute respiratory syndrome coronavirus 2.</p></div></figcaption></figure></div><p>The effect of vaccination on the various potential adverse events included in this study is presented in <a href=\"#t2\">Table 2</a>. The risk was substantially higher on either the multiplicative (risk ratio) or additive (risk difference) scales in the vaccinated group than in the unvaccinated group for myocarditis (risk ratio, 3.24; 95% confidence interval [CI], 1.55 to 12.44; risk difference, 2.7 events per 100,000 persons; 95% CI, 1.0 to 4.6), lymphadenopathy (risk ratio, 2.43; 95% CI, 2.05 to 2.78; risk difference, 78.4 events per 100,000 persons; 95% CI, 64.1 to 89.3), appendicitis (risk ratio, 1.40; 95% CI, 1.02 to 2.01; risk difference, 5.0 events per 100,000 persons; 95% CI, 0.3 to 9.9), and herpes zoster infection (risk ratio, 1.43; 95% CI, 1.20 to 1.73; risk difference, 15.8 events per 100,000 persons; 95% CI, 8.2 to 24.2). Vaccination was substantially protective against adverse events such as anemia, acute kidney injury, intracranial hemorrhage, and lymphopenia.</p><div data-presentation=\"diminished-in-flow\"><header><p>Table 2</p></header><figure id=\"t2\"><p><img src=\"/cms/10.1056/NEJMoa2110475/asset/7591f5c4-9026-47f3-8f22-be6cedd96bbf/assets/images/large/nejmoa2110475_t2.jpg\" height=\"1472\" width=\"1500\" loading=\"lazy\"></p><div data-presentation=\"suppressed-in-flow\"><table data-shading=\"custom\"><thead><tr><th data-xml-align=\"left\">Event</th><th>Adverse-Event Cohort in Each Group</th><th>Vaccinated<br> Group</th><th>Control<br> Group</th><th>Risk Ratio<br> (95% CI)</th><th>Risk Difference<br> (95% CI)</th></tr><tr><td>&nbsp;</td><th>no. of persons</th><th colspan=\"2\"><span>no. of events</span></th><td>&nbsp;</td><th>no. of events/100,000 persons</th></tr></thead><tbody><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Acute kidney injury</td><td>912,019</td><td>20</td><td>45</td><td>0.44 (0.23 to 0.73)</td><td>−4.6 (−7.8 to −1.8)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Anemia</td><td>709,267</td><td>298</td><td>378</td><td>0.79 (0.67 to 0.93)</td><td>−18.7 (−32.1 to −6.1)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Appendicitis</td><td>900,289</td><td>95</td><td>66</td><td>1.40 (1.02 to 2.01)</td><td>5.0 (0.3 to 9.9)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Arrhythmia</td><td>856,152</td><td>254</td><td>284</td><td>0.89 (0.74 to 1.04)</td><td>−6.1 (−14.7 to 1.8)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Arthritis or arthropathy</td><td>731,340</td><td>64</td><td>70</td><td>0.95 (0.65 to 1.34)</td><td>−0.8 (−6.3 to 4.2)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Bell’s palsy</td><td>923,692</td><td>81</td><td>59</td><td>1.32 (0.92 to 1.86)</td><td>3.5 (−1.1 to 7.8)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Cerebrovascular accident</td><td>917,598</td><td>45</td><td>55</td><td>0.84 (0.54 to 1.27)</td><td>−1.6 (−5.3 to 2.0)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Deep-vein thrombosis</td><td>925,380</td><td>39</td><td>47</td><td>0.87 (0.55 to 1.40)</td><td>−1.1 (−4.5 to 2.7)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Herpes simplex infection</td><td>876,328</td><td>219</td><td>205</td><td>1.13 (0.95 to 1.38)</td><td>4.8 (−1.9 to 12.4)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Herpes zoster infection</td><td>888,647</td><td>283</td><td>204</td><td>1.43 (1.20 to 1.73)</td><td>15.8 (8.2 to 24.2)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Intracranial hemorrhage</td><td>933,130</td><td>13</td><td>30</td><td>0.48 (0.20 to 0.89)</td><td>−2.9 (−5.6 to −0.5)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Lymphadenopathy</td><td>823,006</td><td>660</td><td>279</td><td>2.43 (2.05 to 2.78)</td><td>78.4 (64.1 to 89.3)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Lymphopenia</td><td>938,939</td><td>2</td><td>7</td><td>0.26 (0.00 to 1.03)</td><td>−0.9 (−2.0 to &lt;0.1)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Myocardial infarction</td><td>892,785</td><td>59</td><td>60</td><td>1.07 (0.74 to 1.60)</td><td>0.8 (−3.3 to 5.2)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Myocarditis</td><td>938,812</td><td>21</td><td>6</td><td>3.24 (1.55 to 12.44)</td><td>2.7 (1.0 to 4.6)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Neutropenia</td><td>919,291</td><td>20</td><td>22</td><td>0.87 (0.46 to 1.66)</td><td>−0.5 (−2.8 to 1.8)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Other thrombosis<a href=\"#t2fn2\" role=\"doc-noteref\">†</a></td><td>932,469</td><td>12</td><td>22</td><td>0.46 (0.19 to 0.91)</td><td>−2.2 (−4.6 to −0.3)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Paresthesia</td><td>827,478</td><td>552</td><td>496</td><td>1.12 (0.98 to 1.24)</td><td>10.8 (−1.8 to 21.4)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Pericarditis</td><td>936,197</td><td>27</td><td>18</td><td>1.27 (0.68 to 2.31)</td><td>1.0 (−1.6 to 3.4)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Pulmonary embolism</td><td>937,116</td><td>10</td><td>17</td><td>0.56 (0.21 to 1.15)</td><td>−1.5 (−3.6 to 0.4)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Seizure</td><td>913,091</td><td>36</td><td>35</td><td>0.99 (0.62 to 1.64)</td><td>−0.4 (−3.0 to 3.1)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Syncope</td><td>858,068</td><td>326</td><td>267</td><td>1.12 (0.94 to 1.34)</td><td>6.2 (−3.2 to 15.4)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Thrombocytopenia</td><td>923,123</td><td>56</td><td>60</td><td>0.94 (0.63 to 1.27)</td><td>−0.6 (−4.6 to 2.3)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Uveitis</td><td>933,217</td><td>26</td><td>20</td><td>1.27 (0.68 to 2.67)</td><td>1.0 (−1.5 to 3.8)</td></tr><tr data-xml-align=\"center\"><td data-xml-align=\"left\">Vertigo</td><td>773,263</td><td>433</td><td>395</td><td>1.12 (0.97 to 1.28)</td><td>9.3 (−2.5 to 20.0)</td></tr></tbody></table></div><figcaption><p>Adverse Events Associated with SARS-CoV-2 Vaccination.<a href=\"#t2fn1\" role=\"doc-noteref\">*</a></p><div><div role=\"doc-footnote\" data-has=\"label\"><p>*</p><p>Estimates were calculated with the use of the Kaplan–Meier estimator 42 days after vaccination or SARS-CoV-2 infection. Confidence intervals (CIs) were estimated with the use of the percentile bootstrap method with 500 repetitions.</p></div><div role=\"doc-footnote\" data-has=\"label\"><p>†</p><p>The “other thrombosis” category is a composite diagnosis that includes arterial embolism and thrombosis, venous embolism and thrombosis, vascular insufficiency of the intestine, portal-vein thrombosis, or cranial venous sinus thrombosis.</p></div></div></figcaption></figure></div><p>Figure S1 shows the cumulative incidence (risk) curves for each specific adverse event. Spikes in the incidence of lymphadenopathy were seen after both the first and second doses of vaccine, whereas the incidence of myocarditis spiked mainly after the second dose of vaccine.</p></section><section id=\"sec-2-2\"><h3>SARS-CoV-2 Infection Analysis</h3><p>A total of 233,392 persons (median age, 36 years) were eligible to be included in the SARS-CoV-2 infection cohort (<a href=\"#f2\">Figure 2</a>). On average, across the adverse event–specific cohorts, 75.8% of the eligible persons were successfully matched. <a href=\"#t1\">Table 1</a> shows the average distribution of characteristics in these cohorts, across the two study groups (infected and noninfected). The characteristics of each adverse event–specific cohort are provided in Table S5. The cohorts for the analysis of SARS-CoV-2 infection comprised a mean of 173,106 SARS-CoV-2–infected persons (median age, 34 years). A total of 54% of these persons were female.</p><div data-presentation=\"diminished-in-flow\"><header><p>Figure 2</p></header><figure id=\"f2\"><img src=\"/cms/10.1056/NEJMoa2110475/asset/938326b3-ed95-4627-9316-17222e41f18f/assets/images/large/nejmoa2110475_f2.jpg\" height=\"1500\" width=\"1075\" aria-labelledby=\"f2\" loading=\"lazy\"><figcaption><p>Study Population for the SARS-CoV-2 Analysis.</p><div><p>Absolute numbers and percentage changes are shown for each inclusion and exclusion criterion. The chart focuses on the SARS-CoV-2–infected population. The derivation group includes the entire population, including uninfected persons. The shaded boxes indicate the two study groups. The same exclusion criteria were applied to the uninfected persons for each index date on which they were considered for matching. Covid-19 denotes coronavirus disease 2019.</p></div></figcaption></figure></div><p>Table S6 shows the effect of SARS-CoV-2 infection on the incidence of various adverse events. Infection substantially increased the risk of many different adverse events, including myocarditis (risk ratio, 18.28; 95% CI, 3.95 to 25.12; risk difference, 11.0 events per 100,000 persons; 95% CI, 5.6 to 15.8), acute kidney injury (risk ratio, 14.83; 95% CI, 9.24 to 28.75; risk difference, 125.4 events per 100,000 persons; 95% CI, 107.0 to 142.6), pulmonary embolism (risk ratio, 12.14; 95% CI, 6.89 to 29.20; risk difference, 61.7 events per 100,000 persons; 95% CI, 48.5 to 75.4), intracranial hemorrhage (risk ratio, 6.89; 95% CI, 1.90 to 19.16; risk difference, 7.6 events per 100,000 persons; 95% CI, 2.7 to 12.6), pericarditis (risk ratio, 5.39; 95% CI, 2.22 to 23.58; risk difference, 10.9 events per 100,000 persons; 95% CI, 4.9 to 16.9), myocardial infarction (risk ratio, 4.47; 95% CI, 2.47 to 9.95; risk difference, 25.1 events per 100,000 persons; 95% CI, 16.2 to 33.9), deep-vein thrombosis (risk ratio, 3.78; 95% CI, 2.50 to 6.59; risk difference, 43.0 events per 100,000 persons; 95% CI, 29.9 to 56.6), and arrhythmia (risk ratio, 3.83; 95% CI, 3.07 to 4.95; risk difference, 166.1 events per 100,000 persons; 95% CI, 139.6 to 193.2).</p></section><section id=\"sec-2-3\"><h3>Both Analyses</h3><p><a href=\"#f3\">Figure 3</a> shows estimated risk ratios in both the vaccination and SARS-CoV-2 infection analyses for adverse events in which vaccination or infection substantially increased the risk. <a href=\"#f4\">Figure 4</a> shows the absolute risk associated with vaccination, alongside the absolute risk associated with SARS-CoV-2 infection, for the same adverse events.</p><div data-presentation=\"diminished-in-flow\"><header><p>Figure 3</p></header><figure id=\"f3\"><img src=\"/cms/10.1056/NEJMoa2110475/asset/6bb7e88d-d03d-48d4-8d70-ef4adb4ff49f/assets/images/large/nejmoa2110475_f3.jpg\" height=\"1139\" width=\"1500\" aria-labelledby=\"f3\" loading=\"lazy\"><figcaption><p>Risk Ratios for Adverse Events after Vaccination or SARS-CoV-2 Infection.</p><div><p>Estimated risk ratios for adverse events after vaccination or SARS-CoV-2 infection are shown. The risk ratio on the y axis is presented on a logarithmic scale to facilitate comparison of both increased and decreased risk. 𝙸 bars indicate 95% confidence intervals.</p></div></figcaption></figure></div><div data-presentation=\"diminished-in-flow\"><header><p>Figure 4</p></header><figure id=\"f4\"><img src=\"/cms/10.1056/NEJMoa2110475/asset/29e40d5c-aa86-45bd-9439-5b174b45d147/assets/images/large/nejmoa2110475_f4.jpg\" height=\"943\" width=\"1500\" aria-labelledby=\"f4\" loading=\"lazy\"><figcaption><p>Absolute Excess Risk of Various Adverse Events after Vaccination or SARS-CoV-2 Infection.</p><div><p>Point estimates of the risk differences for selected adverse events are shown. Estimates were derived 42 days after vaccination or SARS-CoV-2 infection with the use of the Kaplan–Meier estimator. Risk differences are shown per 100,000 persons and rounded to the nearest integer. Negative differences (decreased risk) are represented as negative values on the y axis, and positive differences (increased risk) are represented as positive values on the y axis. The abbreviation mRNA denotes messenger RNA.</p></div></figcaption></figure></div></section></section><section id=\"sec-3\" data-type=\"discussion\"><h2>Discussion</h2><p>We used a data set involving more than 2.4 million vaccinated persons from an integrated health care organization to evaluate the safety profile of the BNT162b2 mRNA Covid-19 vaccine. The main potential adverse events identified included an excess risk of lymphadenopathy (78.4 events per 100,000 persons), herpes zoster infection (15.8 events), appendicitis (5.0 events), and myocarditis (2.7 events).</p><p>To place these risks in context, we also examined data on more than 240,000 infected persons to estimate the effects of a documented SARS-CoV-2 infection on the incidence of the same adverse events. SARS-CoV-2 infection was not estimated to have a meaningful effect on the incidence of lymphadenopathy, herpes zoster infection, or appendicitis, but it was estimated to result in a substantial excess risk of myocarditis (11.0 events per 100,000 persons). SARS-CoV-2 infection was also estimated to substantially increase the risk of several adverse events for which vaccination was not found to increase the risk, including an estimated excess risk of arrhythmia (166.1 events per 100,000 persons), acute kidney injury (125.4 events), pulmonary embolism (61.7 events), deep-vein thrombosis (43.0 events), myocardial infarction (25.1 events), pericarditis (10.9 events), and intracranial hemorrhage (7.6 events).</p><p>An association between Covid-19 vaccination and myocarditis has been previously reported.<sup><a href=\"#r20\" role=\"doc-biblioref\" data-xml-rid=\"r20\">20</a></sup> Although no cases of myocarditis were reported in the BNT162b2 (Pfizer–BioNTech),<sup><a href=\"#r2\" role=\"doc-biblioref\" data-xml-rid=\"r2\">2</a></sup> mRNA-1273 (Moderna),<sup><a href=\"#r3\" role=\"doc-biblioref\" data-xml-rid=\"r3\">3</a></sup> or ChAdOx1 nCoV-19 (AstraZeneca)<sup><a href=\"#r4\" role=\"doc-biblioref\" data-xml-rid=\"r4\">4</a></sup> phase 3 clinical trials, multiple cases of myocarditis after Covid-19 vaccination have recently been reported in the literature,<sup><a href=\"#r21\" role=\"doc-biblioref\" data-xml-rid=\"r21 r22 r23 r24 r25\">21-25</a></sup> and both the Israeli Ministry of Health<sup><a href=\"#r26\" role=\"doc-biblioref\" data-xml-rid=\"r26\">26</a></sup> and the CDC have investigated this association.<sup><a href=\"#r27\" role=\"doc-biblioref\" data-xml-rid=\"r27\">27</a></sup> The risk appears to be highest among young men.<sup><a href=\"#r26\" role=\"doc-biblioref\" data-xml-rid=\"r26 r27\">26,27</a></sup> We found that the risk of myocarditis increased by a factor of three after vaccination, which translated to approximately 3 excess events per 100,000 persons; the 95% confidence interval indicated that values between 1 and 5 excess events per 100,000 persons were compatible with our data. Among the 21 persons with myocarditis in the vaccinated group, the median age was 25 years (interquartile range, 20 to 34), and 90.9% were male.</p><p>Another vaccine-related adverse event that has recently received attention in the medical literature is Bell’s palsy. In a recent article based on publicly available data from the BNT162b2 and mRNA-1273 vaccine trials, Ozonoff et al.<sup><a href=\"#r28\" role=\"doc-biblioref\" data-xml-rid=\"r28\">28</a></sup> suggested a possible association between these vaccines and Bell’s palsy and estimated a rate ratio of approximately 7.0. This conclusion differed from the Food and Drug Administration briefing on these vaccines in December 2020; that briefing considered the incidence of Bell’s palsy to be similar to the background incidence.<sup><a href=\"#r5\" role=\"doc-biblioref\" data-xml-rid=\"r5\">5</a></sup> A small number of cases of Bell’s palsy after Covid-19 vaccination have also been reported in the literature.<sup><a href=\"#r29\" role=\"doc-biblioref\" data-xml-rid=\"r29 r30\">29,30</a></sup> In the current study, the effect estimate was consistent with a potentially mild increase in the risk of Bell’s palsy after vaccination, with a risk ratio of 1.32 (95% CI, 0.92 to 1.86). The absolute effect was small, with up to 8 excess events per 100,000 persons being highly compatible with our data according to the 95% confidence interval. Herpes zoster infection, the incidence of which we found to be increased after vaccination, is one of the potential causes of facial-nerve palsy.<sup><a href=\"#r31\" role=\"doc-biblioref\" data-xml-rid=\"r31\">31</a></sup></p><p>Another particularly notable class of adverse events that has been reported in the context of Covid-19 vaccines is thromboembolic events. These adverse events, which primarily affect young women, have been linked with the ChAdOx1 nCoV-19<sup><a href=\"#r32\" role=\"doc-biblioref\" data-xml-rid=\"r32\">32</a></sup> and Ad26.COV2.S (Johnson &amp; Johnson–Janssen) Covid-19 vaccines,<sup><a href=\"#r33\" role=\"doc-biblioref\" data-xml-rid=\"r33\">33</a></sup> both of which are adenoviral vector vaccines. However, we did not find an association between the BNT162b2 vaccine and various thromboembolic events in this study.</p><p>Some initially unexpected effects were seen in the results of the current study. The BNT162b2 vaccine appears to be protective against certain conditions such as anemia and intracranial hemorrhage. These same adverse events are also identified in this study as complications of SARS-CoV-2 infection, so it appears likely that the protective effect of the vaccine is mediated through its protection against undiagnosed SARS-CoV-2 infection, which may be undiagnosed either because of a lack of testing or because of false negative PCR results.</p><p>This study has several limitations. First, persons in the study were not randomly assigned according to exposures (vaccinations and SARS-CoV-2 infections); this may have introduced confounding at baseline and selection bias at censoring, especially since a single set of confounders was used for adjustment in the assessment of many disparate adverse events. Second, the matching process that was necessary to attain exchangeability between the study groups resulted in a study population with a different composition than the eligible population (e.g., median age, 38 years rather than 43 years). Because this different composition changes the population over which the causal effect is being estimated, different estimates might be found for adverse events for which the incidence may differ substantially between subgroups (e.g., myocarditis). Also, we excluded certain populations (such as health care workers and persons residing in long-term care facilities) that could be at particularly high risk for certain adverse events. Both of these issues should be taken into account when considering the generalizability of the findings.</p><p>Third, some diagnoses that were recorded in out-of-network hospitals, which were delayed in being reported to the insurer and were not entered by the person’s general practitioner from the hospital discharge notes into the outpatient medical record, could have been missed. Fourth, it is possible that persons are more likely to increase their levels of clinical awareness, concern, or both after vaccination or SARS-CoV-2 infection, and thus they may be more likely to report or seek medical care for their symptoms, resulting in a spuriously increased incidence of the various adverse events in the vaccinated or infected groups. Similarly, among persons with SARS-CoV-2 infection, the spike in the incidence of certain adverse events in the first day of follow-up could indicate the initial clinical manifestation of the infection, but it could also be related to active testing for SARS-CoV-2. Fifth, all the effect measures that we presented are based only on a new incidence of the specific adverse event under study; thus, less light was shed on the potential additional risk among persons with a medical history of each of these adverse events. However, this choice was necessary to distinguish between true new diagnoses of a given adverse event and recoding of past diagnoses and to ensure the accuracy of the adverse-event labels.</p><p>In this study, we sought to place the increased risk of adverse events caused by the BNT162b2 vaccine in context by contrasting this risk with that of the same adverse events after documented infection with SARS-CoV-2. We thought that this was necessary because vaccination and its potential risks do not occur in a void but rather in the context of an ongoing pandemic. Although the general risks of hospitalization, severe disease, and death from Covid-19 are widely recognized, secondary complications of infection are less well known. Therefore, in this analysis, we sought to estimate the effects of SARS-CoV-2 infection on the incidence of the same list of adverse events examined in the vaccination analysis. Because the cohorts that we used to study the vaccine and infection effects were different in composition, care should be taken when comparing the resulting risk estimates. In addition, knowledge of these risks alone is insufficient for a complete decision-theoretic analysis. When a person decides to become vaccinated, this choice results in a probability of 100% for the vaccination, whereas the alternative of contracting SARS-CoV-2 infection is an event with uncertain probability that depends on the person, place, and time. Moreover, infection with SARS-CoV-2 has many other adverse effects beyond those considered here, including the risk of transmission to family members and others.</p><p>We estimated that the BNT162b2 vaccine resulted in an increased incidence of a few adverse events over a 42-day follow-up period. Although most of these events were mild, some of them, such as myocarditis, could be potentially serious. However, our results indicate that SARS-CoV-2 infection is itself a very strong risk factor for myocarditis, and it also substantially increases the risk of multiple other serious adverse events. These findings help to shed light on the short- and medium-term risks of the vaccine and place them in clinical context. Further studies will be needed to estimate the potential of long-term adverse events.</p></section>\n\n\n\n        \n        \n</div><div id=\"backmatter\" data-extent=\"backmatter\" data-location=\"articleTab_article\"><section id=\"backnotes\" data-location=\"notes_article\"><h2>Notes</h2><p>Because of data privacy regulations, the raw data for this study cannot be shared.</p><p>This article was published on August 25, 2021, at NEJM.org.</p><p>Supported by the Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at <span data-type=\"funder\">Harvard Medical School</span> and <span data-type=\"funder\">Clalit Research Institute</span>. Dr. Lipsitch receives support from the <span data-type=\"funder\">Morris–Singer Foundation</span>.</p><p><a href=\"#ap2\">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</p><p>We thank Oren Miron for his valuable advice.</p></section><section id=\"supplementary-materials\"><h2>Supplementary Material</h2><div role=\"list\"><div id=\"ap1\" role=\"listitem\"><p><span>Supplementary Appendix</span> <span>(nejmoa2110475_appendix.pdf)</span></p><div><ul><li><a href=\"/doi/suppl/10.1056/NEJMoa2110475/suppl_file/nejmoa2110475_appendix.pdf\" download=\"nejmoa2110475_appendix.pdf\" data-interactiontype=\"multimedia_download\" data-multimedia-type=\"Supplementary Material\" data-behavior=\"trackDownloadEvent\" data-multimedia-filename=\"nejmoa2110475_appendix.pdf\" data-doi=\"10.1056/NEJMoa2110475\">Download</a></li><li>4.32 MB</li></ul></div></div><div id=\"ap2\" role=\"listitem\"><p><span>Disclosure Forms</span> <span>(nejmoa2110475_disclosures.pdf)</span></p><div><ul><li><a href=\"/doi/suppl/10.1056/NEJMoa2110475/suppl_file/nejmoa2110475_disclosures.pdf\" download=\"nejmoa2110475_disclosures.pdf\" data-interactiontype=\"multimedia_download\" data-multimedia-type=\"Supplementary Material\" data-behavior=\"trackDownloadEvent\" data-multimedia-filename=\"nejmoa2110475_disclosures.pdf\" data-doi=\"10.1056/NEJMoa2110475\">Download</a></li><li>447.73 KB</li></ul></div></div></div></section><section id=\"bibliography\" role=\"doc-bibliography\" data-location=\"references_article\"><h2>References</h2><div role=\"list\"><div role=\"listitem\" data-has=\"label\"><p>2.</p><div id=\"r2\"><p>Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. <em>N Engl J Med</em> 2020;383:2603-2615.</p></div></div><div role=\"listitem\" data-has=\"label\"><p>3.</p><div id=\"r3\"><p>Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. <em>N Engl J Med</em> 2021;384:403-416.</p></div></div><div role=\"listitem\" data-has=\"label\"><p>4.</p><div id=\"r4\"><p>Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <em>Lancet</em> 2021;397:99-111.</p></div></div><div role=\"listitem\" data-has=\"label\"><p>7.</p><div id=\"r7\"><p>World Health Organization. Background paper on Covid-19 disease and vaccines: prepared by the Strategic Advisory Group of Experts (SAGE) on immunization working group on COVID-19 vaccines. December 22, 2020 (<a href=\"https://apps.who.int/iris/handle/10665/338095\">https://apps.who.int/iris/handle/10665/338095</a>).</p></div></div><div role=\"listitem\" data-has=\"label\"><p>10.</p><div id=\"r10\"><p>Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. <em>N Engl J Med</em> 2021;384:1412-1423.</p></div></div><div role=\"listitem\" data-has=\"label\"><p>11.</p><div id=\"r11\"><p>Hall VJ, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. <em>Lancet</em> 2021;397:1725-1735.</p></div></div><div role=\"listitem\" data-has=\"label\"><p>12.</p><div id=\"r12\"><p>Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. <em>Lancet Infect Dis</em> 2021;21:939-949.</p></div></div><div role=\"listitem\" data-has=\"label\"><p>13.</p><div id=\"r13\"><p>Mathioudakis AG, Ghrew M, Ustianowski A, et al. Self-reported real-world safety and reactogenicity of COVID-19 vaccines: a vaccine recipient survey. <em>Life (Basel)</em> 2021;11:249-249.</p></div></div><div role=\"listitem\" data-has=\"label\"><p>14.</p><div id=\"r14\"><p>Song JY, Cheong HJ, Kim SR, et al. Early safety monitoring of COVID-19 vaccines in healthcare workers. <em>J Korean Med Sci</em> 2021;36(15):e110-e110.</p></div></div><div role=\"listitem\" data-has=\"label\"><p>15.</p><div id=\"r15\"><p>Chen G, Li X, Sun M, et al. COVID-19 mRNA vaccines are generally safe in the short term: a vaccine vigilance real-world study says. <em>Front Immunol</em> 2021;12:669010-669010.</p></div></div><div role=\"listitem\" data-has=\"label\"><p>16.</p><div id=\"r16\"><p>Bardenheier BH, Gravenstein S, Blackman C, et al. Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents. <em>Vaccine</em> 2021;39:3844-3851.</p></div></div><div role=\"listitem\" data-has=\"label\"><p>19.</p><div id=\"r19\"><p>Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. <em>J Am Stat Assoc</em> 1958;53:457-481.</p></div></div><div role=\"listitem\" data-has=\"label\"><p>20.</p><div id=\"r20\"><p>Castiello T, Georgiopoulos G, Finocchiaro G, et al. COVID-19 and myocarditis: a systematic review and overview of current challenges. <em>Heart Fail Rev</em> 2021 March 24 (Epub ahead of print).</p></div></div><div role=\"listitem\" data-has=\"label\"><p>21.</p><div id=\"r21\"><p>Ammirati E, Cavalotti C, Milazzo A, et al. Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection. <em>Int J Cardiol Heart Vasc</em> 2021;34:100774-100774.</p></div></div><div role=\"listitem\" data-has=\"label\"><p>22.</p><div id=\"r22\"><p>Abu Mouch S, Roguin A, Hellou E, et al. Myocarditis following COVID-19 mRNA vaccination. <em>Vaccine</em> 2021;39:3790-3793.</p></div></div><div role=\"listitem\" data-has=\"label\"><p>23.</p><div id=\"r23\"><p>Marshall M, Ferguson ID, Lewis P, et al. Symptomatic acute myocarditis in seven adolescents following Pfizer-BioNTech COVID-19 vaccination. <em>Pediatrics</em> 2021 June 4 (Epub ahead of print).</p></div></div><div role=\"listitem\" data-has=\"label\"><p>24.</p><div id=\"r24\"><p>Albert E, Aurigemma G, Saucedo J, Gerson DS. Myocarditis following COVID-19 vaccination. <em>Radiol Case Rep</em> 2021;16:2142-2145.</p></div></div><div role=\"listitem\" data-has=\"label\"><p>25.</p><div id=\"r25\"><p>Bautista García J, Peña Ortega P, Bonilla Fernández JA, Cárdenes León A, Ramírez Burgos L, Caballero Dorta E. Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19. <em>Rev Esp Cardiol (Engl Ed)</em> 2021 April 27 (Epub ahead of print).</p></div></div><div role=\"listitem\" data-has=\"label\"><p>28.</p><div id=\"r28\"><p>Ozonoff A, Nanishi E, Levy O. Bell’s palsy and SARS-CoV-2 vaccines. <em>Lancet Infect Dis</em> 2021;21:450-452.</p></div></div><div role=\"listitem\" data-has=\"label\"><p>29.</p><div id=\"r29\"><p>Repajic M, Lai XL, Xu P, Liu A. Bell’s palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell’s palsy. <em>Brain Behav Immun Health</em> 2021;13:100217-100217.</p></div></div><div role=\"listitem\" data-has=\"label\"><p>30.</p><div id=\"r30\"><p>Colella G, Orlandi M, Cirillo N. Bell’s palsy following COVID-19 vaccination. <em>J Neurol</em> 2021 February 21 (Epub ahead of print).</p></div></div><div role=\"listitem\" data-has=\"label\"><p>31.</p><div id=\"r31\"><p>Peitersen E. Bell’s palsy: the spontaneous course of 2,500 peripheral facial nerve palsies of different etiologies. <em>Acta Otolaryngol Suppl</em> 2002;549:4-30.</p></div></div><div role=\"listitem\" data-has=\"label\"><p>32.</p><div id=\"r32\"><p>Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. <em>N Engl J Med</em> 2021;384:2092-2101.</p></div></div><div role=\"listitem\" data-has=\"label\"><p>33.</p><div id=\"r33\"><p>Centers for Disease Control and Prevention, Health Alert Network. Emergency preparedness and response: cases of cerebral venous sinus thrombosis with thrombocytopenia after receipt of the Johnson &amp; Johnson COVID-19 vaccine. April 13, 2021 (<a href=\"https://emergency.cdc.gov/han/2021/han00442.asp\">https://emergency.cdc.gov/han/2021/han00442.asp</a>).</p></div></div></div></section></div><div><div id=\"core-collateral-info\" role=\"tabpanel\"><header><h2>Information &amp; Authors</h2></header><section id=\"tab-information\" aria-labelledby=\"information\" role=\"tabpanel\"><h3>Information</h3><section><h4>Published In</h4><div><p><span property=\"name\">New England Journal of Medicine</span></p></div></section><section><h4>Copyright</h4><p>Copyright © 2021 Massachusetts Medical Society. All rights reserved.</p></section><section data-translation=\"YXQYoa2110475\"><h4>Translation</h4></section><section><h4>History</h4><p><b>Published online</b>: August 25, 2021</p><p><b>Published in issue</b>: September 16, 2021</p></section><section data-location=\"recirc_topics_article\"><h4>Topics</h4><div><ol><li><a href=\"/browse/topic/cardiomyopathy-myocarditis-pericarditis\" alt=\"View article keyword Cardiomyopathy/Myocarditis/Pericarditis\" data-interactiontype=\"article_recirculation_click\">Cardiomyopathy/Myocarditis/Pericarditis</a></li><li><a href=\"/browse/topic/coronavirus\" alt=\"View article keyword Coronavirus\" data-interactiontype=\"article_recirculation_click\">Coronavirus</a></li><li><a href=\"/browse/topic/vaccines\" alt=\"View article keyword Vaccines\" data-interactiontype=\"article_recirculation_click\">Vaccines</a></li></ol></div></section></section><section id=\"tab-contributors\" aria-labelledby=\"contributors\" role=\"tabpanel\"><h3>Authors</h3><section><h4>Authors</h4><div role=\"paragraph\"><p><span property=\"author\" typeof=\"Person\"><span property=\"givenName\">Noam</span> <span property=\"familyName\">Barda</span>, <span property=\"honorificSuffix\">M.D.</span></span>, <span property=\"author\" typeof=\"Person\"><span property=\"givenName\">Noa</span> <span property=\"familyName\">Dagan</span>, <span property=\"honorificSuffix\">M.D.</span> <a href=\"https://orcid.org/0000-0001-8811-7825\" property=\"identifier\" aria-label=\"ORCID identifier\" target=\"_blank\">https://orcid.org/0000-0001-8811-7825</a></span>, <span property=\"author\" typeof=\"Person\"><span property=\"givenName\">Yatir</span> <span property=\"familyName\">Ben-Shlomo</span>, <span property=\"honorificSuffix\">B.Sc.</span></span>, <span property=\"author\" typeof=\"Person\"><span property=\"givenName\">Eldad</span> <span property=\"familyName\">Kepten</span>, <span property=\"honorificSuffix\">Ph.D.</span></span>, <span property=\"author\" typeof=\"Person\"><span property=\"givenName\">Jacob</span> <span property=\"familyName\">Waxman</span>, <span property=\"honorificSuffix\">M.D.</span></span>, <span property=\"author\" typeof=\"Person\"><span property=\"givenName\">Reut</span> <span property=\"familyName\">Ohana</span>, <span property=\"honorificSuffix\">M.Sc.</span></span>, <span property=\"author\" typeof=\"Person\"><span property=\"givenName\">Miguel A.</span> <span property=\"familyName\">Hernán</span>, <span property=\"honorificSuffix\">M.D.</span> <a href=\"https://orcid.org/0000-0003-1619-8456\" property=\"identifier\" aria-label=\"ORCID identifier\" target=\"_blank\">https://orcid.org/0000-0003-1619-8456</a></span>, <span property=\"author\" typeof=\"Person\"><span property=\"givenName\">Marc</span> <span property=\"familyName\">Lipsitch</span>, <span property=\"honorificSuffix\">D.Phil.</span> <a href=\"https://orcid.org/0000-0003-1504-9213\" property=\"identifier\" aria-label=\"ORCID identifier\" target=\"_blank\">https://orcid.org/0000-0003-1504-9213</a></span>, <span property=\"author\" typeof=\"Person\"><span property=\"givenName\">Isaac</span> <span property=\"familyName\">Kohane</span>, <span property=\"honorificSuffix\">M.D.</span></span>, <span property=\"author\" typeof=\"Person\"><span property=\"givenName\">Doron</span> <span property=\"familyName\">Netzer</span>, <span property=\"honorificSuffix\">M.D.</span></span>, <span property=\"author\" typeof=\"Person\"><span property=\"givenName\">Ben Y.</span> <span property=\"familyName\">Reis</span>, <span property=\"honorificSuffix\">Ph.D.</span></span>, and <span property=\"author\" typeof=\"Person\"><span property=\"givenName\">Ran D.</span> <span property=\"familyName\">Balicer</span>, <span property=\"honorificSuffix\">M.D.</span></span></p></div></section><section><h4>Affiliations</h4><p><span property=\"name\">From the Clalit Research Institute, Innovation Division (N.B., N.D., Y.B.-S., E.K., J.W., R.O., R.D.B.), and the Community Medical Services Division (D.N.), Clalit Health Services, Tel Aviv, and Software and Information Systems Engineering (N.B., N.D.) and the School of Public Health, Faculty of Health Sciences (R.D.B.), Ben-Gurion University of the Negev, Be’er Sheva — both in Israel; the Department of Biomedical Informatics (N.B., N.D., I.K.), and the Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute (N.B., N.D., I.K., B.Y.R., R.D.B.), Harvard Medical School (B.Y.R.), the Departments of Epidemiology and Biostatistics (M.A.H.), CAUSALab (M.A.H.), and the Center for Communicable Disease Dynamics, Departments of Epidemiology and Immunology and Infectious Diseases (M.L.), Harvard T.H. Chan School of Public Health, and the Predictive Medicine Group, Computational Health Informatics Program, Boston Children’s Hospital (B.Y.R.) — all in Boston.</span></p></section><section><h4>Notes</h4><p>Address reprint requests to Dr. Balicer at the Clalit Research Institute, Innovation Division, Clalit Health Services, 101 Arlozorov St., Tel Aviv, Israel, or at <a href=\"about:/cdn-cgi/l/email-protection#ccbeaeada0a5afa9be8cafa0ada0a5b8e2a3beabe2a5a0\"><span data-cfemail=\"7e0c1c1f12171d1b0c3e1d121f12170a50110c19501712\">[email&nbsp;protected]</span></a>.</p><div role=\"doc-footnote\"><p>Drs. Barda and Dagan and Drs. Reis and Balicer contributed equally to this article.</p></div></section></section></div><div id=\"core-collateral-metrics\" role=\"tabpanel\"><header><h2>Metrics &amp; Citations</h2></header><section id=\"tab-metrics-inner\" aria-labelledby=\"metrics-inner\" role=\"tabpanel\"><h3>Metrics</h3><div data-widget-def=\"UX3HTMLWidget\" data-widget-id=\"95ea9f58-ec0e-4db2-b2ab-280fc876af53\" data-location=\"article_metrics_article\">\n        \n\n\n\n        \n            <h4>\n                Altmetrics\n            </h4>\n        \n        \n\n\n        </div></section><section id=\"tab-citations\" aria-labelledby=\"citations\" role=\"tabpanel\"><h3>Citations</h3><section>\n\n\n\n        \n            <h4>\n                Export citation\n            </h4>\n        \n        <div>\n  <p>Select the format you want to export the citation of this publication.</p>\n  \n</div>\n</section><div data-widget-def=\"UX3CitedByWidget\" data-widget-id=\"efb4df9a-8e1a-47f9-bfb7-271959277a9f\" data-location=\"citedby_article\">\n        \n\n\n\n        \n            <h4>\n                Cited by\n            </h4>\n        \n        <div id=\"cited-by\"><ol data-source=\"/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.385.issue-12%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2110475%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms\" data-lazyload=\"false\" data-total=\"665\"><li><ul><li>Nelson Luis Cahuapaza-Gutierrez, </li><li>Renzo Pajuelo-Vasquez, </li><li>Cristina Quiroz-Narvaez, </li><li>Flavia Rioja-Torres, </li><li>María Quispe-Andahua, </li><li>Fernando M. Runzer-Colmenares, </li></ul><span>Acute abdomen following COVID-19 vaccination: a systematic review, </span><span>Clinical and Experimental Vaccine Research, </span><span><strong>13</strong>, </span><span>1, </span><span>(42), </span><span>(2024).</span><a href=\"https://doi.org/10.7774/cevr.2024.13.1.42\" title=\"Crossref\" target=\"_blank\">https://doi.org/10.7774/cevr.2024.13.1.42</a></li><li><ul><li>Qiong Wu, </li><li>Jiayi Tong, </li><li>Bingyu Zhang, </li><li>Dazheng Zhang, </li><li>Jiajie Chen, </li><li>Yuqing Lei, </li><li>Yiwen Lu, </li><li>Yudong Wang, </li><li>Lu Li, </li><li>Yishan Shen, </li><li>Jie Xu, </li><li>L. Charles Bailey, </li><li>Jiang Bian, </li><li>Dimitri A. Christakis, </li><li>Megan L. Fitzgerald, </li><li>Kathryn Hirabayashi, </li><li>Ravi Jhaveri, </li><li>Alka Khaitan, </li><li>Tianchen Lyu, </li><li>Suchitra Rao, </li><li>Hanieh Razzaghi, </li><li>Hayden T. Schwenk, </li><li>Fei Wang, </li><li>Margot I. Gage Witvliet, </li><li>Eric J. Tchetgen Tchetgen, </li><li>Jeffrey S. Morris, </li><li>Christopher B. Forrest, </li><li>Yong Chen, </li></ul><span>Real-World Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and Adolescents, </span><span>Annals of Internal Medicine, </span><span><strong>177</strong>, </span><span>2, </span><span>(165-176), </span><span>(2024).</span><a href=\"https://doi.org/10.7326/M23-1754\" title=\"Crossref\" target=\"_blank\">https://doi.org/10.7326/M23-1754</a></li><li><ul><li>Henry Krasner, </li><li>Nicolette Harmon, </li><li>Jeffrey Martin, </li><li>Crysty-Ann Olaco, </li><li>Dale M. Netski, </li><li>Kavita Batra, </li></ul><span>Community Level Correlates of COVID-19 Booster Vaccine Hesitancy in the United States: A Cross-Sectional Analysis, </span><span>Vaccines, </span><span><strong>12</strong>, </span><span>2, </span><span>(167), </span><span>(2024).</span><a href=\"https://doi.org/10.3390/vaccines12020167\" title=\"Crossref\" target=\"_blank\">https://doi.org/10.3390/vaccines12020167</a></li><li><ul><li>Tal Gazitt, </li><li>Noa Hayat, </li><li>Nili Stein, </li><li>Amir Haddad, </li><li>Ilan Feldhamer, </li><li>Arnon Dov Cohen, </li><li>Walid Saliba, </li><li>Devy Zisman, </li></ul><span>The Risk of Herpes Zoster Events in Patients with Spondyloarthritis and the Effect of BNT162b2 mRNA COVID-19 Vaccine, </span><span>Vaccines, </span><span><strong>12</strong>, </span><span>1, </span><span>(85), </span><span>(2024).</span><a href=\"https://doi.org/10.3390/vaccines12010085\" title=\"Crossref\" target=\"_blank\">https://doi.org/10.3390/vaccines12010085</a></li><li><ul><li>Jung Yoon Choi, </li><li>Yongjoon Lee, </li><li>Nam Gi Park, </li><li>Mi Sung Kim, </li><li>Sandy Jeong Rhie, </li></ul><span>Serious Safety Signals and Prediction Features Following COVID-19 mRNA Vaccines Using the Vaccine Adverse Event Reporting System, </span><span>Pharmaceuticals, </span><span><strong>17</strong>, </span><span>3, </span><span>(356), </span><span>(2024).</span><a href=\"https://doi.org/10.3390/ph17030356\" title=\"Crossref\" target=\"_blank\">https://doi.org/10.3390/ph17030356</a></li><li><ul><li>Martin Heil, </li></ul><span>Self-DNA driven inflammation in COVID-19 and after mRNA-based vaccination: lessons for non-COVID-19 pathologies, </span><span>Frontiers in Immunology, </span><span><strong>14</strong>, </span><span>(2024).</span><a href=\"https://doi.org/10.3389/fimmu.2023.1259879\" title=\"Crossref\" target=\"_blank\">https://doi.org/10.3389/fimmu.2023.1259879</a></li><li><ul><li>Shir Azrielant, </li><li>Yair Levin, </li><li>Alon Peled, </li><li>Liat Samuelov, </li><li>Eli Sprecher, </li><li>Mor Pavlovsky, </li></ul><span>BioNTech COVID-19 (BNT162b2) Vaccination and Varicella Zoster Reactivation: A Comprehensive Cross-sectional Study, </span><span>Acta Dermato-Venereologica, </span><span><strong>104</strong>, </span><span>(adv18389), </span><span>(2024).</span><a href=\"https://doi.org/10.2340/actadv.v104.18389\" title=\"Crossref\" target=\"_blank\">https://doi.org/10.2340/actadv.v104.18389</a></li><li><ul><li>Jin Kyun Park, </li><li>Eun Bong Lee, </li><li>Kevin L Winthrop, </li></ul><span>What rheumatologists need to know about mRNA vaccines: current status and future of mRNA vaccines in autoimmune inflammatory rheumatic diseases, </span><span>Annals of the Rheumatic Diseases, </span><span>(ard-2024-225492), </span><span>(2024).</span><a href=\"https://doi.org/10.1136/ard-2024-225492\" title=\"Crossref\" target=\"_blank\">https://doi.org/10.1136/ard-2024-225492</a></li><li><ul><li>Fabrizio Martora, </li><li>Matteo Megna, </li><li>Teresa Battista, </li><li>Massimiliano Scalvenzi, </li><li>Alessia Villani, </li><li>Sara Cacciapuoti, </li><li>Luca Potestio, </li></ul><span>Viral reactivation following COVID-19 vaccination: a&nbsp;review of the current literature, </span><span>Clinical and Experimental Dermatology, </span><span>(2024).</span><a href=\"https://doi.org/10.1093/ced/llae061\" title=\"Crossref\" target=\"_blank\">https://doi.org/10.1093/ced/llae061</a></li><li><ul><li>Chunhua Zhou, </li><li>Yuanzheng Qiu, </li><li>Jianxin Wang, </li><li>Xiang Zhong, </li><li>Xiufang Zhu, </li><li>Xiaojing Huang, </li><li>Lan Yang, </li><li>Qiaolei Ji, </li><li>Feifei Zhou, </li><li>Shunquan Wu, </li><li>Mengjie Yang, </li><li>Jing Zhang, </li><li>Kaili Liu, </li><li>Li Ji, </li><li>Hanyu Yang, </li><li>Chunlei Li, </li><li>Yuanyuan Zhao, </li></ul><span>The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial, </span><span>Emerging Microbes &amp; Infections, </span><span><strong>13</strong>, </span><span>1, </span><span>(2024).</span><a href=\"https://doi.org/10.1080/22221751.2024.2320913\" title=\"Crossref\" target=\"_blank\">https://doi.org/10.1080/22221751.2024.2320913</a></li><li>See more</li></ol></div>\n\n        </div></section></div><div id=\"core-collateral-fulltext-options\" role=\"tabpanel\"><header><h2>View Options</h2></header><p tabindex=\"0\"><h3>View options</h3><section><h4> <abbr title=\"Portable Document Format\">PDF</abbr></h4><a href=\"https://www.nejm.org/doi/pdf/10.1056/NEJMoa2110475\" title=\"View PDF\" data-toggle=\"tooltip\" aria-label=\"View PDF\" data-behavior=\"trackDownloadEvent\" data-doi=\"10.1056/NEJMoa2110475\" data-interactiontype=\"article_tools_download_pdf\" data-multimedia-type=\"Article PDF\" data-multimedia-filename=\"nejmoa2110475.pdf\"><span>View PDF</span></a></section></p><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><p id=\"core-collateral-media\" role=\"tabpanel\"><header><h2>Media</h2></header><section id=\"tab-figures\" aria-labelledby=\"figures\" role=\"tabpanel\"><h3>Figures</h3></section><section id=\"tab-other\" aria-labelledby=\"other\" role=\"tabpanel\"><h3>Other</h3></section></p><p id=\"core-collateral-tables\" role=\"tabpanel\"><header><h2>Tables</h2></header><!-- There is no content. --></p></div></article></div>","textContent":"Authors: Noam Barda, M.D., Noa Dagan, M.D. https://orcid.org/0000-0001-8811-7825, Yatir Ben-Shlomo, B.Sc., Eldad Kepten, Ph.D., Jacob Waxman, M.D., Reut Ohana, M.Sc., Miguel A. Hernán, M.D. https://orcid.org/0000-0003-1619-8456, Marc Lipsitch, D.Phil. https://orcid.org/0000-0003-1504-9213, Isaac Kohane, M.D., Doron Netzer, M.D., Ben Y. Reis, Ph.D., and Ran D. Balicer, M.D.Published August 25, 2021N Engl J Med 2021;385:1078-1090DOI: 10.1056/NEJMoa2110475AbstractBackgroundPreapproval trials showed that messenger RNA (mRNA)–based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet these trials were subject to size and patient-mix limitations. An evaluation of the safety of the BNT162b2 mRNA vaccine with respect to a broad range of potential adverse events is needed.MethodsWe used data from the largest health care organization in Israel to evaluate the safety of the BNT162b2 mRNA vaccine. For each potential adverse event, in a population of persons with no previous diagnosis of that event, we individually matched vaccinated persons to unvaccinated persons according to sociodemographic and clinical variables. Risk ratios and risk differences at 42 days after vaccination were derived with the use of the Kaplan–Meier estimator. To place these results in context, we performed a similar analysis involving SARS-CoV-2–infected persons matched to uninfected persons. The same adverse events were studied in the vaccination and SARS-CoV-2 infection analyses.ResultsIn the vaccination analysis, the vaccinated and control groups each included a mean of 884,828 persons. Vaccination was most strongly associated with an elevated risk of myocarditis (risk ratio, 3.24; 95% confidence interval [CI], 1.55 to 12.44; risk difference, 2.7 events per 100,000 persons; 95% CI, 1.0 to 4.6), lymphadenopathy (risk ratio, 2.43; 95% CI, 2.05 to 2.78; risk difference, 78.4 events per 100,000 persons; 95% CI, 64.1 to 89.3), appendicitis (risk ratio, 1.40; 95% CI, 1.02 to 2.01; risk difference, 5.0 events per 100,000 persons; 95% CI, 0.3 to 9.9), and herpes zoster infection (risk ratio, 1.43; 95% CI, 1.20 to 1.73; risk difference, 15.8 events per 100,000 persons; 95% CI, 8.2 to 24.2). SARS-CoV-2 infection was associated with a substantially increased risk of myocarditis (risk ratio, 18.28; 95% CI, 3.95 to 25.12; risk difference, 11.0 events per 100,000 persons; 95% CI, 5.6 to 15.8) and of additional serious adverse events, including pericarditis, arrhythmia, deep-vein thrombosis, pulmonary embolism, myocardial infarction, intracranial hemorrhage, and thrombocytopenia.ConclusionsIn this study in a nationwide mass vaccination setting, the BNT162b2 vaccine was not associated with an elevated risk of most of the adverse events examined. The vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse event and of many other serious adverse events was substantially increased after SARS-CoV-2 infection. (Funded by the Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute.)More than 1 year into the pandemic of coronavirus disease 2019 (Covid-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an unprecedented number of mass vaccination efforts are under way worldwide. Globally, nearly 3.4 billion doses of vaccine have been administered over the 6-month period since the first vaccines were approved.1Phase 3 clinical trials showed that several Covid-19 vaccines were efficacious and had an acceptable safety profile.2-4 A number of potential adverse events were identified during these trials, including lymphadenopathy and idiopathic facial-nerve (Bell’s) palsy.2,3 Trials of the BNT162b2 vaccine (Pfizer–BioNTech) also showed a mild imbalance between the vaccinated and placebo groups with respect to the number of cases of appendicitis, hypersensitivity reactions, acute myocardial infarction, and cerebrovascular accidents.5 However, phase 3 trials may have inherent limitations in assessing vaccine safety because of a small number of participants and a healthier-than-average sample population. Hence, they are often underpowered to identify less common adverse events. Postmarketing surveillance is required to monitor the safety of new vaccines in real-world settings.Much effort is currently focused on characterizing the safety profiles of the recently approved Covid-19 vaccines. Passive surveillance systems such as the Vaccine Adverse Event Reporting System (VAERS)6 collect information about adverse events that are potentially related to vaccination. This information is voluntarily reported by health care providers and the public. These systems are useful for quickly identifying potential safety signals, which, along with the findings of phase 3 trials, can be translated to lists of adverse events of interest for further exploration (such as that provided by the Safety Platform for Emergency Vaccines [SPEAC]).7,8 Active surveillance systems such as the Biologics Effectiveness and Safety (BEST) system (part of the Sentinel Initiative)9 aim to compare the incidence of adverse events of interest in large electronic health record databases with the background historical incidence. Although active surveillance can help highlight suspicious trends, the lack of a rigorously constructed comparable control group limits the ability of such surveillance to identify causal effects of vaccination.The effectiveness of vaccines against SARS-CoV-2 has been confirmed in real-world studies,10,11 but high-quality real-world safety data on the messenger RNA (mRNA)–based Covid-19 vaccines remain relatively sparse in the literature. The results of a study based on data reported by more than 600,000 vaccinated persons were recently published12; that study mainly assessed common and mild side effects. Two additional studies, which were based on surveys of vaccinated participants, involved small cohorts,13,14 and another study analyzed adverse events reported in the VAERS database.15 All these studies lacked controls. One study that did incorporate a control group included 8533 long-term care facility residents who had received the first dose of vaccine.16 The authors of this study concluded that the mRNA-based vaccines had an acceptable safety profile, and no notable adverse events were reported.As of May 24, 2021, nearly 5 million people in Israel, comprising more than 55% of the population, had received two doses of the BNT162b2 vaccine.1 In this study, we used the integrated data repositories of the largest health care organization in Israel to evaluate the safety profile of the BNT162b2 vaccine. We compared the incidence of a broad set of potential short- and medium-term adverse events among vaccinated persons with the incidence among matched unvaccinated persons. Potential adverse events related to medical interventions are best understood in the context of the risks associated with the disease that these interventions aim to prevent or treat, so we also estimated the effects of SARS-CoV-2 infection on this same set of adverse events.MethodsStudy SettingWe analyzed observational data from Clalit Health Services (CHS) in order to emulate a target trial of the effects of the BNT162b2 vaccine on a broad range of potential adverse events in a population without SARS-CoV-2 infection. CHS is the largest of four integrated payer–provider health care organizations that offer mandatory health care coverage in Israel. CHS insures approximately 52% of the population of Israel (>4.7 million of 9.0 million persons), and the CHS-insured population is approximately representative of the Israeli population at large.17 CHS directly provides outpatient care, and inpatient care is divided between CHS and out-of-network hospitals. CHS information systems are fully digitized and feed into a central data warehouse. Data regarding Covid-19, including the results of all SARS-CoV-2 polymerase-chain-reaction (PCR) tests, Covid-19 diagnoses and severity, and vaccinations, are collected centrally by the Israeli Ministry of Health and shared with each of the four national health care organizations daily.This study was approved by the CHS institutional review board. The study was exempt from the requirement for informed consent.Eligibility CriteriaEligibility criteria included an age of 16 years or older, continuous membership in the health care organization for a full year, no previous SARS-CoV-2 infection, and no contact with the health care system in the previous 7 days (the latter criterion was included as an indicator of a health event not related to subsequent vaccination that could reduce the probability of receiving the vaccine). Because of difficulties in distinguishing the recoding of previous events from true new events, for each adverse event, persons with a previous diagnosis of that event were excluded.As in our previous study of the effectiveness of the BNT162b2 vaccine,10 we also excluded persons from populations in which confounding could not be adequately addressed — long-term care facility residents, persons confined to their homes for medical reasons, health care workers, and persons for whom data on body-mass index or residential area were missing (missing data for these variables are rare in the CHS data). A complete definition of the study variables is included in Table S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org.Study Design and OversightThe target trial for this study would assign eligible persons to either vaccination or no vaccination. To emulate this trial, on each day from the beginning of the vaccination campaign in Israel (December 20, 2020) until the end of the study period (May 24, 2021), eligible persons who were vaccinated on that day were matched to eligible controls who had not been previously vaccinated. Since the matching process each day considered only information available on or before that day (and was thus unaffected by later vaccinations or SARS-CoV-2 infections), unvaccinated persons matched on a given day could be vaccinated on a future date, and on that future date they could become newly eligible for inclusion in the study as a vaccinated person.In an attempt to emulate randomized assignment, vaccinated persons and unvaccinated controls were exactly matched on a set of baseline variables that were deemed to be potential confounders according to domain expertise — namely, variables that were potentially related to vaccination and to a tendency toward the development of a broad set of adverse clinical conditions. These matching criteria included the sociodemographic variables of age (categorized into 2-year age groups), sex (male or female), place of residence (at city- or town-level granularity), socioeconomic status (divided into seven categories), and population sector (general Jewish, Arab, or ultra-Orthodox Jewish). In addition, the matching criteria included clinical factors to account for general clinical condition and disease load, including the number of preexisting chronic conditions (those considered to be risk factors for severe Covid-19 by the Centers for Disease Control and Prevention [CDC] as of December 20, 2020,18 divided into four categories), the number of diagnoses documented in outpatient visits in the year before the index date (categorized into deciles within each age group), and pregnancy status.All the authors designed the study and critically reviewed the manuscript. The first three authors collected and analyzed the data. A subgroup of the authors wrote the manuscript. The last author vouches for the accuracy and completeness of the data and for the fidelity of the study to the protocol. There was no commercial funding for this study, and no confidentiality agreements were in place.Adverse Events of InterestThe set of potential adverse events for the target trial was drawn from several relevant sources, including the VAERS, BEST, and SPEAC frameworks, information provided by the vaccine manufacturer, and relevant scientific publications. We cast a wide net to capture a broad range of clinically meaningful short- and medium-term potential adverse events that would be likely to be documented in the electronic health record. Accordingly, mild adverse events such as fever, malaise, and local injection-site reactions were not included in this study. The study included 42 days of follow-up, which provided 21 days of follow-up after each of the first and second vaccine doses. A total of 42 days was deemed to be sufficient for identifying medium-term adverse events, without being so long as to dilute the incidence of short-term adverse events. Similarly, adverse events that could not plausibly be diagnosed within 42 days (e.g., chronic autoimmune disease) were not included.Adverse events were defined according to diagnostic codes and short free-text phrases that accompany diagnoses in the CHS database. A complete list of the study outcomes (adverse events) and their definitions is provided in Table S2.For each adverse event, persons were followed from the day of matching (time zero of follow-up) until the earliest of one of the following: documentation of the adverse event, 42 days, the end of the study calendar period, or death. We also ended the follow-up of a matched pair when the unvaccinated control received the first dose of vaccine or when either member of the matched pair received a diagnosis of SARS-CoV-2 infection.Risks of SARS-CoV-2 InfectionTo place the magnitude of the adverse effects of the vaccine in context, we also estimated the effects of SARS-CoV-2 infection on these same adverse events during the 42 days after diagnosis. We used the same design as the one that we used to study the adverse effects of vaccination, except that the analysis period started at the beginning of the Covid-19 pandemic in Israel (March 1, 2020) and persons who had had recent contact with the health care system were not excluded (because such contact may be expected in the days before diagnosis).Each day in this SARS-CoV-2 analysis, persons with a new diagnosis of SARS-CoV-2 infection were matched to controls who were not previously infected. As in the vaccine safety analysis, persons could become infected with SARS-CoV-2 after they were already matched as controls on a previous day, in which case their data would be censored from the control group (along with their matched SARS-CoV-2–infected person) and they could then be included in the group of SARS-CoV-2–infected persons with a newly matched control. Follow-up of each matched pair started from the date of the positive PCR test result of the infected member and ended in an analogous manner to the main vaccination analysis, this time ending when the control member was infected or when either of the persons in the matched pair was vaccinated.The effects of vaccination and of SARS-CoV-2 infection were estimated with different cohorts. Thus, they should be treated as separate sets of results rather than directly compared.Statistical AnalysisBecause a large proportion of the unvaccinated controls were vaccinated during the follow-up period, we opted to estimate the observational analogue of the per-protocol effect if all unvaccinated persons had remained unvaccinated during the follow-up. To do so, we censored data on the matched pair if and when the control member was vaccinated. Persons who were first matched as unvaccinated controls and then became vaccinated during the study period could be included again as vaccinated persons with a new matched control. The same procedure was followed in the SARS-CoV-2 infection analysis (i.e., persons who were first matched as uninfected controls and then became infected during the study period could be included again as infected persons with a new matched control).We used the Kaplan–Meier estimator19 to construct cumulative incidence curves and to estimate the risk of each adverse event after 42 days in each group. The risks were compared with ratios and differences (per 100,000 persons).In the vaccination analysis, so as not to attribute complications arising from SARS-CoV-2 infection to the vaccination (or lack thereof), we also censored data on the matched pair if and when either member received a diagnosis of SARS-CoV-2 infection. Similarly, in the SARS-CoV-2 infection analysis, we censored data on the matched pair if and when either member was vaccinated. Additional details are provided in the Supplementary Methods 1 section in the Supplementary Appendix.We calculated confidence intervals using the nonparametric percentile bootstrap method with 500 repetitions. As is standard practice for studies of safety outcomes, no adjustment for multiple comparisons was performed. Analyses were performed with the use of R software, version 4.0.4.ResultsVaccination AnalysisA total of 1,736,832 persons were eligible for inclusion in the vaccination cohort (Figure 1). The median age in the eligible cohort was 43 years (Table S3). The final size of the study population differed for each studied adverse event because of adverse event–specific exclusion of persons with a history of that event. On average, across the adverse event–specific cohorts, 72.4% of the eligible persons were successfully matched. Table 1 shows the baseline characteristics of the total study population, with the mean distribution of characteristics across the various adverse event–specific cohorts. The characteristics of each adverse event–specific cohort are provided in Table S4. The vaccination cohorts included a mean of 884,828 vaccinated persons, with a median age of 38 years (5 years younger than the median age of the eligible cohort). A total of 48% of the population was female.Figure 1Study Population for the Vaccination Analysis.Absolute numbers and percentage changes are shown for each inclusion and exclusion criterion. The chart focuses on the vaccinated population. The derivation group includes the entire population, including unvaccinated persons. The shaded boxes indicate the two study groups. The same exclusion criteria were applied to the unvaccinated persons for each index date on which they were considered for matching. BMI denotes body-mass index, CHS Clalit Health Services, and PCR polymerase chain reaction.Table 1CharacteristicVaccination AnalysisSARS-CoV-2 Analysis Vaccinated Group(N=884,828)Control Group(N=884,828)SARS-CoV-2–Infected Group(N=173,106)Control Group(N=173,106)Median age (IQR) — yr38 (27–53)38 (27–53)34 (24–47)34 (24–47)Age group — no. (%)    16–39 yr472,095 (53)472,095 (53)107,046 (62)107,046 (62)40–49 yr160,413 (18)160,413 (18)28,738 (17)28,738 (17)50–59 yr93,110 (11)93,110 (11)17,851 (10)17,851 (10)60–69 yr87,236 (10)87,236 (10)12,100 (7)12,100 (7)70–79 yr51,924 (6)51,924 (6)5,371 (3)5,371 (3)≥80 yr20,050 (2)20,050 (2)1,999 (1)1,999 (1)Sex — no. (%)    Female423,238 (48)423,238 (48)93,263 (54)93,263 (54)Male461,590 (52)461,590 (52)79,843 (46)79,843 (46)Population sector — no. (%)    General Jewish595,897 (67)595,897 (67)90,903 (53)90,903 (53)Ultra-Orthodox Jewish24,343 (3)24,343 (3)20,864 (12)20,864 (12)Arab264,588 (30)264,588 (30)61,339 (35)61,339 (35)No. of risk factors according to CDC criteria — no. (%)    0571,604 (65)571,604 (65)108,980 (63)108,980 (63)1200,789 (23)200,789 (23)41,502 (24)41,502 (24)261,924 (7)61,924 (7)11,976 (7)11,976 (7)327,175 (3)27,175 (3)5,181 (3)5,181 (3)≥423,335 (3)23,335 (3)5,467 (3)5,467 (3)CDC “certain” risk criteria — no. (%)    Cancer9,957 (1)10,300 (1)2,037 (1)2,308 (1)Chronic kidney disease39,837 (4)40,339 (5)8,269 (5)8,141 (5)Chronic obstructive pulmonary disease10,121 (1)11,498 (1)1,791 (1)2,212 (1)Heart disease31,836 (4)31,596 (4)5,653 (3)5,880 (3)Solid-organ transplantation351 (<1)370 (<1)148 (<1)136 (<1)Obesity: BMI, 30 to 40129,148 (15)125,120 (14)30,558 (18)28,580 (17)Severe obesity: BMI, ≥4011,861 (1)12,568 (1)3,478 (2)3,107 (2)Pregnancy6,082 (1)6,082 (1)4,959 (3)4,959 (3)Sickle cell disease140 (<1)182 (<1)50 (<1)55 (<1)Smoking157,803 (18)187,822 (21)18,899 (11)30,376 (18)Type 2 diabetes mellitus61,865 (7)61,093 (7)12,448 (7)12,396 (7)CDC “possible” risk criteria — no. (%)    Asthma46,836 (5)47,151 (5)10,079 (6)10,413 (6)Cerebrovascular disease14,296 (2)14,919 (2)2,661 (2)2,738 (2)Other respiratory disease1,884 (<1)1,961 (<1)322 (<1)362 (<1)Hypertension94,819 (11)93,357 (11)15,514 (9)15,682 (9)Immunosuppression15,430 (2)15,433 (2)4,346 (2)4,457 (3)Neurologic disease26,340 (3)28,421 (3)5,194 (3)5,455 (3)Liver disease10,491 (1)12,558 (1)2,391 (1)2,600 (2)Overweight: BMI, 25 to 30284,904 (32)271,335 (31)53,374 (31)50,038 (29)Thalassemia5,884 (1)5,644 (1)1,599 (1)1,595 (1)Type 1 diabetes mellitus2,797 (<1)2,648 (<1)694 (<1)763 (<1)Baseline Characteristics of the Study Populations According to Vaccination Status and SARS-CoV-2 Infection Status.**Statistics are based on means and distributions from a pool of all the adverse event–specific cohorts. Characteristics of the various study populations after application of all eligibility criteria and the matching process are listed. BMI denotes body-mass index (the weight in kilograms divided by the square of the height in meters), CDC Centers for Disease Control and Prevention, IQR interquartile range, RT-PCR reverse-transcriptase polymerase chain reaction, and SARS-CoV-2 severe acute respiratory syndrome coronavirus 2.The effect of vaccination on the various potential adverse events included in this study is presented in Table 2. The risk was substantially higher on either the multiplicative (risk ratio) or additive (risk difference) scales in the vaccinated group than in the unvaccinated group for myocarditis (risk ratio, 3.24; 95% confidence interval [CI], 1.55 to 12.44; risk difference, 2.7 events per 100,000 persons; 95% CI, 1.0 to 4.6), lymphadenopathy (risk ratio, 2.43; 95% CI, 2.05 to 2.78; risk difference, 78.4 events per 100,000 persons; 95% CI, 64.1 to 89.3), appendicitis (risk ratio, 1.40; 95% CI, 1.02 to 2.01; risk difference, 5.0 events per 100,000 persons; 95% CI, 0.3 to 9.9), and herpes zoster infection (risk ratio, 1.43; 95% CI, 1.20 to 1.73; risk difference, 15.8 events per 100,000 persons; 95% CI, 8.2 to 24.2). Vaccination was substantially protective against adverse events such as anemia, acute kidney injury, intracranial hemorrhage, and lymphopenia.Table 2EventAdverse-Event Cohort in Each GroupVaccinated GroupControl GroupRisk Ratio (95% CI)Risk Difference (95% CI) no. of personsno. of events no. of events/100,000 personsAcute kidney injury912,01920450.44 (0.23 to 0.73)−4.6 (−7.8 to −1.8)Anemia709,2672983780.79 (0.67 to 0.93)−18.7 (−32.1 to −6.1)Appendicitis900,28995661.40 (1.02 to 2.01)5.0 (0.3 to 9.9)Arrhythmia856,1522542840.89 (0.74 to 1.04)−6.1 (−14.7 to 1.8)Arthritis or arthropathy731,34064700.95 (0.65 to 1.34)−0.8 (−6.3 to 4.2)Bell’s palsy923,69281591.32 (0.92 to 1.86)3.5 (−1.1 to 7.8)Cerebrovascular accident917,59845550.84 (0.54 to 1.27)−1.6 (−5.3 to 2.0)Deep-vein thrombosis925,38039470.87 (0.55 to 1.40)−1.1 (−4.5 to 2.7)Herpes simplex infection876,3282192051.13 (0.95 to 1.38)4.8 (−1.9 to 12.4)Herpes zoster infection888,6472832041.43 (1.20 to 1.73)15.8 (8.2 to 24.2)Intracranial hemorrhage933,13013300.48 (0.20 to 0.89)−2.9 (−5.6 to −0.5)Lymphadenopathy823,0066602792.43 (2.05 to 2.78)78.4 (64.1 to 89.3)Lymphopenia938,939270.26 (0.00 to 1.03)−0.9 (−2.0 to <0.1)Myocardial infarction892,78559601.07 (0.74 to 1.60)0.8 (−3.3 to 5.2)Myocarditis938,8122163.24 (1.55 to 12.44)2.7 (1.0 to 4.6)Neutropenia919,29120220.87 (0.46 to 1.66)−0.5 (−2.8 to 1.8)Other thrombosis†932,46912220.46 (0.19 to 0.91)−2.2 (−4.6 to −0.3)Paresthesia827,4785524961.12 (0.98 to 1.24)10.8 (−1.8 to 21.4)Pericarditis936,19727181.27 (0.68 to 2.31)1.0 (−1.6 to 3.4)Pulmonary embolism937,11610170.56 (0.21 to 1.15)−1.5 (−3.6 to 0.4)Seizure913,09136350.99 (0.62 to 1.64)−0.4 (−3.0 to 3.1)Syncope858,0683262671.12 (0.94 to 1.34)6.2 (−3.2 to 15.4)Thrombocytopenia923,12356600.94 (0.63 to 1.27)−0.6 (−4.6 to 2.3)Uveitis933,21726201.27 (0.68 to 2.67)1.0 (−1.5 to 3.8)Vertigo773,2634333951.12 (0.97 to 1.28)9.3 (−2.5 to 20.0)Adverse Events Associated with SARS-CoV-2 Vaccination.**Estimates were calculated with the use of the Kaplan–Meier estimator 42 days after vaccination or SARS-CoV-2 infection. Confidence intervals (CIs) were estimated with the use of the percentile bootstrap method with 500 repetitions.†The “other thrombosis” category is a composite diagnosis that includes arterial embolism and thrombosis, venous embolism and thrombosis, vascular insufficiency of the intestine, portal-vein thrombosis, or cranial venous sinus thrombosis.Figure S1 shows the cumulative incidence (risk) curves for each specific adverse event. Spikes in the incidence of lymphadenopathy were seen after both the first and second doses of vaccine, whereas the incidence of myocarditis spiked mainly after the second dose of vaccine.SARS-CoV-2 Infection AnalysisA total of 233,392 persons (median age, 36 years) were eligible to be included in the SARS-CoV-2 infection cohort (Figure 2). On average, across the adverse event–specific cohorts, 75.8% of the eligible persons were successfully matched. Table 1 shows the average distribution of characteristics in these cohorts, across the two study groups (infected and noninfected). The characteristics of each adverse event–specific cohort are provided in Table S5. The cohorts for the analysis of SARS-CoV-2 infection comprised a mean of 173,106 SARS-CoV-2–infected persons (median age, 34 years). A total of 54% of these persons were female.Figure 2Study Population for the SARS-CoV-2 Analysis.Absolute numbers and percentage changes are shown for each inclusion and exclusion criterion. The chart focuses on the SARS-CoV-2–infected population. The derivation group includes the entire population, including uninfected persons. The shaded boxes indicate the two study groups. The same exclusion criteria were applied to the uninfected persons for each index date on which they were considered for matching. Covid-19 denotes coronavirus disease 2019.Table S6 shows the effect of SARS-CoV-2 infection on the incidence of various adverse events. Infection substantially increased the risk of many different adverse events, including myocarditis (risk ratio, 18.28; 95% CI, 3.95 to 25.12; risk difference, 11.0 events per 100,000 persons; 95% CI, 5.6 to 15.8), acute kidney injury (risk ratio, 14.83; 95% CI, 9.24 to 28.75; risk difference, 125.4 events per 100,000 persons; 95% CI, 107.0 to 142.6), pulmonary embolism (risk ratio, 12.14; 95% CI, 6.89 to 29.20; risk difference, 61.7 events per 100,000 persons; 95% CI, 48.5 to 75.4), intracranial hemorrhage (risk ratio, 6.89; 95% CI, 1.90 to 19.16; risk difference, 7.6 events per 100,000 persons; 95% CI, 2.7 to 12.6), pericarditis (risk ratio, 5.39; 95% CI, 2.22 to 23.58; risk difference, 10.9 events per 100,000 persons; 95% CI, 4.9 to 16.9), myocardial infarction (risk ratio, 4.47; 95% CI, 2.47 to 9.95; risk difference, 25.1 events per 100,000 persons; 95% CI, 16.2 to 33.9), deep-vein thrombosis (risk ratio, 3.78; 95% CI, 2.50 to 6.59; risk difference, 43.0 events per 100,000 persons; 95% CI, 29.9 to 56.6), and arrhythmia (risk ratio, 3.83; 95% CI, 3.07 to 4.95; risk difference, 166.1 events per 100,000 persons; 95% CI, 139.6 to 193.2).Both AnalysesFigure 3 shows estimated risk ratios in both the vaccination and SARS-CoV-2 infection analyses for adverse events in which vaccination or infection substantially increased the risk. Figure 4 shows the absolute risk associated with vaccination, alongside the absolute risk associated with SARS-CoV-2 infection, for the same adverse events.Figure 3Risk Ratios for Adverse Events after Vaccination or SARS-CoV-2 Infection.Estimated risk ratios for adverse events after vaccination or SARS-CoV-2 infection are shown. The risk ratio on the y axis is presented on a logarithmic scale to facilitate comparison of both increased and decreased risk. 𝙸 bars indicate 95% confidence intervals.Figure 4Absolute Excess Risk of Various Adverse Events after Vaccination or SARS-CoV-2 Infection.Point estimates of the risk differences for selected adverse events are shown. Estimates were derived 42 days after vaccination or SARS-CoV-2 infection with the use of the Kaplan–Meier estimator. Risk differences are shown per 100,000 persons and rounded to the nearest integer. Negative differences (decreased risk) are represented as negative values on the y axis, and positive differences (increased risk) are represented as positive values on the y axis. The abbreviation mRNA denotes messenger RNA.DiscussionWe used a data set involving more than 2.4 million vaccinated persons from an integrated health care organization to evaluate the safety profile of the BNT162b2 mRNA Covid-19 vaccine. The main potential adverse events identified included an excess risk of lymphadenopathy (78.4 events per 100,000 persons), herpes zoster infection (15.8 events), appendicitis (5.0 events), and myocarditis (2.7 events).To place these risks in context, we also examined data on more than 240,000 infected persons to estimate the effects of a documented SARS-CoV-2 infection on the incidence of the same adverse events. SARS-CoV-2 infection was not estimated to have a meaningful effect on the incidence of lymphadenopathy, herpes zoster infection, or appendicitis, but it was estimated to result in a substantial excess risk of myocarditis (11.0 events per 100,000 persons). SARS-CoV-2 infection was also estimated to substantially increase the risk of several adverse events for which vaccination was not found to increase the risk, including an estimated excess risk of arrhythmia (166.1 events per 100,000 persons), acute kidney injury (125.4 events), pulmonary embolism (61.7 events), deep-vein thrombosis (43.0 events), myocardial infarction (25.1 events), pericarditis (10.9 events), and intracranial hemorrhage (7.6 events).An association between Covid-19 vaccination and myocarditis has been previously reported.20 Although no cases of myocarditis were reported in the BNT162b2 (Pfizer–BioNTech),2 mRNA-1273 (Moderna),3 or ChAdOx1 nCoV-19 (AstraZeneca)4 phase 3 clinical trials, multiple cases of myocarditis after Covid-19 vaccination have recently been reported in the literature,21-25 and both the Israeli Ministry of Health26 and the CDC have investigated this association.27 The risk appears to be highest among young men.26,27 We found that the risk of myocarditis increased by a factor of three after vaccination, which translated to approximately 3 excess events per 100,000 persons; the 95% confidence interval indicated that values between 1 and 5 excess events per 100,000 persons were compatible with our data. Among the 21 persons with myocarditis in the vaccinated group, the median age was 25 years (interquartile range, 20 to 34), and 90.9% were male.Another vaccine-related adverse event that has recently received attention in the medical literature is Bell’s palsy. In a recent article based on publicly available data from the BNT162b2 and mRNA-1273 vaccine trials, Ozonoff et al.28 suggested a possible association between these vaccines and Bell’s palsy and estimated a rate ratio of approximately 7.0. This conclusion differed from the Food and Drug Administration briefing on these vaccines in December 2020; that briefing considered the incidence of Bell’s palsy to be similar to the background incidence.5 A small number of cases of Bell’s palsy after Covid-19 vaccination have also been reported in the literature.29,30 In the current study, the effect estimate was consistent with a potentially mild increase in the risk of Bell’s palsy after vaccination, with a risk ratio of 1.32 (95% CI, 0.92 to 1.86). The absolute effect was small, with up to 8 excess events per 100,000 persons being highly compatible with our data according to the 95% confidence interval. Herpes zoster infection, the incidence of which we found to be increased after vaccination, is one of the potential causes of facial-nerve palsy.31Another particularly notable class of adverse events that has been reported in the context of Covid-19 vaccines is thromboembolic events. These adverse events, which primarily affect young women, have been linked with the ChAdOx1 nCoV-1932 and Ad26.COV2.S (Johnson & Johnson–Janssen) Covid-19 vaccines,33 both of which are adenoviral vector vaccines. However, we did not find an association between the BNT162b2 vaccine and various thromboembolic events in this study.Some initially unexpected effects were seen in the results of the current study. The BNT162b2 vaccine appears to be protective against certain conditions such as anemia and intracranial hemorrhage. These same adverse events are also identified in this study as complications of SARS-CoV-2 infection, so it appears likely that the protective effect of the vaccine is mediated through its protection against undiagnosed SARS-CoV-2 infection, which may be undiagnosed either because of a lack of testing or because of false negative PCR results.This study has several limitations. First, persons in the study were not randomly assigned according to exposures (vaccinations and SARS-CoV-2 infections); this may have introduced confounding at baseline and selection bias at censoring, especially since a single set of confounders was used for adjustment in the assessment of many disparate adverse events. Second, the matching process that was necessary to attain exchangeability between the study groups resulted in a study population with a different composition than the eligible population (e.g., median age, 38 years rather than 43 years). Because this different composition changes the population over which the causal effect is being estimated, different estimates might be found for adverse events for which the incidence may differ substantially between subgroups (e.g., myocarditis). Also, we excluded certain populations (such as health care workers and persons residing in long-term care facilities) that could be at particularly high risk for certain adverse events. Both of these issues should be taken into account when considering the generalizability of the findings.Third, some diagnoses that were recorded in out-of-network hospitals, which were delayed in being reported to the insurer and were not entered by the person’s general practitioner from the hospital discharge notes into the outpatient medical record, could have been missed. Fourth, it is possible that persons are more likely to increase their levels of clinical awareness, concern, or both after vaccination or SARS-CoV-2 infection, and thus they may be more likely to report or seek medical care for their symptoms, resulting in a spuriously increased incidence of the various adverse events in the vaccinated or infected groups. Similarly, among persons with SARS-CoV-2 infection, the spike in the incidence of certain adverse events in the first day of follow-up could indicate the initial clinical manifestation of the infection, but it could also be related to active testing for SARS-CoV-2. Fifth, all the effect measures that we presented are based only on a new incidence of the specific adverse event under study; thus, less light was shed on the potential additional risk among persons with a medical history of each of these adverse events. However, this choice was necessary to distinguish between true new diagnoses of a given adverse event and recoding of past diagnoses and to ensure the accuracy of the adverse-event labels.In this study, we sought to place the increased risk of adverse events caused by the BNT162b2 vaccine in context by contrasting this risk with that of the same adverse events after documented infection with SARS-CoV-2. We thought that this was necessary because vaccination and its potential risks do not occur in a void but rather in the context of an ongoing pandemic. Although the general risks of hospitalization, severe disease, and death from Covid-19 are widely recognized, secondary complications of infection are less well known. Therefore, in this analysis, we sought to estimate the effects of SARS-CoV-2 infection on the incidence of the same list of adverse events examined in the vaccination analysis. Because the cohorts that we used to study the vaccine and infection effects were different in composition, care should be taken when comparing the resulting risk estimates. In addition, knowledge of these risks alone is insufficient for a complete decision-theoretic analysis. When a person decides to become vaccinated, this choice results in a probability of 100% for the vaccination, whereas the alternative of contracting SARS-CoV-2 infection is an event with uncertain probability that depends on the person, place, and time. Moreover, infection with SARS-CoV-2 has many other adverse effects beyond those considered here, including the risk of transmission to family members and others.We estimated that the BNT162b2 vaccine resulted in an increased incidence of a few adverse events over a 42-day follow-up period. Although most of these events were mild, some of them, such as myocarditis, could be potentially serious. However, our results indicate that SARS-CoV-2 infection is itself a very strong risk factor for myocarditis, and it also substantially increases the risk of multiple other serious adverse events. These findings help to shed light on the short- and medium-term risks of the vaccine and place them in clinical context. Further studies will be needed to estimate the potential of long-term adverse events.\n\n\n\n        \n        \nNotesBecause of data privacy regulations, the raw data for this study cannot be shared.This article was published on August 25, 2021, at NEJM.org.Supported by the Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute. Dr. Lipsitch receives support from the Morris–Singer Foundation.Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.We thank Oren Miron for his valuable advice.Supplementary MaterialSupplementary Appendix (nejmoa2110475_appendix.pdf)Download4.32 MBDisclosure Forms (nejmoa2110475_disclosures.pdf)Download447.73 KBReferences2.Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383:2603-2615.3.Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403-416.4.Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99-111.7.World Health Organization. Background paper on Covid-19 disease and vaccines: prepared by the Strategic Advisory Group of Experts (SAGE) on immunization working group on COVID-19 vaccines. December 22, 2020 (https://apps.who.int/iris/handle/10665/338095).10.Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021;384:1412-1423.11.Hall VJ, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet 2021;397:1725-1735.12.Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis 2021;21:939-949.13.Mathioudakis AG, Ghrew M, Ustianowski A, et al. Self-reported real-world safety and reactogenicity of COVID-19 vaccines: a vaccine recipient survey. Life (Basel) 2021;11:249-249.14.Song JY, Cheong HJ, Kim SR, et al. Early safety monitoring of COVID-19 vaccines in healthcare workers. J Korean Med Sci 2021;36(15):e110-e110.15.Chen G, Li X, Sun M, et al. COVID-19 mRNA vaccines are generally safe in the short term: a vaccine vigilance real-world study says. Front Immunol 2021;12:669010-669010.16.Bardenheier BH, Gravenstein S, Blackman C, et al. Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents. Vaccine 2021;39:3844-3851.19.Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.20.Castiello T, Georgiopoulos G, Finocchiaro G, et al. COVID-19 and myocarditis: a systematic review and overview of current challenges. Heart Fail Rev 2021 March 24 (Epub ahead of print).21.Ammirati E, Cavalotti C, Milazzo A, et al. Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection. Int J Cardiol Heart Vasc 2021;34:100774-100774.22.Abu Mouch S, Roguin A, Hellou E, et al. Myocarditis following COVID-19 mRNA vaccination. Vaccine 2021;39:3790-3793.23.Marshall M, Ferguson ID, Lewis P, et al. Symptomatic acute myocarditis in seven adolescents following Pfizer-BioNTech COVID-19 vaccination. Pediatrics 2021 June 4 (Epub ahead of print).24.Albert E, Aurigemma G, Saucedo J, Gerson DS. Myocarditis following COVID-19 vaccination. Radiol Case Rep 2021;16:2142-2145.25.Bautista García J, Peña Ortega P, Bonilla Fernández JA, Cárdenes León A, Ramírez Burgos L, Caballero Dorta E. Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19. Rev Esp Cardiol (Engl Ed) 2021 April 27 (Epub ahead of print).28.Ozonoff A, Nanishi E, Levy O. Bell’s palsy and SARS-CoV-2 vaccines. Lancet Infect Dis 2021;21:450-452.29.Repajic M, Lai XL, Xu P, Liu A. Bell’s palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell’s palsy. Brain Behav Immun Health 2021;13:100217-100217.30.Colella G, Orlandi M, Cirillo N. Bell’s palsy following COVID-19 vaccination. J Neurol 2021 February 21 (Epub ahead of print).31.Peitersen E. Bell’s palsy: the spontaneous course of 2,500 peripheral facial nerve palsies of different etiologies. Acta Otolaryngol Suppl 2002;549:4-30.32.Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021;384:2092-2101.33.Centers for Disease Control and Prevention, Health Alert Network. Emergency preparedness and response: cases of cerebral venous sinus thrombosis with thrombocytopenia after receipt of the Johnson & Johnson COVID-19 vaccine. April 13, 2021 (https://emergency.cdc.gov/han/2021/han00442.asp).Information & AuthorsInformationPublished InNew England Journal of MedicineCopyrightCopyright © 2021 Massachusetts Medical Society. All rights reserved.TranslationHistoryPublished online: August 25, 2021Published in issue: September 16, 2021TopicsCardiomyopathy/Myocarditis/PericarditisCoronavirusVaccinesAuthorsAuthorsNoam Barda, M.D., Noa Dagan, M.D. https://orcid.org/0000-0001-8811-7825, Yatir Ben-Shlomo, B.Sc., Eldad Kepten, Ph.D., Jacob Waxman, M.D., Reut Ohana, M.Sc., Miguel A. Hernán, M.D. https://orcid.org/0000-0003-1619-8456, Marc Lipsitch, D.Phil. https://orcid.org/0000-0003-1504-9213, Isaac Kohane, M.D., Doron Netzer, M.D., Ben Y. Reis, Ph.D., and Ran D. Balicer, M.D.AffiliationsFrom the Clalit Research Institute, Innovation Division (N.B., N.D., Y.B.-S., E.K., J.W., R.O., R.D.B.), and the Community Medical Services Division (D.N.), Clalit Health Services, Tel Aviv, and Software and Information Systems Engineering (N.B., N.D.) and the School of Public Health, Faculty of Health Sciences (R.D.B.), Ben-Gurion University of the Negev, Be’er Sheva — both in Israel; the Department of Biomedical Informatics (N.B., N.D., I.K.), and the Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute (N.B., N.D., I.K., B.Y.R., R.D.B.), Harvard Medical School (B.Y.R.), the Departments of Epidemiology and Biostatistics (M.A.H.), CAUSALab (M.A.H.), and the Center for Communicable Disease Dynamics, Departments of Epidemiology and Immunology and Infectious Diseases (M.L.), Harvard T.H. Chan School of Public Health, and the Predictive Medicine Group, Computational Health Informatics Program, Boston Children’s Hospital (B.Y.R.) — all in Boston.NotesAddress reprint requests to Dr. Balicer at the Clalit Research Institute, Innovation Division, Clalit Health Services, 101 Arlozorov St., Tel Aviv, Israel, or at [email protected].Drs. Barda and Dagan and Drs. Reis and Balicer contributed equally to this article.Metrics & CitationsMetrics\n        \n\n\n\n        \n            \n                Altmetrics\n            \n        \n        \n\n\n        Citations\n\n\n\n        \n            \n                Export citation\n            \n        \n        \n  Select the format you want to export the citation of this publication.\n  \n\n\n        \n\n\n\n        \n            \n                Cited by\n            \n        \n        Nelson Luis Cahuapaza-Gutierrez, Renzo Pajuelo-Vasquez, Cristina Quiroz-Narvaez, Flavia Rioja-Torres, María Quispe-Andahua, Fernando M. Runzer-Colmenares, Acute abdomen following COVID-19 vaccination: a systematic review, Clinical and Experimental Vaccine Research, 13, 1, (42), (2024).https://doi.org/10.7774/cevr.2024.13.1.42Qiong Wu, Jiayi Tong, Bingyu Zhang, Dazheng Zhang, Jiajie Chen, Yuqing Lei, Yiwen Lu, Yudong Wang, Lu Li, Yishan Shen, Jie Xu, L. Charles Bailey, Jiang Bian, Dimitri A. Christakis, Megan L. Fitzgerald, Kathryn Hirabayashi, Ravi Jhaveri, Alka Khaitan, Tianchen Lyu, Suchitra Rao, Hanieh Razzaghi, Hayden T. Schwenk, Fei Wang, Margot I. Gage Witvliet, Eric J. Tchetgen Tchetgen, Jeffrey S. Morris, Christopher B. Forrest, Yong Chen, Real-World Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and Adolescents, Annals of Internal Medicine, 177, 2, (165-176), (2024).https://doi.org/10.7326/M23-1754Henry Krasner, Nicolette Harmon, Jeffrey Martin, Crysty-Ann Olaco, Dale M. Netski, Kavita Batra, Community Level Correlates of COVID-19 Booster Vaccine Hesitancy in the United States: A Cross-Sectional Analysis, Vaccines, 12, 2, (167), (2024).https://doi.org/10.3390/vaccines12020167Tal Gazitt, Noa Hayat, Nili Stein, Amir Haddad, Ilan Feldhamer, Arnon Dov Cohen, Walid Saliba, Devy Zisman, The Risk of Herpes Zoster Events in Patients with Spondyloarthritis and the Effect of BNT162b2 mRNA COVID-19 Vaccine, Vaccines, 12, 1, (85), (2024).https://doi.org/10.3390/vaccines12010085Jung Yoon Choi, Yongjoon Lee, Nam Gi Park, Mi Sung Kim, Sandy Jeong Rhie, Serious Safety Signals and Prediction Features Following COVID-19 mRNA Vaccines Using the Vaccine Adverse Event Reporting System, Pharmaceuticals, 17, 3, (356), (2024).https://doi.org/10.3390/ph17030356Martin Heil, Self-DNA driven inflammation in COVID-19 and after mRNA-based vaccination: lessons for non-COVID-19 pathologies, Frontiers in Immunology, 14, (2024).https://doi.org/10.3389/fimmu.2023.1259879Shir Azrielant, Yair Levin, Alon Peled, Liat Samuelov, Eli Sprecher, Mor Pavlovsky, BioNTech COVID-19 (BNT162b2) Vaccination and Varicella Zoster Reactivation: A Comprehensive Cross-sectional Study, Acta Dermato-Venereologica, 104, (adv18389), (2024).https://doi.org/10.2340/actadv.v104.18389Jin Kyun Park, Eun Bong Lee, Kevin L Winthrop, What rheumatologists need to know about mRNA vaccines: current status and future of mRNA vaccines in autoimmune inflammatory rheumatic diseases, Annals of the Rheumatic Diseases, (ard-2024-225492), (2024).https://doi.org/10.1136/ard-2024-225492Fabrizio Martora, Matteo Megna, Teresa Battista, Massimiliano Scalvenzi, Alessia Villani, Sara Cacciapuoti, Luca Potestio, Viral reactivation following COVID-19 vaccination: a review of the current literature, Clinical and Experimental Dermatology, (2024).https://doi.org/10.1093/ced/llae061Chunhua Zhou, Yuanzheng Qiu, Jianxin Wang, Xiang Zhong, Xiufang Zhu, Xiaojing Huang, Lan Yang, Qiaolei Ji, Feifei Zhou, Shunquan Wu, Mengjie Yang, Jing Zhang, Kaili Liu, Li Ji, Hanyu Yang, Chunlei Li, Yuanyuan Zhao, The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial, Emerging Microbes & Infections, 13, 1, (2024).https://doi.org/10.1080/22221751.2024.2320913See more\n\n        View OptionsView options PDFView PDFMediaFiguresOtherTables","length":48600,"excerpt":"Preapproval trials showed that messenger RNA (mRNA)–based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet these trials were subject to s...","byline":"Ran D. Balicer","dir":"ltr","siteName":"The New England Journal of Medicine","lang":"en"},"finalizedMeta":{"title":"Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting | NEJM","description":"Preapproval trials showed that messenger RNA (mRNA)–based vaccines against severe\nacute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet\nthese trials were subject to s...","author":false,"creator":"","publisher":false,"date":"2024-10-10T15:43:34.765Z","topics":[]},"jsonLd":{"@type":false,"headline":false,"description":false,"image":[],"mainEntityOfPage":{"@type":false,"@id":false},"datePublished":false,"dateModified":false,"isAccessibleForFree":false,"isPartOf":{"@type":[],"name":false,"productID":false},"discussionUrl":false,"license":false,"author":{"@type":false,"name":false,"description":false,"sameAs":false,"image":{"@type":false,"url":false},"givenName":false,"familyName":false,"alternateName":false,"publishingPrinciples":false},"publisher":{"@type":false,"name":false,"description":false,"sameAs":false,"logo":{"@type":false,"url":false},"publishingPrinciples":false},"editor":{"@type":false,"name":false,"description":false,"sameAs":false,"image":{"@type":false,"url":false},"givenName":false,"familyName":false,"alternateName":false,"publishingPrinciples":false}},"twitterObj":false,"status":200,"metadata":{"author":false,"title":"Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting | New England Journal of Medicine","description":false,"canonical":"https://www.nejm.org/doi/full/10.1056/NEJMoa2110475","keywords":[],"image":"/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg","firstParagraph":"Subscribe\n    or Renew \n    \n    "},"dublinCore":{},"opengraph":{"title":"Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting | NEJM","description":"Preapproval trials showed that messenger RNA (mRNA)–based vaccines against severe\nacute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet\nthese trials were subject to s...","url":"https://www.nejm.org/doi/full/10.1056/nejmoa2110475","site_name":"The New England Journal of Medicine","locale":false,"type":"article","typeObject":{"published_time":false,"modified_time":false,"author":false,"publisher":false,"section":false,"tag":[]},"image":"https://www.nejm.org/cms/asset/03921378-0cc4-472f-ac47-21060786e63e/nejmoa2110475_f1.jpg","image:width":"988","image:height":"1500"},"twitter":{"site":"@NEJM","description":"Preapproval trials showed that messenger RNA (mRNA)–based vaccines against severe\nacute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet\nthese trials were subject to s...","card":"summary","creator":false,"title":"Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting | NEJM","image":"https://www.nejm.org/cms/asset/03921378-0cc4-472f-ac47-21060786e63e/nejmoa2110475_f1.jpg"},"archivedData":{"link":false,"wayback":false}}}